<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer - Hoon, S-N - 2021 | Cochrane Library</title> <meta content="Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer - Hoon, S-N - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011220.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer - Hoon, S-N - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011220.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011220.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer" name="citation_title"/> <meta content="Siao-Nge Hoon&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Peter K H Lau&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Alison M White" name="citation_author"/> <meta content="Max K Bulsara" name="citation_author"/> <meta content="Patricia D Banks" name="citation_author"/> <meta content="Andrew D Redfern" name="citation_author"/> <meta content="andrew.redfern@health.wa.gov.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD011220.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/05/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011220.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011220.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011220.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antimetabolites, Antineoplastic [adverse effects, *therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [adverse effects, *therapeutic use]; Bias; Breast Neoplasms [chemistry, *drug therapy, mortality, pathology]; Capecitabine [adverse effects, *therapeutic use]; Chemotherapy, Adjuvant; Disease-Free Survival; Neoadjuvant Therapy; Quality of Life; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011220.pub2&amp;doi=10.1002/14651858.CD011220.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011220\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011220\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011220.pub2",title:"Capecitabine for hormone receptor\\u2010positive versus hormone receptor\\u2010negative breast cancer",firstPublishedDate:"May 26, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Breast Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011220.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011220.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011220.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011220.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011220.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011220.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011220.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011220.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011220.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011220.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3224 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011220.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-sec-0121"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-sec-0051"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-sec-0115"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/appendices#CD011220-sec-0126"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/table_n/CD011220StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/table_n/CD011220StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information#CD011220-cr-0004">Siao-Nge Hoon</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information#CD011220-cr-0005">Peter K H Lau</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information#CD011220-cr-0006">Alison M White</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information#CD011220-cr-0007">Max K Bulsara</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information#CD011220-cr-0008">Patricia D Banks</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information#CD011220-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Andrew D Redfern</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information/en#CD011220-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 May 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011220.pub2">https://doi.org/10.1002/14651858.CD011220.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011220-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011220-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011220-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011220-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011220-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011220-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011220-abs-0001" lang="en"> <section id="CD011220-sec-0001"> <h3 class="title" id="CD011220-sec-0001">Background</h3> <p>Retrospective analyses suggest that capecitabine may carry superior activity in hormone receptor‐positive relative to hormone receptor‐negative metastatic breast cancer. This review examined the veracity of that finding and explored whether this differential activity extends to early breast cancer. </p> </section> <section id="CD011220-sec-0002"> <h3 class="title" id="CD011220-sec-0002">Objectives</h3> <p>To assess effects of chemotherapy regimens containing capecitabine compared with regimens not containing capecitabine for women with hormone receptor‐positive versus hormone receptor‐negative breast cancer across the three major treatment scenarios: neoadjuvant, adjuvant, metastatic. </p> </section> <section id="CD011220-sec-0003"> <h3 class="title" id="CD011220-sec-0003">Search methods</h3> <p>On 4 June 2019, we searched the Cochrane Breast Cancer Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 5) in the Cochrane Library; MEDLINE; Embase; the World Health Organization International Clinical Trials Registry Platform; and ClinicalTrials.gov. </p> </section> <section id="CD011220-sec-0004"> <h3 class="title" id="CD011220-sec-0004">Selection criteria</h3> <p>Randomised controlled trials looking at chemotherapy regimens containing capecitabine alone or in combination with other agents versus a control or similar regimen without capecitabine for treatment of breast cancer at any stage. The primary outcome measure for metastatic and adjuvant trials was overall survival (OS), and for neoadjuvant studies pathological complete response (pCR). </p> </section> <section id="CD011220-sec-0005"> <h3 class="title" id="CD011220-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed risk of bias and certainty of evidence using the GRADE approach. Hazard ratios (HRs) were derived for time‐to‐event outcomes, and odds ratios (ORs) for dichotomous outcomes, and meta‐analysis was performed using a fixed‐effect model. </p> </section> <section id="CD011220-sec-0006"> <h3 class="title" id="CD011220-sec-0006">Main results</h3> <p>We included 26 studies with outcome data by hormone receptor: 12 metastatic studies (n = 4325), 6 neoadjuvant trials (n = 3152), and 8 adjuvant studies (n = 13,457). </p> <p>Capecitabine treatment was added in several different ways across studies. These could be classified as capecitabine alone compared to another treatment, capecitabine substituted for part of the control chemotherapy, and capecitabine added to control chemotherapy. </p> <p>In the metastatic setting, the effect of capecitabine was heterogenous between hormone receptor‐positive and ‐negative tumours. For OS, no difference between capecitabine‐containing and non‐capecitabine‐containing regimens was observed for all participants taken together (HR 1.01, 95% confidence interval (CI) 0.98 to 1.05; 12 studies, 4325 participants; high‐certainty evidence), for those with hormone receptor‐positive disease (HR 0.93, 95% CI 0.84 to 1.04; 7 studies, 1834 participants; high‐certainty evidence), and for those with hormone receptor‐negative disease (HR 1.00, 95% CI 0.88 to 1.13; 8 studies, 1577 participants; high‐certainty evidence). For progression‐free survival (PFS), a small improvement was seen for all people (HR 0.89, 95% CI 0.82 to 0.96; 12 studies, 4325 participants; moderate‐certainty evidence). This was largely accounted for by a moderate improvement in PFS for inclusion of capecitabine in hormone receptor‐positive cancers (HR 0.82, 95% CI 0.73 to 0.91; 7 studies, 1594 participants; moderate‐certainty evidence) compared to no difference in PFS for hormone receptor‐negative cancers (HR 0.96, 95% CI 0.83 to 1.10; 7 studies, 1122 participants; moderate‐certainty evidence). Quality of life was assessed in five studies; in general there did not seem to be differences in global health scores between the two treatment groups at around two years' follow‐up. </p> <p>Neoadjuvant studies were highly variable in design, having been undertaken to test various experimental regimens using pathological complete response (pCR) as a surrogate for disease‐free survival (DFS) and OS. Across all patients, capecitabine‐containing regimens resulted in little difference in pCR in comparison to non‐capecitabine‐containing regimens (odds ratio (OR) 1.12, 95% CI 0.94 to 1.33; 6 studies, 3152 participants; high‐certainty evidence). By subtype, no difference in pCR was observed for either hormone receptor‐positive (OR 1.22, 95% CI 0.76 to 1.95; 4 studies, 964 participants; moderate‐certainty evidence) or hormone receptor‐negative tumours (OR 1.28, 95% CI 0.61 to 2.66; 4 studies, 646 participants; moderate‐certainty evidence). Four studies with 2460 people reported longer‐term outcomes: these investigators detected no difference in either DFS (HR 1.02, 95% CI 0.86 to 1.21; high‐certainty evidence) or OS (HR 0.97, 95% CI 0.77 to 1.23; high‐certainty evidence). </p> <p>In the adjuvant setting, a modest improvement in OS was observed across all participants (HR 0.89, 95% CI 0.81 to 0.98; 8 studies, 13,547 participants; moderate‐certainty evidence), and no difference in OS was seen in hormone receptor‐positive cancers (HR 0.86, 95% CI 0.68 to 1.09; 3 studies, 3683 participants), whereas OS improved in hormone receptor‐negative cancers (HR 0.72, 95% CI 0.59 to 0.89; 5 studies, 3432 participants). No difference in DFS or relapse‐free survival (RFS) was observed across all participants (HR 0.93, 95% CI 0.86 to 1.01; 8 studies, 13,457 participants; moderate‐certainty evidence). As was observed for OS, no difference in DFS/RFS was seen in hormone receptor‐positive cancers (HR 1.03, 95% CI 0.91 to 1.17; 5 studies, 5604 participants; moderate‐certainty evidence), and improvements in DFS/RFS with inclusion of capecitabine were observed for hormone receptor‐negative cancers (HR 0.74, 95% CI 0.64 to 0.86; 7 studies, 3307 participants; moderate‐certainty evidence). </p> <p>Adverse effects were reported across all three scenarios. When grade 3 or 4 febrile neutropenia was considered, no difference was seen for capecitabine compared to non‐capecitabine regimens in neoadjuvant studies (OR 1.31, 95% CI 0.97 to 1.77; 4 studies, 2890 participants; moderate‐certainty evidence), and a marked reduction was seen for capecitabine in adjuvant studies (OR 0.55, 95% CI 0.47 to 0.64; 5 studies, 8086 participants; moderate‐certainty evidence). There was an increase in diarrhoea and hand‐foot syndrome in neoadjuvant (diarrhoea: OR 1.95, 95% CI 1.32 to 2.89; 3 studies, 2686 participants; hand‐foot syndrome: OR 6.77, 95% CI 4.89 to 9.38; 5 studies, 3021 participants; both moderate‐certainty evidence) and adjuvant trials (diarrhoea: OR 2.46, 95% CI 2.01 to 3.01; hand‐foot syndrome: OR 13.60, 95% CI 10.65 to 17.37; 8 studies, 11,207 participants; moderate‐certainty evidence for both outcomes). </p> </section> <section id="CD011220-sec-0007"> <h3 class="title" id="CD011220-sec-0007">Authors' conclusions</h3> <p>In summary, a moderate PFS benefit by including capecitabine was seen only in hormone receptor‐positive cancers in metastatic studies. No benefit of capecitabine for pCR was noted overall or in hormone receptor subgroups when included in neoadjuvant therapy. In contrast, the addition of capecitabine in the adjuvant setting led to improved outcomes for OS and DFS in hormone receptor‐negative cancer. Future studies should stratify by hormone receptor and triple‐negative breast cancer (TNBC) status to clarify the differential effects of capecitabine in these subgroups across all treatment scenarios, to optimally guide capecitabine inclusion. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011220-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011220-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011220-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011220-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011220-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011220-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011220-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011220-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011220-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011220-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011220-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011220-abs-0002" lang="en"> <h3>Benefits of capecitabine in hormone receptor‐positive compared to hormone receptor‐negative breast cancer </h3> <p><b>What is the aim of this review?</b> </p> <p>The aims of this Cochrane Review were to find out whether capecitabine is more useful in hormone receptor‐positive or ‐negative breast cancers, and to see whether this differs depending on how advanced the cancer is. We collected and analysed all relevant studies to answer this question. </p> <p><b>What was studied in the review?</b> </p> <p>Capecitabine is an anti‐breast cancer drug in tablet form that has relatively few side effects in many people and can control cases of advanced breast cancer, sometimes for long periods. Some trials aiming to stop the return of cancer after treatment for early breast cancer also suggest modest benefits from adding capecitabine. We compared the use of capecitabine in breast cancer as palliative treatment (incurable metastatic or advanced disease), as neoadjuvant treatment (before surgery for early breast cancer), and as adjuvant treatment (after surgery for early breast cancer). We found a total of 26 studies, with 12 studies in the metastatic setting, 6 in the neoadjuvant setting, and 8 in the adjuvant setting. We found that capecitabine treatment was added in a number of different ways in different trials. These could be classified as monotherapy, where capecitabine alone was compared to another treatment (often another single drug); substitution, where capecitabine was used in place of another drug within a combined drug treatment; and addition, where capecitabine was added to standard treatment using one or more drugs. </p> <p><b>Key messages</b> </p> <p>In the setting of advanced disease, there was a modest increase in time to cancer progression (how long cancer growth is stopped) with the addition of capecitabine in hormone receptor‐positive but not in hormone receptor‐negative breast cancer, although no survival benefit was seen in either group. However, when broken down by how capecitabine was added to the regimen, the addition of capecitabine to other chemotherapy was most effective, demonstrating both longer time to progression in both groups and improved survival in hormone receptor‐positive cancers. </p> <p>In the neoadjuvant setting, capecitabine‐containing chemotherapy regimens showed no difference compared with non‐capecitabine‐containing chemotherapy regimens: no significant impact on the pathological complete response rate (the proportion of patients for whom all traces of cancer in the breast have been eradicated by treatment by the time of surgery), on disease‐free survival (the number of people who remain cancer‐free at a certain time after surgery), or on overall survival, regardless of hormone receptor subgroup. </p> <p>In the adjuvant setting, there was a small benefit for overall survival with capecitabine‐containing compared to non‐capecitabine‐containing chemotherapy regimens, when all patients were looked at together. In triple‐negative and hormone receptor‐negative breast cancers, reductions in both cancer return rates and deaths from breast cancer were substantial for capecitabine‐containing chemotherapy regimens compared with non‐capecitabine‐containing regimens. In contrast, for hormone receptor‐positive breast cancers, there was no significant impact of capecitabine on either cancer return rates or deaths from cancer. </p> <p>The common side effects of capecitabine were as expected, with the most common being diarrhoea and hand‐foot syndrome (redness, tightness, and discomfort or pain in the soles and palms). </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review authors searched for studies that had been published up to June 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011220-sec-0121" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011220-sec-0121"></div> <h3 class="title" id="CD011220-sec-0122">Implications for practice</h3> <section id="CD011220-sec-0122"> <p>In metastatic disease, a signal for greater activity was seen for capecitabine in hormone receptor‐positive cancers compared to no benefit for hormone receptor‐negative cancers. However, the core driver of this result was the use of capecitabine in combination with docetaxel, where excess toxicity prevents widespread use. Overall, capecitabine as a single agent had comparable efficacy to other single agents, and so is a reasonable choice for all subtypes in this setting due to a relatively favourable toxicity profile. </p> <p>Differential sensitivity of relevance to clinical practice was again observed in the adjuvant setting, albeit in the reverse direction. Although no significant benefit was observed for capecitabine inclusion in the hormone receptor‐positive population, we identified statistically and clinically significant disease‐free survival and overall survival benefits for the addition of capecitabine to docetaxel, when given sequentially either before or after an anthracycline‐based component, in hormone receptor‐negative or triple‐negative breast cancer. Heterogeneity was very low despite involved studies carried out in racially diverse populations. Capecitabine inclusion should therefore be considered, at least in high‐risk triple‐negative cases, after surgery. When patients treated with standard neoadjuvant chemotherapy for triple‐negative breast cancer have failed to achieve a pathological complete response, addition of capecitabine post surgery at a starting dose of 1250 mg/m² twice daily is warranted based on <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a> study outcomes, given that a corroborating trial in a more racially diverse population would strengthen the case for widespread application of these data. </p> </section> <h3 class="title" id="CD011220-sec-0123">Implications for research</h3> <section id="CD011220-sec-0123"> <p>The differential activity of capecitabine between hormone receptor‐positive and ‐negative cancers in micro‐metastatic and macro‐metastatic settings could provide an opportunity to better understand the differential biology between these settings. The active moiety from capecitabine metabolism, 5‐fluorouracil, was developed in the 1950s, thereby pre‐dating knowledge of oestrogen receptor signalling in breast cancer cell lines, such that this differential sensitivity has not been established nor explored in vitro or in vivo. </p> <p>Translational laboratory work exploring the differential impact of fluorouracil on dormant and cycling as well as hormone receptor‐positive and ‐negative cell lines may yield biological insights to allow better selection of patients or to even improve sensitivity to fluorouracil‐based treatments.<br/>Demonstrated overall survival benefit of capecitabine in the adjuvant setting for triple‐negative cancers warrants further investigation with additional randomised trials to confirm our findings. Pending such trials, consideration of capecitabine inclusion with docetaxel in high‐risk triple‐negative breast cancer patients adjuvantly appears justified. Internationally, the addition of platinum‐based agents to adjuvant chemotherapy in triple‐negative disease has gained considerable traction based on theoretically heightened sensitivity due to an increased incidence of DNA‐repair deficits, as well as observations of increased pathological complete response rates with platinum agent inclusion in neoadjuvant studies. However, to date, confirmation of overall survival benefit has not been achieved. Further studies into the biology of triple‐negative breast cancer are urgently required to assess the benefits of capecitabine, platinum, and anti‐programmed cell death‐1 immunotherapy. Our study suggests that capecitabine may have strong utility in the adjuvant setting for triple‐negative breast cancer. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011220-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011220-sec-0008"></div> <div class="table" id="CD011220-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Capecitabine‐containing regimens compared to chemotherapy regimens without capecitabine for metastatic breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Capecitabine‐containing regimens compared to chemotherapy regimens without capecitabine for metastatic breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with metastatic breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> capecitabine‐containing regimens<br/><b>Comparison:</b> chemotherapy regimens without capecitabine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy regimens without capecitabine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with capecitabine‐containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Overall survival (OS)<br/>median follow‐up: range 18.6 months to 37.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of death<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 1.01<br/>(0.98 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4325<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Heterogeneity was detected and was explained by variations in chemotherapy backbones. The certainty of evidence was not downgraded, as variations in chemotherapy are likely to occur in clinical practice </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000<br/>(361 to 381) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OS: hormone receptor‐positive<br/>median follow‐up: range 18.6 months to 37.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of death<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 0.90<br/>(0.80 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1565<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>As above</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>338 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000<br/>(281 to 343) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OS: hormone receptor‐negative<br/>median follow‐up: range 18.6 months to 34.3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of death<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 1.05<br/>(0.91 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1408<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>As above</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000<br/>(556 to 657) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Progression‐free survival (PFS)<br/>median follow‐up: range 18.6 months to 37.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of progression<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 0.89<br/>(0.83 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4325<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>745 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>704 per 1000<br/>(678 to 731) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PFS: hormone receptor‐positive<br/>median follow‐up: range 18.6 months to 37.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of progression<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 0.77<br/>(0.68 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1372<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>656 per 1000<br/>(610 to 701) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PFS: hormone receptor‐negative<br/>median follow‐up: range 20.6 months to 34.3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of progression<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 1.01<br/>(0.85 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>900<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>880 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>883 per 1000<br/>(835 to 920) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective response rate<br/>follow‐up range: 1.5 months to 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000<br/>(268 to 354) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/>(0.84 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4200<br/>(12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/>assessed with: EORTC QLQ‐C30 or Rotterdam Symptom Checklist<br/>assessed at baseline and at 2 years (or later) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable. In general, there did not seem to be differences in global health scores between the 2 treatment groups at around 2 years' follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most studies used the validated EORTC QLQ‐C30 questionnaire (4 studies) or the Rotterdam Symptom Checklist (1 study), and measures were patient‐reported </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/>CI: confidence interval; EORTC QLQ‐C30: European Organization for Research and Treatment of Cancer core quality of life questionnaire; HR:<b>h</b>azard ratio; ORR: objective response rate; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk in the comparator arm was based on 1‐year estimates from 11 studies for OS (<a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>; <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a>; <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a>; <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a>; <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>; <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a>; <a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a>; <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>; <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>; <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a>; <a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a>), as well as on data from a subset of studies that reported the event rate at 1 year in the comparator arm based on hormone receptor status (i.e. hormone receptor‐positive: <a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>; <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>; <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>; hormone receptor‐negative: <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>; <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a>; <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>).<br/><sup>b</sup>Baseline risk in the comparator arm was based on 1‐year estimates from all 12 studies that reported on PFS, as well as on data from one study for hormone receptor status (i.e. hormone receptor‐positive: <a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>; hormone receptor‐negative: <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a>).<br/><sup>c</sup>Studies were open‐label with limited independent assessment/central review of these outcomes. We thought some bias may be introduced by lack of blinding when PFS and ORR were assessed; therefore we downgraded the certainty of evidence by one level for risk of bias.<br/><sup>d</sup>This outcome was downgraded because all measures were patient‐reported, taking place in open‐label studies, and therefore was at high risk of bias. Although most studies used the validated EORTC QLQ‐C30 questionnaire; there was also variability in time frames when women were given the questionnaires and different lengths of follow‐up. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011220-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens for neoadjuvant treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Capecitabine‐containing regimens compared to non‐capecitabine‐containing for neoadjuvant treatment of ER‐positive versus ER‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> capecitabine‐containing regimens<br/><b>Comparison:</b> regimens without capecitabine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐capecitabine‐containing regimens</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with capecitabine‐containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pathological complete response (pCR): breast and axillary nodes<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221 per 1000<br/>(193 to 252) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.12<br/>(0.94 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3152<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious concerns, although it is noted that <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a> was deemed to be at high risk of selection bias </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pCR: hormone receptor‐positive<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/>(42 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.22<br/>(0.76 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>964<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pCR: hormone receptor‐negative<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>219 per 1000<br/>(118 to 368) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.28<br/>(0.61 to 2.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>646<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease‐free survival<br/>median follow‐up: range 3 years to 5.4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of recurrence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.02<br/>(0.86 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2499<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000<br/>(218 to 292) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>median follow‐up: range 3 years to 5.4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.97<br/>(0.77 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2499<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000<br/>(129 to 198) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Febrile neutropenia<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/>(64 to 112) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.31<br/>(0.97 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2890<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000<br/>(50 to 104) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.95<br/>(1.32 to 2.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2686<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hand‐foot syndrome<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000<br/>(136 to 232) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 6.77<br/>(4.89 to 9.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3021<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; ER: oestrogen receptor; HR: hazard ratio; OR: odds ratio; RCT: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk in the control arm was based on three studies (<a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>; <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a>; <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a>), which reported on hormone receptor‐positive and hormone receptor‐negative data separately.<br/><sup>b</sup>Downgraded by 1/2 point due to imprecision (confidence intervals include no effect; appreciable benefit and harm) and by an additional 1/2 point for reporting bias (neither of the two largest studies reported pCR by hormone receptor status).<br/><sup>c</sup>Baseline risk in the control arm was based on 5‐year estimates from two studies (<a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>; <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>).<br/><sup>d</sup>Downgraded by 1/2 point due to imprecision (wide confidence intervals) and by 1/2 point for risk of detection bias because all studies were open‐label, and toxicity assessment (by assessor or patient) may be influenced by lack of blinding of treatment arm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011220-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens or no chemotherapy for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens or no chemotherapy for ER‐positive vs ER‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with early breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> capecitabine‐containing regimens<br/><b>Comparison:</b> non‐capecitabine‐containing regimens or no chemotherapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐capecitabine‐containing regimens or no chemotherapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with capecitabine‐containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease‐free survival (DFS)<br/>median follow‐up: range 3.6 years to 10.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of recurrence<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/>(0.86 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13547<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000<br/>(145 to 168) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>DFS: hormone receptor‐positive<br/>median follow‐up: range 3.6 years to 10.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of recurrence<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.03<br/>(0.91 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5604<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>289 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/>(267 to 329) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>DFS: hormone receptor‐negative<br/>median follow‐up: range 3.6 years to 10.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of recurrence<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.76<br/>(0.65 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2879<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>347 per 1000<br/>(305 to 389) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>median follow‐up: range 3.6 years to 10.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of death<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.89<br/>(0.81 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13547<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/>(85 to 102) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Febrile neutropenia<br/>follow‐up: range 4 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/>(54 to 73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.55<br/>(0.47 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8086<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea<br/>follow‐up: range 4 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/>(48 to 71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 2.46<br/>(2.01 to 3.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11207<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hand‐foot syndrome<br/>follow‐up: range 4 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(112 to 171) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 13.60<br/>(10.65 to 17.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11207<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; ER: oestrogen receptor; HR: hazard ratio; OR: odds ratio; RCT: randomised controlled trial; RFS: recurrence‐free survival. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk in the control arm was based on 5‐year estimates from seven studies for DFS/RFS (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>; <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>; <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>), and data from the Oxford overview on women ≥ 50 years of age with ER‐positive breast cancer (Figure 5 in <a href="./references#CD011220-bbs2-0117" title="Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365(9472):1687-717.">EBCTCG 2005</a>) and &lt; 50 years of with ER‐poor breast cancer (Figure 5 in <a href="./references#CD011220-bbs2-0117" title="Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365(9472):1687-717.">EBCTCG 2005</a>) for DFS hormone receptor‐positive and hormone receptor‐negative breast cancer, respectively.<br/><sup>b</sup>Downgraded by 1/2 point due to some concerns related to attrition bias in three studies and by 1/2 point for indirectness due to inclusion in some studies of people with worse prognosis than in other studies.<br/><sup>c</sup>Baseline risk in the control arm was based on 5‐year estimates from seven studies (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>; <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>; <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>).<br/><sup>d</sup>Downgraded by 1/2 point due to inconsistency (substantial heterogeneity; confidence intervals do not overlap in the case of febrile neutropenia or diarrhoea) and by 1/2 point for risk of detection bias because all studies were open‐label and toxicity assessment (by assessor or patient) may be influenced by lack of blinding of treatment arm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011220-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011220-sec-0009"></div> <section id="CD011220-sec-0010"> <h3 class="title" id="CD011220-sec-0010">Description of the condition</h3> <p>Breast cancer is the most common malignancy among women in the world, with an estimated 2.1 million new cases diagnosed in 2018, accounting for 24% of all cancers in women (<a href="./references#CD011220-bbs2-0116" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians2018;68(6):394-424.">Bray 2018</a>). Breast cancer is the fifth leading cause of cancer‐related death worldwide. In more developed regions, it is the second leading cause of cancer‐related mortality among women, and it is the leading cause in less‐developed regions (<a href="./references#CD011220-bbs2-0121" title="FerlayJ , SoerjomataramI , ErvikM , DikshitR , EserS , MathersC , et al. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0. IARC Cancer Base No. 112012.">Ferlay 2012</a>). </p> <p>Five‐year survival following a diagnosis of breast cancer has significantly increased over the past 20 years. This is due in part to the implementation of population screening resulting in diagnosis of breast cancer at earlier stages and in part to improvements in adjuvant systemic treatment. The development and availability of additional endocrine therapies (<a href="./references#CD011220-bbs2-0117" title="Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365(9472):1687-717.">EBCTCG 2005</a>), human epidermal growth factor receptor 2 (HER2)‐targeted agents (<a href="./references#CD011220-bbs2-0135" title="MojaL , TagliabueL , BalduzziS , ParmelliE , PistottiV , GuarneriV , D’AmicoR . Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews2012, Issue 4. Art. No: CD006243. [DOI: 10.1002/14651858.CD006243.pub2]">Moja 2012</a>), and new chemotherapeutic drug classes, such as taxanes (<a href="./references#CD011220-bbs2-0120" title="FergusonT , WilckenN , VaggR , GhersiD , NowakAK . Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD004421. [DOI: 10.1002/14651858.CD004421.pub2]">Ferguson 2007</a>), have contributed significantly to better outcomes. The expansion of available cytotoxic agents, including capecitabine, vinorelbine, and eribulin, has also coincided with improved survival for women with metastatic breast cancer, although trials confirming survival advantages are relatively scarce due to the allowance of cross‐over within many trial designs. Evidence guiding the use of endocrine and HER2‐targeted therapies is well defined. In contrast, despite evidence for a substantial difference in overall chemotherapy sensitivity between endocrine responsive and non‐responsive breast cancers, as judged by pathological complete response (pCR) rates in the neoadjuvant setting (<a href="./references#CD011220-bbs2-0126" title="HoussamiN , MacaskillP , vonMinckwitzG , MarinovichML , MamounasE . Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.. European Journal of Cancer2012;48(18):3342-54.">Houssami 2012</a>), there is a paucity of data guiding the selection of chemotherapeutic agents with respect to hormone receptor status or other tumour features. Such guidance is particularly important in triple‐negative breast cancer (TNBC), which carries the poorest prognosis of all breast cancer subtypes, and when chemotherapy is the only option for systemic treatment. In the adjuvant setting, optimising the treatment regimen should improve cure rates. Platinum‐based compounds have been investigated for adjuvant treatment of TNBC, but results are conflicting, with generally improved pCR rates not translating into consistent survival advantages (<a href="./references#CD011220-bbs2-0122" title="GerratanaL , FanottoV , PelizzariG , AgostinettoE , PuglisiF . Do platinum salts fit all triple negative breast cancers?Cancer Treatment Reviews2016;48:34-41.">Gerratana 2016</a>). Capecitabine is an alternative agent that has been investigated. It is generally well tolerated, lacks cross‐resistance with other adjuvant agents due to a different mechanism of action, and is readily integrated into existing standard treatments. However, data regarding the efficacy of capecitabine‐containing chemotherapy regimens compared to similar non‐capecitabine‐containing regimens according to cancer subtype, including TNBC, are fragmented. As such, optimal selection of chemotherapy in breast cancer within the oestrogen‐driven, HER2, and TNBC subgroups remains to be defined. </p> </section> <section id="CD011220-sec-0011"> <h3 class="title" id="CD011220-sec-0011">Description of the intervention</h3> <p>Capecitabine is an oral pro‐drug of fluorouracil. Following absorption, capecitabine is metabolised in the normal liver and in cancerous tissue. The final step in the conversion of capecitabine to fluorouracil is catalysed by thymidine phosphorylase, which is highly expressed in many cancer cells (<a href="./references#CD011220-bbs2-0134" title="MiwaM , UraM , NishidaM , SawadaN , IshikawaT , MoriK , et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. European Journal of Cancer1998;34(8):1274-81.">Miwa 1998</a>). As such, the effect of capecitabine is concentrated within these cells, giving a selective treatment advantage. Capecitabine has been used extensively as a single agent and more occasionally as part of combination regimens for metastatic breast cancer. Its use as a component of adjuvant and neoadjuvant therapy for breast cancer has been investigated in clinical trials. </p> <p>Adverse effects commonly reported in association with capecitabine, experienced by 5% or more of patients, include diarrhoea, stomatitis, nausea and vomiting, hand‐foot syndrome (palmar‐plantar erythrodysaesthesia), dermatitis, fatigue, and cytopenia. Coronary artery vasospasm is a less common but clinically important side effect that is reported to affect 0.2% of patients (<a href="./references#CD011220-bbs2-0119" title="FDA 2014. Roche Xeloda (capecitabine) tablets. FDA Access Data (accessdata.fda.gov/drugsatfda_docs/label/2000/20896lbl.pdf) (accessed 17 January 2014).">FDA 2014</a>). </p> </section> <section id="CD011220-sec-0012"> <h3 class="title" id="CD011220-sec-0012">How the intervention might work</h3> <p>A pooled analysis of individual patient data from capecitabine monotherapy trials for locally advanced or metastatic disease demonstrated that patients with hormone receptor‐positive breast cancer experienced significantly higher overall response rates, progression‐free survival, and overall survival compared with patients with hormone receptor‐negative disease (<a href="./references#CD011220-bbs2-0114" title="BlumJ , BarriosC , FeldmanN , VermaS , McKennaE , LeeL , et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment2012;136(3):777-88.">Blum 2012</a>). Several retrospective reviews have identified significantly greater benefits from capecitabine in hormone receptor‐positive metastatic breast cancer (<a href="./references#CD011220-bbs2-0123" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomP , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in patients with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15 Suppl):1024.">Gluck 2009</a>; <a href="./references#CD011220-bbs2-0137" title="OsakoT , ItoY , UshijimaM , TakahashiS , TokudomeN , SugiharaT , et al. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology2009;63(5):865-71.">Osako 2009</a>; <a href="./references#CD011220-bbs2-0142" title="SivaP , CorreaP , SkariaS , CanneyP . Capecitabine in advanced breast cancer: predictive factors for response. Journal of Clinical Oncology2008;26(15 Supplement):1126.">Siva 2008</a>). However, when both overall response rate (ORR) and overall survival (OS) are interpreted in the context of metastatic disease, it is important to take into account the observations that hormone receptor‐negative disease natively tends to have a higher ORR than chemotherapy (particularly anthracyclines and taxanes), whereas hormone receptor‐positive disease is known to carry a longer median OS, regardless of the treatment parameters. </p> <p>In the neoadjuvant setting, capecitabine‐containing chemotherapy regimens have been associated with greater benefit for hormone receptor‐positive breast cancer. In an unplanned subgroup analysis from the large phase 3 GeparTrio trial, investigating a response‐guided treatment switch to capecitabine‐vinorelbine after poor response to two initial cycles of docetaxel ‐ doxorubicin and cyclophosphamide ‐ patients with hormone receptor‐positive breast cancers experienced significantly longer disease‐free survival with the capecitabine combination compared to their hormone receptor‐negative counterparts (<a href="./references#CD011220-bbs2-0144" title="vonMinckwitzG , KummelS , VogelP , HanuschC , EidtmannH , HilfrichJ , et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio Trial. Journal of the National Cancer Institute2008;100(8):542-51.">von Minckwitz 2008</a>). A second phase 3 trial examining the use of neoadjuvant docetaxel‐capecitabine (TX) versus doxorubicin‐cyclophosphamide (AC) found that TX was associated with a higher rate of pathological complete response, at 17% in hormone receptor‐positive breast cancers, compared with 3% for AC (<a href="./references#CD011220-bbs2-0128" title="LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9.">Lee 2008</a>). </p> </section> <section id="CD011220-sec-0013"> <h3 class="title" id="CD011220-sec-0013">Why it is important to do this review</h3> <p>In the adjuvant setting, anthracyclines and taxanes form the backbone of treatment regimens. This remains the optimal treatment scenario in which the plethora of newer agents could contribute further to cure rates. However, their potential incorporation has been hampered by trials with large numbers of low‐risk patients, heterogenous patient populations, and diverse designs. The division of breast cancers into oestrogen receptor‐positive (ER+) versus oestrogen receptor‐negative (ER‐) tumours represents the most fundamental biological classification. This concept, combined with the above evidence for a dichotomous effect between the two groups, has led us to investigate whether collation of existing capecitabine trial outcome data by hormone receptor status could reveal a group significantly advantaged by routine incorporation of the drug in adjuvant or neoadjuvant therapy, thereby guiding the selection of chemotherapy. </p> <p>In metastatic breast cancer, ideally patients would receive the majority of active agents at some time during their disease course. However, data from Australia and from a large insured cohort in the USA show that less than half of patients are treated beyond a second line of therapy, making selection of the most effective agents for early‐line treatments crucial (<a href="./references#CD011220-bbs2-0132" title="MartinHL , OharaK , ChinW , DavidsonA , BaylissE , RedfernA , KhattakMA . Cancer services in Western Australia: a comparison of regional outcomes with metropolitan Perth. Australian Journal of Rural Health2015;23(5):302-8.">Martin 2015</a>; <a href="./references#CD011220-bbs2-0139" title="RayS , BonthapallyV , McMorrowD , BonafedeM , Landsman-BlumbergP . Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population. Journal of Comparative Effectiveness Research2013;2(2):195-206.">Ray 2013</a>). </p> <p>When data are insufficient to define optimal subtype‐specific treatment pathways, this review may guide the development of randomised trials in more targeted populations. Finally, findings from this study may inform a review of regulations regarding the funding of capecitabine in various settings. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011220-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011220-sec-0014"></div> <p>To assess effects of chemotherapy regimens containing capecitabine compared with regimens not containing capecitabine for women with hormone receptor‐positive versus hormone receptor‐negative breast cancer across the three major treatment scenarios: neoadjuvant, adjuvant, metastatic. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011220-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011220-sec-0015"></div> <section id="CD011220-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011220-sec-0017"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) comparing chemotherapy regimens containing capecitabine alone or in combination versus a control employing a similar regimen without capecitabine for treatment of breast cancer were included. Randomised studies that included a capecitabine‐containing regimen but did not directly compare this against a non‐capecitabine‐containing regimen as the primary trial endpoint were also included. Additionally, trials in which a capecitabine‐containing regimen was part of a "pooled comparator" or was included as "physician's choice" were included, as long as capecitabine outcomes were reported. Full‐text review was performed when available, and data were extracted by ER, hormone receptor, or TNBC status, if provided. </p> <p>We anticipated that we would identify three or more RCTs for each section of this review. However, if we identified fewer than three RCTs for any of the three sections of this review, we would consider well‐designed non‐randomised controlled trials. </p> </section> <section id="CD011220-sec-0018"> <h4 class="title">Types of participants</h4> <p>Trials studying women with a histological diagnosis of breast adenocarcinoma were included. Treatment could be provided at any stage (adjuvant, neoadjuvant, or metastatic) and for any line of treatment in the metastatic setting. We applied no age restrictions. Only studies in which at least 75% of participants had a defined hormone receptor status were eligible. </p> </section> <section id="CD011220-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD011220-list-0001"> <li> <p>Intervention: chemotherapy regimens containing capecitabine alone or as part of combination therapy in hormone receptor‐positive and hormone receptor‐negative breast cancer (<a href="#CD011220-tbl-0004">Table 1</a>) </p> </li> <li> <p>Comparator: similar chemotherapy regimens not containing capecitabine in hormone receptor‐positive and hormone receptor‐negative breast cancer. The comparator could include: </p> <ul id="CD011220-list-0002"> <li> <p>the same chemotherapy regimen without capecitabine;</p> </li> <li> <p>a different chemotherapy regimen without capecitabine;</p> </li> <li> <p>the same chemotherapy regimen with another drug or drugs substituting for capecitabine; or </p> </li> <li> <p>no active agents in the adjuvant setting (<a href="#CD011220-tbl-0004">Table 1</a>). </p> </li> </ul> </li> </ul> </p> <div class="table" id="CD011220-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies summarising treatment regimens</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Capecitabine‐containing arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + epirubicin + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin + cyclophosphamide &gt; docetaxel &gt; capecitabine or epirubicin + cyclophosphamide &gt; docetaxel + capecitabine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin + cyclophosphamide &gt; docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin + cyclophosphamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel &gt; doxorubicin + cyclophosphamide ± bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Docetaxel or docetaxel + gemcitabine &gt; doxorubicin + cyclophosphamide ± bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + vinorelbine &gt; docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin + cyclophosphamide &gt; docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + epirubicin + cyclophosphamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluorouracil + epirubicin + cyclophosphamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel &gt; epirubicin + cyclophosphamide + capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Docetaxel &gt; fluorouracil + epirubicin + cyclophosphamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant chemotherapy &gt; adjuvant capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant chemotherapy &gt; adjuvant capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel &gt; epirubicin + cyclophosphamide + capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Docetaxel &gt; fluorouracil + epirubicin + cyclophosphamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + epirubicin + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin + cyclophosphamide &gt; docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + ibandronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitibine + epirubicin (dose dense or standard)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin (dose dense or standard) &gt; cyclophosphamide + methotrexate + fluorouracil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin + cyclophosphamide &gt; docetaxel + capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin + cyclophosphamide &gt; docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus ± exemestane</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gemcitabine + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + trastuzumab + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trastuzumab + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cisplatin + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glembatumumb vedotin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinorelbine + gemcitabine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gemcitabine + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eribulin mesylate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab + docetaxel OR paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + docetaxel OR paclitaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + paclitaxel</p> </td> </tr> </tbody> </table> </div> <p>Comparisons included:</p> <p> <ul id="CD011220-list-0003"> <li> <p>capecitabine‐containing regimen versus non‐capecitabine‐containing regimen in hormone receptor‐positive breast cancer; </p> </li> <li> <p>capecitabine‐containing regimen versus non‐capecitabine‐containing regimen in hormone receptor‐negative breast cancer; and </p> </li> <li> <p>capecitabine‐containing regimen versus non‐capecitabine‐containing regimen in TNBC.</p> </li> </ul> </p> <p>We also included studies in which the strategy was:</p> <p> <ul id="CD011220-list-0004"> <li> <p>chemotherapy given as neoadjuvant, adjuvant, or palliative treatment;</p> </li> <li> <p>inclusive of biologic agents such as trastuzumab and bevacizumab, if relevant, and provided identical biologics are included in capecitabine‐containing and non‐capecitabine‐containing arms; or </p> </li> <li> <p>chemotherapy given as first or subsequent line of treatment in the context of metastatic disease. </p> </li> </ul> </p> </section> <section id="CD011220-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD011220-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD011220-sec-0022"> <h6 class="title">Palliative chemotherapy</h6> <p> <ul id="CD011220-list-0005"> <li> <p>Overall survival (OS)</p> </li> </ul> </p> </section> <section id="CD011220-sec-0023"> <h6 class="title">Neoadjuvant chemotherapy</h6> <p> <ul id="CD011220-list-0006"> <li> <p>Pathological complete response rate (pCR)</p> </li> </ul> </p> </section> <section id="CD011220-sec-0024"> <h6 class="title">Adjuvant chemotherapy</h6> <p> <ul id="CD011220-list-0007"> <li> <p>Overall survival (OS)</p> </li> </ul> </p> </section> </section> <section id="CD011220-sec-0025"> <h5 class="title">Secondary outcomes</h5> <section id="CD011220-sec-0026"> <h6 class="title">Palliative chemotherapy</h6> <p> <ul id="CD011220-list-0008"> <li> <p>Overall response rate (ORR)</p> </li> <li> <p>Progression‐free survival (PFS)</p> </li> <li> <p>Clinical benefit rate (CBR)</p> </li> <li> <p>Quality of life (QoL)</p> </li> </ul> </p> </section> <section id="CD011220-sec-0027"> <h6 class="title">Neoadjuvant chemotherapy</h6> <p> <ul id="CD011220-list-0009"> <li> <p>Disease‐free survival (DFS)</p> </li> <li> <p>Recurrence‐free survival (RFS)</p> </li> <li> <p>Overall survival (OS)</p> </li> </ul> </p> </section> <section id="CD011220-sec-0028"> <h6 class="title">Adjuvant chemotherapy</h6> <p> <ul id="CD011220-list-0010"> <li> <p>Disease‐free survival (DFS)</p> </li> <li> <p>Recurrence‐free survival (RFS)</p> </li> </ul> </p> <p>Specific information on adverse events was collected from studies in each of the neoadjuvant, adjuvant, and palliative chemotherapy groups. The total number of grade 3 and 4 adverse events and the total number of participants at risk in each trial were summated to calculate a single odds ratio. For the following specific toxicities of interest, the total number of toxic events was calculated. </p> <p> <ul id="CD011220-list-0011"> <li> <p>Cytopenias.</p> </li> <li> <p>Febrile neutropenia.</p> </li> <li> <p>Hand‐foot syndrome.</p> </li> <li> <p>Mucositis and stomatitis.</p> </li> <li> <p>Diarrhoea.</p> </li> <li> <p>Ischaemic cardiac disease.</p> </li> </ul> </p> <p>The following outcome definitions were applied.</p> <p> <ul id="CD011220-list-0012"> <li> <p>pCR defined in <a href="#CD011220-sec-0038">Measures of treatment effect</a> section. </p> </li> <li> <p>DFS defined as time from randomisation to time of identification of recurrent or metastatic cancer or death from any cause. </p> </li> <li> <p>RFS defined as time from randomisation to date of diagnosis of invasive breast cancer recurrence or death if the patient died before cancer recurrence. </p> </li> <li> <p>PFS defined as time from randomisation to time of tumour progression or death from any cause. If time to progression or time to treatment failure was recorded as an endpoint rather than PFS, these could be used in place of PFS. </p> </li> <li> <p>OS defined as time from randomisation to death from any cause.</p> </li> <li> <p>Breast cancer‐specific survival (BCSS) defined as time from randomisation to death due to breast cancer. </p> </li> <li> <p>Response rate defined by Response Evaluation Criteria In Solid Tumours (RECIST) (<a href="./references#CD011220-bbs2-0118" title="EisenhauerE , TherasseP , BogaertsJ , SchwartzL , SargentD , FordR , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer2009;45(2):228-47.">Eisenhauer 2009</a>). </p> </li> <li> <p>ORR defined as the sum of complete and partial responses, representing the best response for each patient. </p> </li> <li> <p>CBR defined as the sum of complete response, partial response, and stable disease rate. </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD011220-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011220-sec-0030"> <h4 class="title">Electronic searches</h4> <p>Details of search strategies used by the Cochrane Breast Cancer Group (CBCG) for identification of studies and the procedure used to code references are outlined in the Group's module <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html" target="_blank">(http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/BREASTCA/frame.html)</a>. Trials with the key words 'breast neoplasm; breast cancer; breast carcinoma; breast adenocarcinoma; breast tumour/tumor; capecitabine; and xeloda' were extracted and considered for inclusion in the review. We searched the following databases. </p> <p> <ul id="CD011220-list-0013"> <li> <p>CBCG Specialised Register (4 June 2019).</p> </li> <li> <p>MEDLINE Ovid (1946 to 4 June 2019; see <a href="./appendices#CD011220-sec-0127">Appendix 1</a>). </p> </li> <li> <p>Embase Ovid (1974 to 4 June 2019; see <a href="./appendices#CD011220-sec-0128">Appendix 2</a>). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library (searched 4 June 2019; see <a href="./appendices#CD011220-sec-0129">Appendix 3</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://apps.who.int/trialsearch/Default.aspx" target="_blank">http://apps.who.int/trialsearch/Default.aspx</a>; searched 4 June 2019; see <a href="./appendices#CD011220-sec-0130">Appendix 4</a>). </p> </li> <li> <p>Clinicaltrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a>; searched 4 June 2019; see <a href="./appendices#CD011220-sec-0131">Appendix 5</a>). </p> </li> </ul> </p> </section> <section id="CD011220-sec-0031"> <h4 class="title">Searching other resources</h4> <section id="CD011220-sec-0032"> <h5 class="title">Bibliographic searching</h5> <p>We identified further studies from the reference lists of relevant trials or reviews identified above. We obtained a copy of the full article for each reference reporting a potentially eligible trial. When this was not possible, we attempted to contact study authors to request additional information. </p> </section> <section id="CD011220-sec-0033"> <h5 class="title">Grey literature searching</h5> <p>We searched conference proceedings of the following conferences from 1996 to the present for relevant abstracts. </p> <p> <ul id="CD011220-list-0014"> <li> <p>American Society of Clinical Oncology Annual Scientific Meeting.</p> </li> <li> <p>San Antonio Breast Cancer Symposium.</p> </li> <li> <p>American Society of Clinical Oncology Breast Cancer Symposium.</p> </li> <li> <p>European Society of Medical Oncology Annual Scientific Meeting.</p> </li> <li> <p>European Breast Cancer Conference.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011220-sec-0034"> <h3 class="title" id="CD011220-sec-0034">Data collection and analysis</h3> <section id="CD011220-sec-0035"> <h4 class="title">Selection of studies</h4> <p>We applied the selection criteria to each reference identified independently by two review authors (of PL, AW, SH, PB, AR). We linked records identified at the initial screening stage to studies at the full‐text screening stage. </p> <p>With regard to selection of studies,</p> <p> <ul id="CD011220-list-0015"> <li> <p>review authors were not blinded to study title, authors, or publication details;</p> </li> <li> <p>any disagreements regarding selection of a study were resolved by a third review author (AR or MB, unless AR was an initial assessor); </p> </li> <li> <p>PL, AW, SH, and PB are not content experts, although all are knowledgeable in the field; </p> </li> <li> <p>AR is a content expert, and MB is an expert in statistics;</p> </li> <li> <p>all relevant studies were included (no studies required translation); and</p> </li> <li> <p>we recorded significant excluded studies in the <a href="./references#CD011220-sec-0143" title="">Characteristics of excluded studies</a> table (references were not included in this table if they obviously did not fulfil the inclusion criteria). </p> </li> </ul> </p> </section> <section id="CD011220-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (of PL, AW, SH, PB, AR) independently extracted data from each publication or abstract. </p> <p>We performed data extraction by using standard electronic extraction forms (see <a href="./appendices#CD011220-sec-0132">Appendix 6</a>) and entered the data into Covidence (http://www.covidence.org). We designed individual data extraction forms for each of the three treatment types studied: neoadjuvant, adjuvant, and palliative treatment. When data from trials were presented in multiple publications, we amalgamated the information and reported it as a single trial, with all relevant publications listed. </p> <p>Disagreements regarding extraction of quantitative data were resolved by a third review author (AR or PL). </p> </section> <section id="CD011220-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias by using Cochrane's risk of bias assessment tool, provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapter 8.5 (<a href="./references#CD011220-bbs2-0124" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). Two review authors (of PL, AW, SH, PB, AR) independently assessed risk of bias, with disagreements resolved by a third review author (AR or PL). Areas of bias assessed were: </p> <p> <ul id="CD011220-list-0016"> <li> <p>selection bias;</p> </li> <li> <p>performance bias;</p> </li> <li> <p>detection bias;</p> </li> <li> <p>attrition bias;</p> </li> <li> <p>reporting bias; and</p> </li> <li> <p>other biases;</p> <ul id="CD011220-list-0017"> <li> <p>recruitment bias ‐ recruitment based on differential response; and</p> </li> <li> <p>use of interim results.</p> </li> </ul> </li> </ul> </p> <p>We described risk of bias assessments in a 'Risk of bias' table (see <a href="./references#CD011220-sec-0142" title="">Characteristics of included studies</a> table), and we presented summary graphs for palliative, neoadjuvant, and adjuvant trials. </p> </section> <section id="CD011220-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011220-sec-0039"> <h5 class="title">Palliative trials</h5> <p>The primary outcome for palliative intent trials was OS, which was analysed as a time‐to‐event outcome and was expressed as a hazard ratio (HR). We used the HR provided in each study or estimated the HR indirectly by using the methods described by Tierney et al and Parmar as above, and we documented this information as above. For meta‐analytical pooling, we used the generic‐inverse variance method as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapters 7.7.6 and 9.4.9, as for other outcomes. </p> <p>Secondary outcomes for palliative intent trials were overall response rate (ORR), progression‐free survival (PFS), and clinical benefit rate (CBR). ORR is considered a small ordinal scale that was expressed as a dichotomous outcome, with complete response (CR) and partial response (PR) representing response, and stable disease (SD) and progressive disease (PD) representing no response. This outcome has been presented as a risk ratio (RR) with 95% confidence interval (CI) and has been reported for randomised and assessable patients. We have reported the ratio of treatment effect for response, so that an RR less than 1.0 favours non‐capecitabine‐containing regimens and a RR equal to or greater than 1.0 favours capecitabine‐containing regimens. CBR was also considered a small ordinal scale and was expressed as a dichotomous outcome, with CR, PR, and SD (for three months or longer) representing clinical benefit, and PD representing no benefit. We presented the outcome as an RR with 95% CI, as per the ORR above. We analysed PFS as a time‐to‐event outcome, also as above. </p> <p>When both ORR and OS are interpreted in the context of metastatic disease, it is important to take into account that hormone receptor‐negative disease natively tends to have a higher ORR than chemotherapy, whereas hormone receptor‐positive disease is known to carry a longer median OS, regardless of the treatment parameters. In this setting, an absolute 10% or greater improvement in ORR in hormone receptor‐positive disease for capecitabine‐containing regimens compared with non‐capecitabine‐containing regimens was considered a clinically significant difference. </p> </section> <section id="CD011220-sec-0040"> <h5 class="title">Neoadjuvant trials</h5> <p>The primary outcome for neoadjuvant trials was the pathological complete response rate (pCR). In most trials, this was measured on the Modified Regression Scale (<a href="./references#CD011220-bbs2-0144" title="vonMinckwitzG , KummelS , VogelP , HanuschC , EidtmannH , HilfrichJ , et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio Trial. Journal of the National Cancer Institute2008;100(8):542-51.">von Minckwitz 2008</a>), with response graded as follows. </p> <p> <ul id="CD011220-list-0018"> <li> <p>Grade 5 ‐ no microscopic evidence of residual tumour cells in the breast or axillary nodes. </p> </li> <li> <p>Grade 4 ‐ no microscopic evidence of residual tumour cells in the breast, but axillary nodes involved. </p> </li> <li> <p>Grade 3 ‐ residual non‐invasive tumour cells in the breast.</p> </li> <li> <p>Grade 2 ‐ residual focal invasive tumour cells in the breast ≤ 5 mm.</p> </li> <li> <p>Grade 0 to 1 ‐ all remaining scenarios including the presence of new invasive tumour.</p> </li> </ul> </p> <p>Grades 4 and 5 were considered to represent pCR. This is a small ordinal scale on which the event of pCR was considered as a dichotomous outcome with grades 4 and 5 representing pCR, and all other grades representing no pCR. This outcome has been presented as a risk ratio (RR) with 95% confidence interval (CI) and has been reported for randomised and assessable patients. We reported the ratio of treatment effect for response, so that an RR less than 1.0 favours non‐capecitabine‐containing regimens and an RR equal to or greater than 1.0 favours capecitabine‐containing regimens. In the context of neoadjuvant treatment, pCR rates are typically significantly higher in hormone receptor‐negative cancers relative to hormone receptor‐positive cancers. Thus, in hormone receptor‐positive disease, an absolute difference of 5% or greater for capecitabine‐containing regimens compared with non‐capecitabine‐containing regimens was considered a clinically significant difference. </p> <p>Secondary outcomes for neoadjuvant trials were disease‐free survival (DFS), recurrence‐free survival (RFS), and overall survival (OS). These have been analysed as time‐to‐event outcomes and expressed as hazard ratios (HRs). We used the HR provided in each study or estimated the HR indirectly using methods described by Tierney and Parmar (<a href="./references#CD011220-bbs2-0138" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. 1998 Statistics in Medicine;17(24):2815-34.">Parmar 1998</a>; <a href="./references#CD011220-bbs2-0143" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>). We recorded the use of indirect methods in the Notes sections of the <a href="./references#CD011220-sec-0142" title="">Characteristics of included studies</a> table. For meta‐analytical pooling, we employed the generic‐inverse variance method as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapters 7.7.6 and 9.4.9 (<a href="./references#CD011220-bbs2-0124" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> </section> <section id="CD011220-sec-0041"> <h5 class="title">Adjuvant trials</h5> <p>The primary outcome for adjuvant trials was overall survival (OS), which was analysed as a time‐to‐event outcome and was expressed as an HR. We used the HR reported in each study or estimated the HR indirectly, again using methods described by Tierney and Parmar (<a href="./references#CD011220-bbs2-0138" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. 1998 Statistics in Medicine;17(24):2815-34.">Parmar 1998</a>; <a href="./references#CD011220-bbs2-0143" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>). Similarly, for meta‐analytical pooling, we used the generic‐inverse variance method as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, Chapters 7.7.6 and 9.4.9. </p> <p>Secondary outcomes for adjuvant trials were DFS, RFS, and breast cancer‐specific survival (BCSS). We analysed these as time‐to‐event outcomes and expressed them as HRs. We used the HR provided in each trial publication or estimated the HR indirectly using methods described by Tierney and Parmar, as above, and we will document this as above. Again, for meta‐analytical pooling, we used the generic‐inverse variance method as described above. </p> <p>In the adjuvant setting, an absolute improvement of 5% or greater in DFS, RFS, and OS for capecitabine‐containing regimens compared with non‐capecitabine‐containing regimens was considered a clinically significant difference for hormone receptor‐positive disease. </p> </section> <section id="CD011220-sec-0042"> <h5 class="title">Adverse events</h5> <p>All grade 3 and 4 adverse events, along with the total number of participants at risk, were recorded from each trial. When possible, data on adverse events were collected for the treated population rather than for the intention‐to‐treat population. A pooled odds ratio (OR) with 95% CI was calculated for each toxicity that was reported in two or more studies. Total numbers of the following specific adverse events were recorded in this review: cytopenias, febrile neutropenia, hand‐foot syndrome, mucositis, diarrhoea, and ischaemic cardiac disease. </p> </section> </section> <section id="CD011220-sec-0043"> <h4 class="title">Unit of analysis issues</h4> <p>We did not include cross‐over trials in this systematic review. Exceptions to this criterion were made if a trial detailed outcome data for capecitabine‐containing chemotherapy regimens that were not affected by cross‐over. For example, ORR and PFS in metastatic trials are outcomes that are not intuitively affected by cross‐over; thus we included such trials if data were available for full‐text review. In contrast, OS differences might be expected to be attenuated by cross‐over and so were not included. </p> <p>Some included studies contained multiple intervention groups. The review author MB provided specialist statistical advice regarding the manner in which multiple intervention groups were dealt with. Each study utilising multiple groups was considered independently and multiple groups were handled in various ways, including by combining intervention groups or dividing the control group, as deemed appropriate to enable pair‐wise comparisons and to ensure that no unit of analysis issues arose. </p> </section> <section id="CD011220-sec-0044"> <h4 class="title">Dealing with missing data</h4> <p>In planning this systematic review, we considered missing data to be of likely significance, as we anticipated that many of the studies meeting eligibility criteria for inclusion would not report outcomes based on the tumour hormone receptor status of participants. For such cases, this meant that analysis of the study for inclusion in the systematic review was not possible. </p> <p>We did not contact the original investigators regarding missing hormone receptor status data of participants. Studies for which this information was not available have been included in the review, and we have discussed the impact of the missing data for these studies in the <a href="#CD011220-sec-0115">Discussion</a> section of the review. </p> <p>With regard to studies in which other data are missing, for example, participants lost to follow‐up or data for study objectives were not reported: </p> <p> <ul id="CD011220-list-0019"> <li> <p>analysis has been done by intention‐to‐treat, with a sensitivity analysis conducted to consider the impact of the missing results; </p> </li> <li> <p>missing data have not been imputed; and</p> </li> <li> <p>the impact of missing data with regard to assessment of bias has been discussed in the <a href="#CD011220-sec-0115">Discussion</a> section of the review. </p> </li> </ul> </p> </section> <section id="CD011220-sec-0045"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity by using:</p> <p> <ul id="CD011220-list-0020"> <li> <p>visual inspection of forest plots;</p> </li> <li> <p>the chi² test, with a cut‐off point of P = 0.1; and</p> </li> <li> <p>the I² statistic (heterogeneity was considered if I² value exceeded 50%).</p> </li> </ul> </p> <p>We used a random‐effects model to address heterogeneity, depending on evidence of statistical heterogeneity, and we identified potential sources of heterogeneity. </p> <p>We carried out pre‐planned comparative analyses of outcomes by hormone receptor status, as heterogeny by this tumour demographic parameter was the core topic of the review. Although heterogeny was seen for outcomes in all three scenarios, this disappeared in the adjuvant setting when analysis was performed by hormone receptor status, but not in metastatic or neoadjuvant settings. </p> <p>Additionally, as relevant studies were compiled, it became apparent in both adjuvant and metastatic scenarios that the manner of capecitabine incorporation varied. In the metastatic setting, this could be done by adding capecitabine to an existing regimen, substituting for a component of an existing regimen, or using monotherapy. In the adjuvant setting, capecitabine could be added immediately after surgery as part of standard fully adjuvant treatment, or it could be added sequentially following (neo)adjuvant chemotherapy. Analyses by trial incorporation type were consequently carried out with the goal of assessing impact on heterogeny, and because choice of incorporation method is a pertinent clinical question that the clinician is required to answer when applying trial findings. </p> <p>When we encountered heterogeny that was unexplained by the above sources, we considered further potential clinical factors, including differences in comparator cytotoxic drugs, racial origins of patient populations, drug dosages and schedules, and disease stage. </p> </section> <section id="CD011220-sec-0046"> <h4 class="title">Assessment of reporting biases</h4> <p>Testing for funnel plot asymmetry in this review was limited by the number of studies included for each of the primary outcome measures, as we identified fewer than 10 studies for two of the three arms of this review. However, in the metastatic arm, the number of studies was sufficient, and so funnel plot asymmetry was tested according to the methods listed in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 10.4.3), and this was overseen by our statistician (MB). </p> <p>In some instances, publication bias may not lead to asymmetry in the funnel plot. Furthermore, visual inspection of the funnel plot for asymmetry alone is subjective and may lead to failure to detect publication bias. Thus, funnel plot asymmetry is limited with respect to determination of publication bias. Funnel plot asymmetry may also be caused by: </p> <p> <ul id="CD011220-list-0021"> <li> <p>differences in methodological quality between studies;</p> </li> <li> <p>true heterogeneity between studies; or</p> </li> <li> <p>chance.</p> </li> </ul> </p> <p>Funnel plots were used only in the metastatic setting to detect publication bias. When possible, we reviewed the protocols of included studies in all three settings to assess outcome reporting bias. When additional studies were available from review updates, we assessed publication or other bias by visually examining funnel plot symmetry in neoadjuvant and adjuvant settings, provided at least 10 studies were available for examination in each area. </p> <p>In the metastatic setting, we created funnel plots for OS, PFS, and ORR. In our plots, there were no points in the second half of the plot, which may indicate publication bias; however small and large sample sizes did not yield different results, and studies were few. Supplementary to visual inspection of the funnel plot, we conducted Egger’s test for OS, PFS, and ORR, using R (metaphor package; R). We found no significant results. </p> <p> <ul id="CD011220-list-0022"> <li> <p>OS: t = ‐0.7601, df = 10, P = 0.4647.</p> </li> <li> <p>PFS: t = 1.2136, df = 10, P = 0.2528.</p> </li> <li> <p>ORR: t = ‐0.3509, df = 10, P = 0.7330.</p> </li> </ul> </p> <p>Other possible sources of publication bias considered include duplicate or multiple publication bias, location bias, citation bias, language bias, and outcome reporting bias, all of which could have affected this review. We endeavoured to detect duplicate or multiple publications of the same study, although we appreciated the difficulties involved in doing this. We searched numerous electronic databases, including those of trial registries and those citing grey literature, to minimise location biases. We did not limit our inclusion criteria by language. </p> </section> <section id="CD011220-sec-0047"> <h4 class="title">Data synthesis</h4> <p>We pooled dichotomous outcomes by using the Mantel‐Haenszel fixed‐effect model method. We pooled time‐to‐event outcomes by using the generic inverse‐variance method, allowing a mixture of log‐rank and Cox model estimates to be obtained from these studies. We used <a href="./references#CD011220-bbs2-0140" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan</a> version 5.32 software to perform the analysis. </p> <p>When no events are observed in one or both groups in an individual study, computational problems can occur when relative effect measures (such as odds ratios) are calculated by Mantel‐Haenszel methods. To deal with this, <a href="./references#CD011220-bbs2-0140" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan</a> automatically adds 0.5 to all cells if the same cell is zero in all included studies (see <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, version 5, Chapter 16). <a href="./references#CD011220-bbs2-0140" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan</a> excludes studies from the meta‐analysis when there are no events in both arms, because such studies do not provide any indication of the direction or magnitude of the relative effect (see <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, version 5, Chapter 16). </p> </section> <section id="CD011220-sec-0048"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Some of the pre‐planned subgroup assessments as outlined in the protocol were not performed. Details of this are discussed in the section <a href="#CD011220-sec-0140">Differences between protocol and review</a>. </p> <p>We presented data separately for participants receiving neoadjuvant, adjuvant, and palliative chemotherapy. We also presented data separately for the following pre‐specified patient subgroups. </p> <p> <ul id="CD011220-list-0023"> <li> <p>Hormone receptor‐positive disease.</p> </li> <li> <p>Hormone receptor‐negative disease.</p> </li> <li> <p>Triple‐negative disease.</p> </li> </ul> </p> <p>As previously discussed, after identifying studies that could be categorised by method of capecitabine incorporation, we performed subgroup analyses by study design for all patients and for all hormone receptor subgroups. </p> </section> <section id="CD011220-sec-0049"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analysis to assess the robustness of results. Due to imbalanced reporting of DFS and RFS, we combined these outcomes and performed a sensitivity analysis to ensure that there was not a significant difference due to this. Additionally, in the metastatic setting, we included a pooled analysis (<a href="./references#CD011220-bbs2-0141" title="SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. Oncologist2014;19(5):443-52. [DOI: http://dx.doi.org/10.1634/theoncologist.2013-0428]">Seidman 2014</a>; pooled analysis of <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> and <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>), as primary outcome data by hormone receptor status were not reported individually. We performed a sensitivity analysis to assess the impact of <a href="./references#CD011220-bbs2-0141" title="SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. Oncologist2014;19(5):443-52. [DOI: http://dx.doi.org/10.1634/theoncologist.2013-0428]">Seidman 2014</a>. We acknowledge this to be a source of potential bias in the review process. We initially considered a second pooled analysis for inclusion (<a href="./references#CD011220-bbs2-0089" title="PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. ">Pivot 2016</a>; pooled analysis of <a href="./references#CD011220-bbs2-0035" title="BlumJL , TwelvesCJ , AkereleC , SeegobinS , WandersJ , CortesJ . Abstract P6-13-01: Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or metastatic breast cancer treated with eribulin mesylate: results from the Phase III EMBRACE study 941. Cancer Research2010;70(24 Suppl):6-13. CardosoF , TwelvesC , VahdatLT , DutcusC , SeegobinS , WandersJ , CortesJ , et al. Eribulin mesylate EMBRACE study - Survival analysis excluding patients re-challenged with therapies of the same class. European Journal of Cancer2011;47:S331-2. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , O'ShaughnessyJ , LoeschD , BlumJL , VahdatLT , PetrakovaK , et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet2011;377(9769):914-23. CortesJ , TwelvesC , WandersJ , WangW , VahdatL , DutcusC . Clinical response to eribulin in patients with metastatic breast cancer is independent of time to first metastatic event. EMBRACE Study Group. Breast2011;20(4 Suppl):S48-9. [DOI: 10.1016/j.breast.2011.08.106]DonoghueM , LemergySJ , YuanW , HeK , SridharaR , ShordS , et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a &quot;physician's choice&quot; control arm in a randomized approval trial. Clinical Cancer Research2012;18(6):1496-505. [DOI: 10.1158/1078-0432.CCR-11-2149]TwelvesC , AkereleC , WandersJ , CortesJA . Eribulin mesylate (e7389) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Annals of Oncology2010;21:viii96. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , LoescheD , BlumJL , VahdatLT , PetrakovaK , CholletPJ , et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2010;28(18 Suppl):Abstract no. CRA1004. VahdatLT , TwelvesCJ , SeegobinS , AkereleC , WandersJ , CortesJ . Abstract P6-13-02: Survival outcomes with eribulin mesylate vs. treatment of the physician's choice (TPC) in heavily pretreated subjects with locally recurrent or metastatic breast cancer in North America, Western Europe, and Australia: results of the Phase III EMBRACE Study 942 2699. Cancer Research2010;70(24 Suppl):Abstract no. P6-13-02. ">EMBRACE</a> and <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a>), but subsequently, outcome data by hormone receptor status for <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> were published, and we deemed that, given (1) uncertainty in the heterogeneity of pooled effect estimates, (2) undue weighting of pooled effect estimates, and (3) the small number of patients that <a href="./references#CD011220-bbs2-0035" title="BlumJL , TwelvesCJ , AkereleC , SeegobinS , WandersJ , CortesJ . Abstract P6-13-01: Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or metastatic breast cancer treated with eribulin mesylate: results from the Phase III EMBRACE study 941. Cancer Research2010;70(24 Suppl):6-13. CardosoF , TwelvesC , VahdatLT , DutcusC , SeegobinS , WandersJ , CortesJ , et al. Eribulin mesylate EMBRACE study - Survival analysis excluding patients re-challenged with therapies of the same class. European Journal of Cancer2011;47:S331-2. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , O'ShaughnessyJ , LoeschD , BlumJL , VahdatLT , PetrakovaK , et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet2011;377(9769):914-23. CortesJ , TwelvesC , WandersJ , WangW , VahdatL , DutcusC . Clinical response to eribulin in patients with metastatic breast cancer is independent of time to first metastatic event. EMBRACE Study Group. Breast2011;20(4 Suppl):S48-9. [DOI: 10.1016/j.breast.2011.08.106]DonoghueM , LemergySJ , YuanW , HeK , SridharaR , ShordS , et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a &quot;physician's choice&quot; control arm in a randomized approval trial. Clinical Cancer Research2012;18(6):1496-505. [DOI: 10.1158/1078-0432.CCR-11-2149]TwelvesC , AkereleC , WandersJ , CortesJA . Eribulin mesylate (e7389) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Annals of Oncology2010;21:viii96. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , LoescheD , BlumJL , VahdatLT , PetrakovaK , CholletPJ , et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2010;28(18 Suppl):Abstract no. CRA1004. VahdatLT , TwelvesCJ , SeegobinS , AkereleC , WandersJ , CortesJ . Abstract P6-13-02: Survival outcomes with eribulin mesylate vs. treatment of the physician's choice (TPC) in heavily pretreated subjects with locally recurrent or metastatic breast cancer in North America, Western Europe, and Australia: results of the Phase III EMBRACE Study 942 2699. Cancer Research2010;70(24 Suppl):Abstract no. P6-13-02. ">EMBRACE</a> contributed to the overall number of patients in the pooled analysis (44 patients from <a href="./references#CD011220-bbs2-0035" title="BlumJL , TwelvesCJ , AkereleC , SeegobinS , WandersJ , CortesJ . Abstract P6-13-01: Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or metastatic breast cancer treated with eribulin mesylate: results from the Phase III EMBRACE study 941. Cancer Research2010;70(24 Suppl):6-13. CardosoF , TwelvesC , VahdatLT , DutcusC , SeegobinS , WandersJ , CortesJ , et al. Eribulin mesylate EMBRACE study - Survival analysis excluding patients re-challenged with therapies of the same class. European Journal of Cancer2011;47:S331-2. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , O'ShaughnessyJ , LoeschD , BlumJL , VahdatLT , PetrakovaK , et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet2011;377(9769):914-23. CortesJ , TwelvesC , WandersJ , WangW , VahdatL , DutcusC . Clinical response to eribulin in patients with metastatic breast cancer is independent of time to first metastatic event. EMBRACE Study Group. Breast2011;20(4 Suppl):S48-9. [DOI: 10.1016/j.breast.2011.08.106]DonoghueM , LemergySJ , YuanW , HeK , SridharaR , ShordS , et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a &quot;physician's choice&quot; control arm in a randomized approval trial. Clinical Cancer Research2012;18(6):1496-505. [DOI: 10.1158/1078-0432.CCR-11-2149]TwelvesC , AkereleC , WandersJ , CortesJA . Eribulin mesylate (e7389) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Annals of Oncology2010;21:viii96. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , LoescheD , BlumJL , VahdatLT , PetrakovaK , CholletPJ , et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2010;28(18 Suppl):Abstract no. CRA1004. VahdatLT , TwelvesCJ , SeegobinS , AkereleC , WandersJ , CortesJ . Abstract P6-13-02: Survival outcomes with eribulin mesylate vs. treatment of the physician's choice (TPC) in heavily pretreated subjects with locally recurrent or metastatic breast cancer in North America, Western Europe, and Australia: results of the Phase III EMBRACE Study 942 2699. Cancer Research2010;70(24 Suppl):Abstract no. P6-13-02. ">EMBRACE</a>, out of a total of 698 in the pooled analysis), it would pose less of a risk of potential bias to exclude both <a href="./references#CD011220-bbs2-0035" title="BlumJL , TwelvesCJ , AkereleC , SeegobinS , WandersJ , CortesJ . Abstract P6-13-01: Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or metastatic breast cancer treated with eribulin mesylate: results from the Phase III EMBRACE study 941. Cancer Research2010;70(24 Suppl):6-13. CardosoF , TwelvesC , VahdatLT , DutcusC , SeegobinS , WandersJ , CortesJ , et al. Eribulin mesylate EMBRACE study - Survival analysis excluding patients re-challenged with therapies of the same class. European Journal of Cancer2011;47:S331-2. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , O'ShaughnessyJ , LoeschD , BlumJL , VahdatLT , PetrakovaK , et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet2011;377(9769):914-23. CortesJ , TwelvesC , WandersJ , WangW , VahdatL , DutcusC . Clinical response to eribulin in patients with metastatic breast cancer is independent of time to first metastatic event. EMBRACE Study Group. Breast2011;20(4 Suppl):S48-9. [DOI: 10.1016/j.breast.2011.08.106]DonoghueM , LemergySJ , YuanW , HeK , SridharaR , ShordS , et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a &quot;physician's choice&quot; control arm in a randomized approval trial. Clinical Cancer Research2012;18(6):1496-505. [DOI: 10.1158/1078-0432.CCR-11-2149]TwelvesC , AkereleC , WandersJ , CortesJA . Eribulin mesylate (e7389) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Annals of Oncology2010;21:viii96. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , LoescheD , BlumJL , VahdatLT , PetrakovaK , CholletPJ , et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2010;28(18 Suppl):Abstract no. CRA1004. VahdatLT , TwelvesCJ , SeegobinS , AkereleC , WandersJ , CortesJ . Abstract P6-13-02: Survival outcomes with eribulin mesylate vs. treatment of the physician's choice (TPC) in heavily pretreated subjects with locally recurrent or metastatic breast cancer in North America, Western Europe, and Australia: results of the Phase III EMBRACE Study 942 2699. Cancer Research2010;70(24 Suppl):Abstract no. P6-13-02. ">EMBRACE</a> and <a href="./references#CD011220-bbs2-0089" title="PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. ">Pivot 2016</a>. </p> </section> <section id="CD011220-sec-0050"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach to assess the certainty of evidence and <a href="https://archie.cochrane.org/sections/documents/view?version=z2003052218286570504522650374196&amp;format=JATS#REF-GRADEproGDT" target="_blank">GRADEproGDT</a> software to develop the 'Summary of findings' table, in accordance with GRADE guidance (<a href="https://archie.cochrane.org/sections/documents/view?version=z2003052218286570504522650374196&amp;format=JATS#REF-GRADEproGDT" target="_blank">GRADEproGDT</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z2003052218286570504522650374196&amp;format=JATS#REF-Sch_x00fc_nemann-2019" target="_blank">Schünemann 2019</a>). Two review authors (TB, MW) graded the certainty of evidence for this review update. </p> <p>Key outcomes for palliative chemotherapy were overall survival, progression‐free survival, objective response rate, and quality of life; for neoadjuvant chemotherapy pCR, disease‐free survival, overall survival, febrile neutropenia, diarrhoea, and hand‐foot syndrome; and for adjuvant chemotherapy disease‐free survival, overall survival, febrile neutropenia, diarrhoea, and hand‐foot syndrome. </p> <p>To calculate absolute risk of the comparator group for time‐to‐event outcomes, we estimated the event rate at specific time points (i.e. palliative chemotherapy: one year for overall survival and progression‐free survival; neoadjuvant chemotherapy: five years for disease‐free survival and overall survival; adjuvant chemotherapy: disease‐free survival and overall survival) from the Kaplan‐Meier curves or reported event rates. We entered these estimated values into <a href="https://archie.cochrane.org/sections/documents/view?version=z2003052218286570504522650374196&amp;format=JATS#REF-GRADEproGDT" target="_blank">GRADEproGDT</a>, and corresponding absolute risks for the intervention group at one or five years were automatically populated by <a href="https://archie.cochrane.org/sections/documents/view?version=z2003052218286570504522650374196&amp;format=JATS#REF-GRADEproGDT" target="_blank">GRADEproGDT</a>. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011220-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011220-sec-0051"></div> <section id="CD011220-sec-0052"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011220-sec-0142" title="">Characteristics of included studies</a>; <a href="./references#CD011220-sec-0143" title="">Characteristics of excluded studies</a>; Characteristics of studies awaiting classification; and Characteristics of ongoing studies. </p> <section id="CD011220-sec-0053"> <h4 class="title">Results of the search</h4> <p>The capecitabine‐related terms outlined in the search strategy yielded 4105 records through medical databases, the Specialised Register, clinical trial registers, and handsearching (see <a href="#CD011220-fig-0001">Figure 1</a>). Following duplicate exclusion and initial screening, 525 records remained for full‐text review. A further 498 references initially deemed potentially eligible were excluded; the most common reasons for exclusion were irrelevance to the review question (105), representing a review or meta‐analysis (80), involving a wrong comparator (62), and having inadequate outcome data reported by hormone receptor status (50), leaving 26 suitable studies for inclusion in the review. </p> <div class="figure" id="CD011220-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram." data-id="CD011220-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> </div> </section> <section id="CD011220-sec-0054"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD011220-sec-0142" title="">Characteristics of included studies</a> and <a href="#CD011220-tbl-0004">Table 1</a>, which outline the treatment regimens across studies. </p> <p>A total of 26 RCTs evaluated the efficacy of capecitabine in breast cancer, with available outcome data stratified by hormone receptor status, ER status, or TNBC status. Metastatic RCTs (n = 12) included <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>, <a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a>, <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a>, <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a>, <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a>, <a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a>, <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a>, <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>, <a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>, <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a>, <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a>, <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>, and <a href="./references#CD011220-bbs2-0141" title="SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. Oncologist2014;19(5):443-52. [DOI: http://dx.doi.org/10.1634/theoncologist.2013-0428]">Seidman 2014</a> (pooled analysis of <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> and <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>). The six neoadjuvant RCTs included were <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>, <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a>, <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>, <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>, <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a>, and <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a>. The eight adjuvant studies that provided data by hormone receptor or TNBC status were <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>, <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>, <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>, <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>, <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>, <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>, <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>, and <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>. </p> <p>All metastatic trials except one ‐ <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> ‐ have been published in peer‐reviewed journals. The overall number of patients ranged from 53 in <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a> (single centre, phase 2) to 1102 in <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> (169 sites, phase 3). Median follow‐up of trials varied from 18.6 months in <a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a> to 37.6 months in <a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>. Although the proportion of patients with unknown hormone receptor status exceeded our threshold of 25% in <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>, this study was nevertheless included based on the details of available data. Both <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> and <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> compared docetaxel‐gemcitabine versus docetaxel‐capecitabine. The dose of capecitabine was higher in <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> (1250 mg/m² twice daily) than in <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> (1000 mg/m² twice daily), but schedules were identical in all other respects. <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> included cross‐over to docetaxel‐capecitabine, but ORR and first‐line PFS data stratified by hormone receptor status were included in the analysis. The results of <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> and <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> were combined into a pooled analysis, which has been included, as it includes further outcomes stratified by hormone receptor status not reported in either of the original studies. <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a> included HER2‐positive breast cancer only. <a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a> included ER‐positive patients only. <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a> and <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> included TNBC patients only. All other trials contained both hormone receptor‐positive and ‐negative patients. </p> <p>Of the adjuvant trials, <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>, <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>, <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>, <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>, and <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a> have been published in peer‐reviewed journals. The remaining adjuvant studies have been presented as conference abstracts or presentations only. The overall number of patients ranged from 636 in <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> to 4391 in <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>. Median follow‐up varied from 2.5 years in the TNBC‐only <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> trial to 10.3 years in <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>. <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>, <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>, <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>, and <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> are adjuvant RCTs investigating the addition or substitution of capecitabine in the taxane component of standard anthracycline‐taxane‐containing regimens, and in the case of <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>, this was limited to a TNBC‐only population. <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a> investigated anthracycline‐taxane (epirubicin‐docetaxel) with sequential capecitabine versus epirubicin‐cyclophosphamide and sequential docetaxel. <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a> and <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> were adjuvant trials investigating capecitabine in patients following prior neoadjuvant chemotherapy, with <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a> including only those HER2‐negative patients who did not achieve pCR with standard anthracycline‐taxane‐containing neoadjuvant chemotherapy, and <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> including TNBC patients regardless of response to neoadjuvant chemotherapy. <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a> was the only trial examining the addition of capecitabine to a bisphosphonate versus a bisphosphonate alone. <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>, <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>, <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>, <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>, and <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a> comprised predominantly Caucasian populations, whereas <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> and <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a> were recruited from Asian countries only. <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> was predominantly recruited from South America or Spain. <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a> investigated "elderly" patients (aged 65 or over), whereas all other trials did not apply this restriction. Trastuzumab was provided for HER2‐positive breast cancer patients in <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>, <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>, <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>, and <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>. In <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>, 18.8% of patients were HER2‐positive but did not receive HER2‐targeted therapy. <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>, <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>, and <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> excluded HER2‐positive patients. </p> <p>All data acquired from neoadjuvant RCTs have been published in peer‐reviewed journals. The overall number of patients ranged from 75 in <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a> to 1421 in <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>. Median follow‐up varied from 4.4 years in <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a> to 5.4 years in <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>. The primary endpoint of <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a> was addition of capecitabine or gemcitabine to an anthracycline‐taxane‐containing neoadjuvant chemotherapy regimen with or without bevacizumab. All other trials did not include bevacizumab‐containing regimens. Pathological complete response was the primary endpoint for all trials. <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>, <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a>, and <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a> were derived from Chinese Asian populations. All other trials involved primarily Caucasian populations. </p> <p>All trials were open‐label studies, and no trial randomised participants to an oral placebo in non‐capecitabine arms. All adjuvant trials were phase 3 studies. <a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>, <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a>, <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a>, and <a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a> were phase 2 metastatic studies, and <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a> was a phase 2 neoadjuvant trial. </p> <p>With regards to sponsorship, Hoffman La Roche/Genentech were sole funders of <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>, <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a>, <a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a>, <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>, <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a>, and <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>, and they co‐funded <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>, <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>, <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>, <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a>, <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>, and <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>. Eisai Pharmaceuticals was the sole sponsor for <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> and <a href="./references#CD011220-bbs2-0035" title="BlumJL , TwelvesCJ , AkereleC , SeegobinS , WandersJ , CortesJ . Abstract P6-13-01: Impact of the number of prior chemotherapy regimens on overall survival (OS) among subjects with locally recurrent or metastatic breast cancer treated with eribulin mesylate: results from the Phase III EMBRACE study 941. Cancer Research2010;70(24 Suppl):6-13. CardosoF , TwelvesC , VahdatLT , DutcusC , SeegobinS , WandersJ , CortesJ , et al. Eribulin mesylate EMBRACE study - Survival analysis excluding patients re-challenged with therapies of the same class. European Journal of Cancer2011;47:S331-2. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , O'ShaughnessyJ , LoeschD , BlumJL , VahdatLT , PetrakovaK , et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet2011;377(9769):914-23. CortesJ , TwelvesC , WandersJ , WangW , VahdatL , DutcusC . Clinical response to eribulin in patients with metastatic breast cancer is independent of time to first metastatic event. EMBRACE Study Group. Breast2011;20(4 Suppl):S48-9. [DOI: 10.1016/j.breast.2011.08.106]DonoghueM , LemergySJ , YuanW , HeK , SridharaR , ShordS , et al. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a &quot;physician's choice&quot; control arm in a randomized approval trial. Clinical Cancer Research2012;18(6):1496-505. [DOI: 10.1158/1078-0432.CCR-11-2149]TwelvesC , AkereleC , WandersJ , CortesJA . Eribulin mesylate (e7389) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC): subgroup analyses from the EMBRACE study. Annals of Oncology2010;21:viii96. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , LoescheD , BlumJL , VahdatLT , PetrakovaK , CholletPJ , et al. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2010;28(18 Suppl):Abstract no. CRA1004. VahdatLT , TwelvesCJ , SeegobinS , AkereleC , WandersJ , CortesJ . Abstract P6-13-02: Survival outcomes with eribulin mesylate vs. treatment of the physician's choice (TPC) in heavily pretreated subjects with locally recurrent or metastatic breast cancer in North America, Western Europe, and Australia: results of the Phase III EMBRACE Study 942 2699. Cancer Research2010;70(24 Suppl):Abstract no. P6-13-02. ">EMBRACE</a>. Eli Lily was the sole sponsor for <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> and <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>, and this company co‐funded <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>. Sanofi‐Aventis co‐funded <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>, <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>, <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>, <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a>, and <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>. AstraZeneca co‐funded <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a> and <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>. Pfizer co‐funded <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>. Studies with no reported pharmaceutical funding included <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a>, <a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a>, <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>, <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>, and <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a>. </p> </section> <section id="CD011220-sec-0055"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD011220-sec-0143" title="">Characteristics of excluded studies</a>. </p> <p>We assessed the full text of 525 studies and immediately excluded 414 studies; the most common primary reasons for exclusion were irrelevant (105), duplicate (85), review paper or meta‐analysis (80), wrong comparator (62), and RCT status unknown or still recruiting with no published results (55). After detailed assessment, we excluded a further 91 studies initially thought to be eligible based on initial protocol criteria; the most common primary reasons for exclusion were inadequate outcome data reported by hormone receptor status (50), wrong study design (24), and absence of reported results (23). A full breakdown of the reasons for exclusion is given in <a href="#CD011220-fig-0001">Figure 1</a>. </p> </section> </section> <section id="CD011220-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD011220-fig-0002">Figure 2</a>, <a href="#CD011220-fig-0003">Figure 3</a> and <a href="#CD011220-fig-0004">Figure 4</a> summarise the risk of bias of all included studies. </p> <div class="figure" id="CD011220-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph for metastatic studies." data-id="CD011220-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph for metastatic studies.</p> </div> </div> </div> <div class="figure" id="CD011220-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph for adjuvant studies." data-id="CD011220-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph for adjuvant studies.</p> </div> </div> </div> <div class="figure" id="CD011220-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias graph for neoadjuvant studies." data-id="CD011220-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph for neoadjuvant studies.</p> </div> </div> </div> <section id="CD011220-sec-0057"> <h4 class="title">Allocation</h4> <p>Most of the included studies did not explicitly comment on allocation concealment. We judged those that had centralised randomisation to be at low risk of selection bias. </p> <section id="CD011220-sec-0058"> <h5 class="title">Metastatic settings</h5> <p>Three trials described centralised randomisation without explicit comment on allocation concealment (<a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>; <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>; <a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a>). We judged these to be at low risk of selection bias. </p> <p>Multiple trials did not provide any description of randomisation methods, but given that they were large multi‐centre trials, we judged them to likely have used at least reasonable randomisation methods (<a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a>; <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a>; <a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a>; <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>; <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a>; <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a>). As no description of randomisation method or allocation concealment was provided, we judged these studies to be at unclear risk of selection bias. </p> <p><a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> did not explicitly comment on randomisation method nor on allocation concealment. Given that this study was reported only by poster and abstract, we deemed it to be at unclear risk of selection bias. </p> <p>We judged <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a> to be at high risk of selection bias, as it was a single‐centre trial with no explicit comment on randomisation process or allocation concealment. </p> </section> <section id="CD011220-sec-0059"> <h5 class="title">Neoadjuvant settings</h5> <p>We judged <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a> and <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a> to be at high risk of selection bias, as both were single‐centre trials that provided no explicit comment on the randomisation process nor on allocation concealment. </p> <p>We judged all other trials in this setting to be at low risk of selection bias (<a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a>; <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>; <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>; <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>). </p> </section> <section id="CD011220-sec-0060"> <h5 class="title">Adjuvant settings</h5> <p>We judged <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a> to be at unclear risk, as it has yet to be fully reported, and no details regarding randomisation or allocation concealment were included in any of the information released thus far. <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> also has yet to be fully reported, but this is a very large multi‐centre multi‐national trial, and we deemed it likely to include adequate randomisation methods but to be at unclear risk in terms of allocation concealment. </p> <p>We judged all other trials in this setting to be at low risk of selection bias (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>; <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>). </p> </section> </section> <section id="CD011220-sec-0061"> <h4 class="title">Blinding</h4> <p>We judged that all open‐label studies were at high risk of performance bias. Regarding detection bias, we separated risks by outcomes relevant to each setting. We judged that given both the open‐label nature of all studies and the large difference in toxicity profiles between capecitabine and heterogenous comparators, all toxicity outcomes would be at high risk, regardless of the setting. </p> <section id="CD011220-sec-0062"> <h5 class="title">Metastatic settings</h5> <p>We judged that the outcomes of PFS, OS, ORR, CBR, QoL, and toxicity were most relevant in this setting. </p> <p>We considered that assessment of OS would not be affected by blinding and thus carried low risk. We considered that given the heterogeneity of treatment arms, all studies were unblinded, the outcome was highly subjective, and QoL was judged to be at unclear risk. </p> <p>We considered that when tumour assessment was required (PFS, CBR, ORR), utilisation of centralised radiological assessment would render a trial at low risk; only two studies used centralised radiological assessment and thus were deemed at low risk (<a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a>; <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>). If it was not specified whether centralised radiological assessment was performed, we determined the study to be at high risk (<a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a>; <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a>; <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a>; <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>; <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>; <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a>; <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a>; <a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a>). </p> </section> <section id="CD011220-sec-0063"> <h5 class="title">Neoadjuvant settings</h5> <p>We judged that outcomes of pCR, DFS, and toxicity were most relevant in this setting. We considered that assessment of DFS would not be affected by blinding, and this would suggest low risk. All studies except <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> and <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a> reported DFS. We judged that the outcome of pCR would not be affected by blinding, and thus all neoadjuvant studies would be at low risk (<a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a>; <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>; <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>; <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>; <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a>; <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a>). </p> </section> <section id="CD011220-sec-0064"> <h5 class="title">Adjuvant settings</h5> <p>We judged that the outcomes of DFS, OS, and toxicity were most relevant in this setting. All studies reported these outcomes (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>; <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>; <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>; <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>; <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>), except <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>, which reported RFS instead of DFS. <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> reported both DFS and RFS. We considered that the outcomes of DFS, RFS, and OS would not be affected by blinding and thus carried low risk of detection bias. </p> </section> </section> <section id="CD011220-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>We judged that all studies that reported outcomes by intention‐to‐treat population with accountability for attrition were at low risk of attrition bias. </p> <section id="CD011220-sec-0066"> <h5 class="title">Metastatic settings</h5> <p>We judged <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a> and <a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a> to be at high risk, as not all patients were included in the intention‐to‐treat analysis. We judged the remaining studies to be at low risk of attrition bias. </p> <p>We judged <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> to be at unclear risk, as this study has not been published at the time of writing, and study authors did not report attrition numbers. </p> </section> <section id="CD011220-sec-0067"> <h5 class="title">Neoadjuvant settings</h5> <p>We judged <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a> to be at high risk, as not all randomised patients were included in the intention‐to‐treat analysis. </p> </section> <section id="CD011220-sec-0068"> <h5 class="title">Adjuvant settings</h5> <p>We judged <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> and <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> to be at unclear risk, as these studies had not been published at the time of writing and consequently attrition numbers were not reported. <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a> has not been published at the time of writing, but we believe that reporting of those who ceased treatment was adequate. We judged all other studies to be at low risk of attrition bias (<a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>; <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>; <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>). </p> </section> </section> <section id="CD011220-sec-0069"> <h4 class="title">Selective reporting</h4> <p>We judged that all studies that adequately reported primary and secondary outcomes as well as toxicities were at low risk of reporting bias. </p> <section id="CD011220-sec-0070"> <h5 class="title">Metastatic settings</h5> <p>We deemed <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a> to be at high risk of reporting bias because reporting by hormone receptor status was incomplete. We deemed <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a> to be at high risk of reporting bias, as the secondary endpoints of quality of life and overall survival were not fully reported. We judged <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> to be at high risk, as not all patients were assessed for response, and of those who were assessed, not all were assessed for the primary endpoint of time to progression. We judged <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> to be at high risk of reporting bias, as the secondary endpoint of clinical benefit rate was not reported. </p> <p>We judged <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a> to be at unclear risk of reporting bias, as some data were not yet mature at the time of writing. <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> was not yet published, but these authors appeared to have reported all relevant primary and secondary outcomes, and we judged this study to be at low risk of reporting bias. </p> <p>We judged <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> to be at unclear risk of reporting bias, as outcomes by hormone receptor status were not pre‐planned. </p> <p>We judged the remaining six trials to be at low risk of reporting bias.</p> </section> <section id="CD011220-sec-0071"> <h5 class="title">Neoadjuvant settings</h5> <p>We deemed <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> to be at high risk due to inadequate toxicity reporting, as well as to reporting of multiple additional non‐pre‐specified endpoints and use of a non‐pre‐specified definition for "pCR breast and nodes". Additionally, we excluded HER2‐positive patients from the "non‐TNBC" group; thus reporting is incomplete. </p> <p>We judged the other studies to be at low risk of reporting bias.</p> </section> <section id="CD011220-sec-0072"> <h5 class="title">Adjuvant settings</h5> <p>We judged <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> to have unclear risk, as this study had not been published at the time of writing, and all primary and secondary endpoints were not yet reported. We judged all other studies to have low risk of reporting bias. </p> </section> </section> <section id="CD011220-sec-0073"> <h4 class="title">Other potential sources of bias</h4> <section id="CD011220-sec-0074"> <h5 class="title">Metastatic settings</h5> <p><a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> and <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> underwent subsequent pooled analysis. We judged these studies to be at unclear risk of other bias due to the post‐hoc unplanned nature of the additional analyses. Additionally, we judged <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> to be at unclear risk, as we judged that cross‐over could potentially dilute survival outcomes. </p> <p><a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> underwent subsequent extensive unplanned post‐hoc analyses. Thus, we judged this study to be at unclear risk of bias. </p> <p>We judged <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> to be at unclear risk, as it had not been published at the time of writing. </p> <p>We judged <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> to be at high risk due to early termination of the study due to futility. Additionally, patients initially treated with docetaxel then received paclitaxel due to changes in the licensing of taxane‐bevacizumab, creating heterogeneity in the control arm. </p> <p>We detected no other potential sources of bias in the remaining trials.</p> </section> <section id="CD011220-sec-0075"> <h5 class="title">Neoadjuvant settings</h5> <p>We deemed <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a> to be at high risk of other bias due to unclear reporting of adjuvant treatments, including other chemotherapy, endocrine treatment, and trastuzumab. These weaknesses could influence DFS and OS but did not affect pCR, the primary endpoint of the study. We deemed <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> to be at unclear risk of other bias, as clinically relevant endpoints (OS, DFS) were not included. <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a> also did not report these outcomes but did specify that reporting was planned in due course when the adjuvant component of the trial was complete. As such, we judged this not to be a potential source of bias. </p> <p>We detected no other potential sources of bias in the remaining three trials.</p> </section> <section id="CD011220-sec-0076"> <h5 class="title">Adjuvant settings</h5> <p>We judged <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>, <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>, and <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a> to be at unclear risk, as they were unpublished at the time of writing. </p> <p>We judged that <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a> had a number of issues that could bias outcomes in certain cohorts, and thus DFS outcomes. First, the study excluded from neoadjuvant chemotherapy patients who achieved pCR, thus selecting patients with a potentially worse prognosis. Additionally, in the TNBC cohort design, capecitabine was compared with no treatment, whereas in the hormone receptor‐positive cohort design, capecitabine + AI/tamoxifen was compared with AI/tamoxifen. The consensus was that this could cause potential bias towards the study arm in the TNBC cohort and could influence DFS outcomes. </p> <p>We detected no other potential sources of bias in the remaining trials.</p> </section> </section> </section> <section id="CD011220-sec-0077"> <h3 class="title" id="CD011220-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD011220-tbl-0001"><b>Summary of findings 1</b> Capecitabine‐containing regimens compared to chemotherapy regimens without capecitabine for metastatic breast cancer</a>; <a href="./full#CD011220-tbl-0002"><b>Summary of findings 2</b> Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens for neoadjuvant treatment</a>; <a href="./full#CD011220-tbl-0003"><b>Summary of findings 3</b> Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens or no chemotherapy for early breast cancer</a> </p> <section id="CD011220-sec-0078"> <h4 class="title">Metastatic setting</h4> <p>Twelve studies (75 records) referred to 10 different treatment comparisons in the metastatic setting (<a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>; <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a>; <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a>; <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a>; <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>; <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a>; <a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a>; <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>; <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>; <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a>; <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a>; <a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a>). See <a href="./full#CD011220-tbl-0001">summary of findings Table 1</a>. </p> <p>Of the 12 studies, four used capecitabine monotherapy, four added capecitabine to a chemotherapy regimen, and the remaining four substituted capecitabine into a chemotherapy regimen. </p> <section id="CD011220-sec-0079"> <h5 class="title">Overall survival</h5> <p>Twelve studies with 4325 participants reported data on overall survival (OS). These demonstrated no difference in mortality in capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (hazard ratio (HR) 1.01, 95% confidence interval (CI) 0.98 to 1.05; high‐certainty evidence; <a href="./references#CD011220-fig-0008" title="">Analysis 1.1</a>), although with relatively high heterogeneity (I² = 67%). The four studies adding capecitabine to standard chemotherapy regimens demonstrated moderate improvement in mortality (HR 0.78, 95% CI 0.66 to 0.92; <a href="./references#CD011220-fig-0033" title="">Analysis 3.1</a>). Neither capecitabine monotherapy nor capecitabine substitution demonstrated this benefit (four studies ‐ capecitabine monotherapy; HR 1.00, 95% CI 0.93 to 1.08; <a href="./references#CD011220-fig-0022" title="">Analysis 2.1</a>; four studies ‐ capecitabine substitution; HR 1.03, 95% CI 0.99 to 1.07; <a href="./references#CD011220-fig-0046" title="">Analysis 4.1</a>). Heterogeneity remained high across all subgroup analyses of capecitabine addition by trial design type when unsegregated by hormone receptor status. A funnel plot and Egger's test did not support any publication bias for the studies reviewed (<a href="#CD011220-fig-0005">Figure 5</a>; Egger's test: P = 0.47). </p> <div class="figure" id="CD011220-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.1 OS all." data-id="CD011220-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.1 OS all. </p> </div> </div> </div> <section id="CD011220-sec-0080"> <h6 class="title">Hormone receptor‐positive disease</h6> <p>Seven studies with 1834 participants reported data on OS in patients with hormone receptor‐positive disease. These studies demonstrated no difference in mortality for capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (HR 0.93, 95% CI 0.84 to 1.04; high‐certainty evidence; <a href="./references#CD011220-fig-0009" title="">Analysis 1.2</a>), although with high heterogeneity (I² = 65%). The addition of capecitabine demonstrated a substantial difference in OS in patients with hormone receptor‐positive disease (HR 0.62, 95% CI 0.47 to 0.81; <a href="./references#CD011220-fig-0034" title="">Analysis 3.2</a>), with low heterogeneity. However, only two studies reported outcomes in this particular setting. Neither capecitabine as monotherapy nor substitution of capecitabine into standard chemotherapy regimens demonstrated any benefit in OS for hormone receptor‐positive disease (three studies ‐ capecitabine monotherapy; HR 1.00, 95% CI 0.86 to 1.17; <a href="./references#CD011220-fig-0023" title="">Analysis 2.2</a>; two studies ‐ capecitabine substitution; HR 1.02, 95% CI 0.84 to 1.23; <a href="./references#CD011220-fig-0047" title="">Analysis 4.2</a>), although with high heterogeneity in both cases (I² &gt; 50%). </p> </section> <section id="CD011220-sec-0081"> <h6 class="title">Hormone receptor‐negative disease</h6> <p>Eight studies with 1577 participants reported data on OS in patients with hormone receptor‐negative disease. These studies demonstrated no difference in mortality in the overall comparison between capecitabine‐containing regimens and non‐capecitabine‐containing regimens (HR 1.00, 95% CI 0.88 to 1.13; high‐certainty evidence; <a href="./references#CD011220-fig-0010" title="">Analysis 1.3</a>), with high heterogeneity (I² = 63%). The addition of capecitabine showed a non‐significant trend towards benefit (two studies ‐ HR 0.79, 95% CI 0.59 to 1.06; <a href="./references#CD011220-fig-0035" title="">Analysis 3.3</a>), with high heterogeneity (I² = 70%), whereas neither capecitabine monotherapy (three studies ‐ HR 1.09, 95% CI 0.91 to 1.29; <a href="./references#CD011220-fig-0024" title="">Analysis 2.3</a>) nor substitution with capecitabine (three studies ‐ HR 1.00, 95% CI 0.79 to 1.26; <a href="./references#CD011220-fig-0048" title="">Analysis 4.3</a>) showed any difference in OS, although again both with high heterogeneity (I² &gt; 50%). </p> </section> <section id="CD011220-sec-0082"> <h6 class="title">Triple‐negative disease</h6> <p>Five studies reported OS outcomes with patients with triple‐negative disease, and these studies demonstrated increased mortality with capecitabine (HR 1.20, 95% CI 1.01 to 1.43; <a href="./references#CD011220-fig-0011" title="">Analysis 1.6</a>), again with high heterogeneity (I² = 69%). There was no difference in OS for capecitabine monotherapy (two studies ‐ HR 1.19, 95% CI 0.98 to 1.45; <a href="./references#CD011220-fig-0025" title="">Analysis 2.4</a>), with high heterogeneity (I² = 76%), or substitution with capecitabine (two studies ‐ HR 1.59, 95% CI 1.03 to 2.43; <a href="./references#CD011220-fig-0049" title="">Analysis 4.4</a>), with low heterogeneity. Only <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a> reported OS for the addition of capecitabine in triple‐negative disease, which showed a strong trend towards OS benefit (HR 0.44, 95% CI 0.19 to 1.02). </p> </section> </section> <section id="CD011220-sec-0083"> <h5 class="title">Progression‐free survival</h5> <p>Twelve studies with 4325 participants reported data on progression‐free survival (PFS). These demonstrated a small improvement in PFS in capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (HR 0.89, 95% CI 0.82 to 0.96; moderate‐certainty evidence; <a href="./references#CD011220-fig-0012" title="">Analysis 1.7</a>), with high heterogeneity (I² = 84%). A funnel plot and Egger's test did not support any publication bias for the studies reviewed (<a href="#CD011220-fig-0006">Figure 6</a>; Egger's test: P = 0.26). </p> <div class="figure" id="CD011220-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.7 PFS all." data-id="CD011220-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.7 PFS all. </p> </div> </div> </div> <p>A more substantial effect was seen with the addition of capecitabine (four studies ‐ HR 0.69, 95% CI 0.60 to 0.78; <a href="./references#CD011220-fig-0037" title="">Analysis 3.5</a>), again with high heterogeneity (I² = 82%). However there was no difference in PFS with capecitabine monotherapy (four studies ‐ HR 0.92, 95% CI 0.82 to 1.04; <a href="./references#CD011220-fig-0026" title="">Analysis 2.5</a>), with low heterogeneity, or with capecitabine substitution (four studies ‐ HR 1.06, 95% CI 0.93 to 1.20; <a href="./references#CD011220-fig-0050" title="">Analysis 4.5</a>), with high heterogeneity (I² = 87%). </p> <section id="CD011220-sec-0084"> <h6 class="title">Hormone receptor‐positive disease</h6> <p>Seven studies with 1594 participants reported data on PFS for patients with hormone receptor‐positive disease. These data show a small improvement in PFS in the comparison between capecitabine‐containing regimens and non‐capecitabine‐containing regimens (HR 0.82, 95% CI 0.73 to 0.91; moderate‐certainty evidence; <a href="./references#CD011220-fig-0013" title="">Analysis 1.8</a>), with high heterogeneity (I² = 81%). This effect was present and was of similar magnitude for the use of capecitabine monotherapy (three studies ‐ HR 0.84, 95% CI 0.72 to 0.99; <a href="./references#CD011220-fig-0027" title="">Analysis 2.6</a>), with low heterogeneity, and was more substantial for the addition of capecitabine (three studies ‐ HR 0.67, 95% CI 0.55 to 0.82; <a href="./references#CD011220-fig-0038" title="">Analysis 3.6</a>), although with high heterogeneity (I² = 91%). The only study that substituted capecitabine into a chemotherapy regimen and reported outcome data for PFS in hormone receptor‐positive disease was the pooled analysis (<a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>), which did not demonstrate any improvement (HR 0.95, 95% CI 0.78 to 1.17; <a href="./references#CD011220-fig-0051" title="">Analysis 4.6</a>). </p> </section> <section id="CD011220-sec-0085"> <h6 class="title">Hormone receptor‐negative disease</h6> <p>Seven studies with 1122 participants reported data on PFS in patients with hormone receptor‐negative disease. These studies showed no difference in PFS in the comparison between capecitabine‐containing regimens and non‐capecitabine‐containing regimens (HR 0.96, 95% CI 0.83 to 1.10; moderate‐certainty evidence; <a href="./references#CD011220-fig-0014" title="">Analysis 1.9</a>), with low heterogeneity. This finding was consistent across both capecitabine monotherapy (three studies ‐ HR 1.01, 95% CI 0.84 to 1.21; <a href="./references#CD011220-fig-0028" title="">Analysis 2.7</a>), with low heterogeneity, and substitution of capecitabine into a chemotherapy regimen (two studies ‐ HR 1.02, 95% CI 0.79 to 1.31; <a href="./references#CD011220-fig-0052" title="">Analysis 4.7</a>), with high heterogeneity (I² = 93%). The addition of capecitabine demonstrated improvement in PFS in the two studies reporting this outcome for hormone receptor‐negative patients (HR 0.60, 95% CI 0.39 to 0.93; <a href="./references#CD011220-fig-0039" title="">Analysis 3.7</a>), with low heterogeneity. </p> </section> <section id="CD011220-sec-0086"> <h6 class="title">Triple‐negative disease</h6> <p>Five studies reported data on PFS in patients with TNBC. These data show worse PFS for capecitabine‐containing regimens relative to non‐capecitabine‐containing regimens overall (HR 1.22, 95% CI 1.04 to 1.44; <a href="./references#CD011220-fig-0015" title="">Analysis 1.12</a>), with high heterogeneity (I² = 78%). This result was driven by the two studies of capecitabine substitution (HR 1.78, 95% CI 1.28 to 2.47; <a href="./references#CD011220-fig-0053" title="">Analysis 4.8</a>), although high heterogeneity remained (I² = 84%). There was no difference in PFS in TNBC for capecitabine monotherapy (two studies ‐ HR 1.16, 95% CI 0.94 to 1.41; <a href="./references#CD011220-fig-0029" title="">Analysis 2.8</a>), with low heterogeneity. Only one study in the addition of capecitabine subgroup reported PFS for TNBC (<a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>). This study showed no difference but trended towards benefit in contrast to the other subgroups (HR 0.57, 95% CI 0.31 to 1.05). </p> </section> </section> <section id="CD011220-sec-0087"> <h5 class="title">Objective response rate</h5> <p>Twelve studies with 4200 participants reported data on objective response rate (ORR). These studies demonstrated no overall difference in ORR for the comparison between capecitabine‐containing regimens and non‐capecitabine‐containing regimens (odds ratio (OR) 0.97, 95% CI 0.84 to 1.11; moderate‐certainty evidence; <a href="./references#CD011220-fig-0016" title="">Analysis 1.13</a>), with high heterogeneity (I² = 73%). A funnel plot and Egger's test did not support any publication bias for the studies reviewed (<a href="#CD011220-fig-0007">Figure 7</a>; Egger's test: P = 0.73). </p> <div class="figure" id="CD011220-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.13 ORR all." data-id="CD011220-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.13 ORR all. </p> </div> </div> </div> <p>The use of capecitabine monotherapy compared to non‐capecitabine regimens demonstrated no difference in ORR (four studies ‐ OR 0.96, 95% CI 0.74 to 1.26; <a href="./references#CD011220-fig-0030" title="">Analysis 2.9</a>), with low heterogeneity. In contrast, the addition of capecitabine demonstrated a modest improvement in ORR (four studies ‐ OR 1.37, 95% CI 1.07 to 1.75; <a href="./references#CD011220-fig-0041" title="">Analysis 3.9</a>), also with low heterogeneity, whereas in the four studies of capecitabine substitution, ORR was decreased (OR 0.73, 95% CI 0.58 to 0.91; <a href="./references#CD011220-fig-0054" title="">Analysis 4.9</a>), with high heterogeneity (I² = 87%). </p> <p>No specific ORR data were available for hormone receptor‐positive or ‐negative disease. Participants with TNBC had lower ORR with capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (three studies ‐ OR 0.42, 95% CI 0.27 to 0.65; <a href="./references#CD011220-fig-0017" title="">Analysis 1.14</a>), with high heterogeneity (I² = 80%). </p> </section> <section id="CD011220-sec-0088"> <h5 class="title">Complete response rate</h5> <p>Six studies documented 77 of 2242 participants achieving a complete response (CR), with no difference in benefit with capecitabine‐containing relative to non‐capecitabine‐containing therapy (OR 1.36, 95% CI 0.85 to 2.18; <a href="./references#CD011220-fig-0019" title="">Analysis 1.16</a>), with low heterogeneity. Benefit was seen in the hormone receptor‐positive group (two studies ‐ OR 4.75, 95% CI 1.17 to 19.33; <a href="./references#CD011220-fig-0020" title="">Analysis 1.17</a>), but not in the hormone receptor‐negative group (two studies ‐ OR 0.82, 95% CI 0.39 to 1.73; <a href="./references#CD011220-fig-0021" title="">Analysis 1.18</a>), with low heterogeneity in both cases. </p> </section> <section id="CD011220-sec-0089"> <h5 class="title">Clinical benefit rate</h5> <p>Four studies reported clinical benefit rate (CBR) but demonstrated no difference between capecitabine‐ and non‐capecitabine‐containing regimens (OR 0.96, 95% CI 0.76 to 1.21; <a href="./references#CD011220-fig-0018" title="">Analysis 1.15</a>), with low heterogeneity. </p> </section> <section id="CD011220-sec-0090"> <h5 class="title">Quality of life</h5> <p>Five studies reported quality of life data (see <a href="#CD011220-tbl-0005">Table 2</a>). Four studies used the European Organisation for Research and Treatment of Cancer core quality of life questionnaire (EORTC QLQ‐C30), and the other study used the Rotterdam Symptom Checklist. Given differences in measurement and in the degree to which this outcome was reported, a quantitative estimate of effect was not calculated for this review. However, in general, no differences in global health scores were evident between the two treatment groups at around two years of follow‐up (low‐certainty evidence). </p> <div class="table" id="CD011220-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality of life assessments in patients with metastatic breast cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL collected or reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Questionnaire and any methods used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Main results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Collected as listed in NCT01783444 trial record but not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotterdam Symptom Checklist at baseline and on Day 1 of each cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"QoL was not different between treatment arms. There was no decrease in the overall valuation of life in either arm. Additional data will be presented in a separate publication" (p 1758) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire‐C30, completed at screening, at randomisation, every 3 cycles before progression, and at (but not after) disease progression </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Mean change from baseline for global health score did not differ between the treatment groups (data not shown). More detailed patient‐reported outcome results and exploratory analyses will be reported separately" (p 1358) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30 but only in selected centres, where there were validated EORTC questionnaire translations. Primary QoL analysis used the "last observation forward' approach to replacing missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Analysis included 454 patients from 15 countries. Global Health Score was selected as the primary parameter for statistical testing. No significant differences between treatment arms at Day 127 were noted. There was a trend towards less deterioration of GHS in the combination arm over time" (p 2817) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (version 3.0) and breast module Quality of Life Questionnaire BR23 (version 1.0) at baseline, at 6 weeks, and at 3, 6, 12, 18, and 24 months, or until disease progression or initiation of other antitumour treatment. The principal pre‐specified outcome was overall QoL, expressed as change from baseline in Global Health Status (GHS)/QoL measured on a 0 (worst) to 100 (best) scale </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"&gt; 95% available at baseline, completion rates decreased with time in both treatment arms. GHS/QoL scores low at baseline in both eribulin and capecitabine arms. Over time, average GHS/QoL scores improved in both arms; linear‐mixed and pattern‐mixed model showed no significant difference between groups" (p 599) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORCT QLQ‐30 at baseline, at each tumour assessment (every 12 weeks), and 28 days after discontinuation of study treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Baseline QoL questionnaires available from all participants in safety population in both arms. End of treatment QoL questionnaires were available from 49% in paclitaxel group and 51% in capecitabine group. Analysis of mean global health status showed no major difference between treatment groups and little change from baseline over time. Highest mean baseline symptom scores in both groups were for fatigue, pain, and insomnia; mean scores showed no meaningful increase (reflecting deterioration in QoL) over time. Mean scores for appetite loss, dyspnoea, and financial difficulties varied slightly over time with little difference between groups. Mean scores for physical, emotional, role, cognitive, and social functioning showed slight or no change over time and no differences between treatment groups" (p 130) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EORTC QLQ‐C30: European Organization for Research and Treatment of Cancer core quality of life questionnaire. </p> <p>GHS: global health status.</p> <p>N/A: not applicable.</p> <p>QoL: quality of life.</p> </div> </div> </section> <section id="CD011220-sec-0091"> <h5 class="title">Toxicity</h5> <p>All 12 studies reported some toxicity data (see <a href="#CD011220-tbl-0006">Table 3</a>). Given the variability in reporting and the heterogeneous nature of the comparators, no new toxicity concerns were noted. Capecitabine‐containing intervention arms showed an overall trend towards higher rates of diarrhoea and hand‐foot syndrome, which would be expected from the known toxicity profile. </p> <div class="table" id="CD011220-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Toxicities for capecitabine‐containing regimens vs non‐capecitabine‐containing regimens for metastatic breast cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Febrile neutropenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Diarrhoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Hand‐foot syndrome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Capecitabine regimen (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Capecitabine regimen (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Capecitabine regimen (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine vs everolimus + exemestane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel vs gemcitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + trastuzumab + docetaxel vs trastuzumab + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel vs cisplatin + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab vs bevacizuamb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine vs glembatumumb vedotin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine vs vinorelbine + gemcitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel vs docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/178</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel vs gemcitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57/226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/237</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine vs eribulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79/546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/544</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab + docetaxel OR paclitaxel vs bevacizumab + docetaxel OR paclitaxel </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab vs bevacizumab + paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/160</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>All toxicities are G3 or G4, except <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>, for which grade of toxicity was not specified in reporting. </p> <p><a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> ‐ 1 episode of fatal neutropenic sepsis noted in the glematumumab vedotin arm, and none in the capecitabine arm, but no rates of febrile neutropenia reported. </p> </div> </div> </section> </section> <section id="CD011220-sec-0092"> <h4 class="title">Neoadjuvant setting</h4> <p>Six included studies (31 records) referred to six treatment comparisons in the neoadjuvant setting (<a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a>; <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>; <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>; <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>; <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a>; <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a>). See <a href="./full#CD011220-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD011220-sec-0093"> <h5 class="title">Pathological complete response</h5> <p>All six studies provided some data related to pathological response. Some studies defined and reported pathological complete response (pCR) for breast, nodes, and breast plus nodes separately. We considered pathological complete response to be inclusive of both breast and breast plus nodes. </p> <p>Across six studies with 3152 participants, capecitabine‐containing regimens resulted in little difference in pCR in comparison to non‐capecitabine‐containing regimens (OR 1.12, 95% CI 0.94 to 1.33; high‐certainty evidence; <a href="./references#CD011220-fig-0091" title="">Analysis 9.1</a>), although with high heterogeneity (I² = 64%). <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a> was deemed at high risk of bias, but this was a relatively small study and was not thought to affect the overall result. </p> <section id="CD011220-sec-0094"> <h6 class="title">Hormone receptor‐positive disease</h6> <p>Four studies with 964 participants showed that capecitabine‐containing regimens resulted in little to no difference in pCR for cancers that were hormone receptor‐positive in comparison to non‐capecitabine‐containing regimens (OR 1.22, 95% CI 0.76 to 1.95; moderate‐certainty evidence; <a href="./references#CD011220-fig-0092" title="">Analysis 9.2</a>), with high heterogeneity (I² = 57%). Two studies did not report pCR by hormone receptor status ‐ these represented more than half of the neoadjuvant cohort, and thus the results need to be considered in light of this (<a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a>; <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>). </p> </section> <section id="CD011220-sec-0095"> <h6 class="title">Hormone receptor‐negative disease</h6> <p>Four studies with 646 participants demonstrated that capecitabine‐containing regimens resulted in little to no difference in pCR for cancers that were hormone receptor‐negative in comparison to non‐capecitabine‐containing regimens (OR 1.28, 95% CI 0.61 to 2.66; moderate‐certainty evidence; <a href="./references#CD011220-fig-0093" title="">Analysis 9.3</a>), with low heterogeneity. Three out of four studies trended towards benefit with capecitabine, albeit all with low numbers. Two studies did not report pCR by hormone receptor status (<a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a>; <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>); these represent more than half of the neoadjuvant cohort, and thus the results need to be considered in light of this. </p> <p>Four studies with 1063 participants demonstrated that capecitabine‐containing regimens resulted in little to no difference in pCR for cancers that were triple‐negative in comparison to non‐capecitabine‐containing regiments (OR 1.03, 95% CI 0.72‐1.46; <a href="./references#CD011220-fig-0094" title="">Analysis 9.4</a>), albeit with high heterogeneity (I² = 73%). </p> </section> </section> <section id="CD011220-sec-0096"> <h5 class="title">Disease‐free survival</h5> <p>Four studies reported data on disease‐free survival (DFS) (<a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>; <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>; <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>; <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a>). Based on these four studies with 2460 participants, capecitabine‐containing regimens showed no difference in DFS compared to non‐capecitabine‐containing regimens (HR 1.02, 95% CI 0.86 to 1.21; high‐certainty evidence; <a href="./references#CD011220-fig-0095" title="">Analysis 9.5</a>), with low heterogeneity. <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a> did not report data for this outcome, as the data were not yet mature, and <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> did not comment on plans to collect or report these data. Note that the median follow‐up is only 3 to 5.4 years, with the lower limit early for relapse expected for this cohort. </p> <p>Outcome data were insufficient for analysis of DFS by hormone receptor subtype.</p> </section> <section id="CD011220-sec-0097"> <h5 class="title">Overall survival</h5> <p>Four studies with 2460 participants reported data on overall survival (OS) (<a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>; <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>; <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>; <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a>). These data demonstrate that capecitabine‐containing regimens resulted in no difference in OS compared to non‐capecitabine‐containing regimens (HR 0.97, 95% CI 0.77 to 1.23; high‐certainty evidence; <a href="./references#CD011220-fig-0096" title="">Analysis 9.6</a>), again with low heterogeneity. Similar to DFS, <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a> did not report data for this outcome, as the data were not yet mature, and <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> did not comment on plans to collect or report these data. Note that the median follow‐up is only 3 to 5.4 years, with the lower limit early for death for this cohort. </p> <p>Again, outcome data were insufficient for analysis of OS by hormone receptor subtype.</p> </section> <section id="CD011220-sec-0098"> <h5 class="title">Adverse events</h5> <section id="CD011220-sec-0099"> <h6 class="title">Febrile neutropenia</h6> <p>Four studies with 2890 participants reported rates of grade 3 or 4 febrile neutropenia. These data demonstrated no significant difference in febrile neutropenia between capecitabine‐ and non‐capecitabine‐containing regimens (OR 1.31, 95% CI 0.97 to 1.77; moderate‐certainty evidence; <a href="./references#CD011220-fig-0099" title="">Analysis 9.9</a>), with low heterogeneity. The other two studies did not specifically report febrile neutropenia, with <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> grouping all haematological adverse effects and <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a> reporting only leukopenia. </p> </section> <section id="CD011220-sec-0100"> <h6 class="title">Diarrhoea</h6> <p>Three studies with 2686 participants reported rates of grade 3 or 4 diarrhoea. These data demonstrated a definitive increase in diarrhoea with capecitabine‐ compared to non‐capecitabine‐containing regimens (OR 1.95, 95% CI 1.32 to 2.89; moderate‐certainty evidence; <a href="./references#CD011220-fig-0103" title="">Analysis 9.13</a>), with low heterogeneity. The other three studies did not specifically report diarrhoea, with <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> grouping together all gastrointestinal adverse effects; <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a> grouping nausea, vomiting, and diarrhoea together; <a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a> reported only "all‐grade" diarrhoea and did not specify grade 3 or 4 diarrhoea. </p> </section> <section id="CD011220-sec-0101"> <h6 class="title">Hand‐foot syndrome</h6> <p>Five studies with 3021 participants reported rates of grade 3 or 4 hand‐foot syndrome. These data demonstrated a definitive increase in hand‐foot syndrome with capecitabine‐ compared to non‐capecitabine‐containing regimens (OR 6.77, 95% CI 4.89 to 9.38; moderate‐certainty evidence; <a href="./references#CD011220-fig-0101" title="">Analysis 9.11</a>), although it is somewhat surprising that this involved high heterogeneity (I² = 80%). <a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> was the only study not to report this; this study did report a marked increase (n = 23 versus n = 0) in "Skin and subcutaneous tissue disorders" in the capecitabine arm, which presumably relates to hand‐foot syndrome, but this was not specified in the paper. </p> </section> </section> </section> <section id="CD011220-sec-0102"> <h4 class="title">Adjuvant setting</h4> <p>Eight studies (45 records) referred to six different treatment comparisons in the adjuvant setting (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>; <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>; <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>; <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>). See:<a href="./full#CD011220-tbl-0003">summary of findings Table 3</a>. </p> <p>Of the eight studies, four studies gave capecitabine as monotherapy and four utilised capecitabine as a substitution into or an addition to a chemotherapy regimen. </p> <section id="CD011220-sec-0103"> <h5 class="title">Disease‐free survival</h5> <p>Eight studies with 13,547 participants reported data on disease‐free survival (DFS) or recurrence‐free survival (RFS). These data demonstrated no overall difference in DFS between capecitabine‐containing regimens and non‐capecitabine‐containing regimens across all patients (HR 0.93, 95% CI 0.86 to 1.01; moderate‐certainty evidence; <a href="./references#CD011220-fig-0071" title="">Analysis 6.1</a>), with relatively high heterogeneity (I² = 54%). <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a> was the only study in this review that consistently reported RFS, and this was combined with DFS in a sensitivity analysis. </p> <p>Of the eight studies, four utilised capecitabine as monotherapy in the adjuvant setting. The use of capecitabine monotherapy did not show a significant difference in DFS between capecitabine‐containing regimens and non‐capecitabine‐containing regimens (HR 0.91, 95% CI 0.82 to 1.01; <a href="./references#CD011220-fig-0083" title="">Analysis 8.1</a>), with low heterogeneity. The remaining four studies utilised capecitabine as an addition to or a substitution into the existing chemotherapy regimen. Capecitabine in this setting also did not show a difference in DFS (HR 0.94, 95% CI 0.83 to 1.07; <a href="./references#CD011220-fig-0075" title="">Analysis 7.1</a>), although with high heterogeneity (I² = 69%). </p> <section id="CD011220-sec-0104"> <h6 class="title">Hormone receptor‐positive disease</h6> <p>Five studies with 5604 participants demonstrated no difference in DFS among patients with hormone receptor‐positive disease with capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (HR 1.03, 95% CI 0.91 to 1.17; moderate‐certainty evidence; <a href="./references#CD011220-fig-0072" title="">Analysis 6.2</a>), with low heterogeneity. </p> <p>In the setting of capecitabine monotherapy, two studies reported results on DFS in hormone receptor‐positive patients. These studies did not demonstrate any difference between capecitabine‐ and non‐capecitabine‐containing regimens (HR 0.96, 95% CI 0.78 to 1.18; <a href="./references#CD011220-fig-0084" title="">Analysis 8.2</a>), with low heterogeneity. Three studies in which capecitabine was used as an addition to or a substitution into the existing chemotherapy regimen reported outcomes among hormone receptor‐positive patients. These studies also did not show any difference in DFS (HR 1.07, 95% CI 0.92 to 1.25; <a href="./references#CD011220-fig-0076" title="">Analysis 7.2</a>), although with high heterogeneity (I² = 55%). </p> </section> <section id="CD011220-sec-0105"> <h6 class="title">Hormone receptor‐negative disease</h6> <p>Seven studies with 2879 participants demonstrated improvement in DFS among patients with hormone receptor‐negative disease with capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (HR 0.74, 95% CI 0.64 to 0.86; moderate‐certainty evidence; <a href="./references#CD011220-fig-0073" title="">Analysis 6.3</a>), with low heterogeneity. </p> <p>All four studies that utilised capecitabine as monotherapy reported DFS outcomes for hormone receptor‐negative patients. These studies demonstrated modest benefit with use of capecitabine as monotherapy (HR 0.84, 95% CI 0.72 to 0.98; <a href="./references#CD011220-fig-0085" title="">Analysis 8.3</a>), with high heterogeneity (I² = 51%). The four studies in which capecitabine was used as an addition to or a substitution into the existing chemotherapy regimen reported similar benefit for DFS (HR 0.74, 95% CI 0.59 to 0.93; <a href="./references#CD011220-fig-0077" title="">Analysis 7.3</a>), with low heterogeneity. </p> </section> <section id="CD011220-sec-0106"> <h6 class="title">Triple‐negative disease</h6> <p>In patients with TNBC, seven studies demonstrated significant improvement in DFS with capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (HR 0.83, 95% CI 0.72 to 0.95; <a href="./references#CD011220-fig-0074" title="">Analysis 6.4</a>), with low heterogeneity. Two of these studies had an entirely triple‐negative cohort (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>). The benefit appeared of greater magnitude when capecitabine was used as an addition/substitution (4 studies; HR 0.76, 95% CI 0.61 to 0.94; <a href="./references#CD011220-fig-0078" title="">Analysis 7.4</a>), with low heterogeneity, than when it was employed as monotherapy (3 studies; HR 0.85, 95% CI 0.71 to 1.01; <a href="./references#CD011220-fig-0086" title="">Analysis 8.4</a>), with high heterogeneity (I² = 66%). </p> </section> </section> <section id="CD011220-sec-0107"> <h5 class="title">Overall survival</h5> <p>Eight studies with 13,547 participants reported data on OS. A modest reduction in mortality was observed for capecitabine‐containing regimens relative to non‐capecitabine‐containing regimens across all patients (HR 0.89, 95% CI 0.81 to 0.98; moderate‐certainty evidence; <a href="./references#CD011220-fig-0058" title="">Analysis 5.1</a>), albeit with high heterogeneity (I² = 52%). In the setting of capecitabine monotherapy, studies demonstrated no difference in mortality between capecitabine‐ and non‐capecitabine‐containing regimens (HR 0.93, 95% CI 0.83 to 1.05; <a href="./references#CD011220-fig-0087" title="">Analysis 8.5</a>), with borderline high heterogeneity (I² = 50%), whereas improved OS was seen with use of capecitabine as an addition to or a substitution into the existing regimen (4 studies; HR 0.83, 95% CI 0.71 to 0.96; <a href="./references#CD011220-fig-0079" title="">Analysis 7.5</a>), again with high heterogeneity (I² = 56%). </p> <section id="CD011220-sec-0108"> <h6 class="title">Hormone receptor‐positive disease</h6> <p>Three studies reported data on OS for patients with hormone receptor‐positive disease. These studies demonstrated no difference in mortality with capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (HR 0.86, 95% CI 0.68 to 1.09; <a href="./references#CD011220-fig-0059" title="">Analysis 5.2</a>), with low heterogeneity. Only <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a> reported outcomes for hormone receptor‐positive disease with capecitabine monotherapy, which did not demonstrate significant benefit, albeit with wide confidence intervals (HR 0.73, 95% CI 0.38 to 1.40). Two studies reported outcomes for hormone receptor‐positive disease with capecitabine as an addition to or a substitution into the existing regimen, and also showed no difference in OS (HR 0.88, 95% CI 0.69 to 1.13; <a href="./references#CD011220-fig-0080" title="">Analysis 7.6</a>), with low heterogeneity. </p> </section> <section id="CD011220-sec-0109"> <h6 class="title">Hormone receptor‐negative disease</h6> <p>Five studies reported data on OS for patients with hormone receptor‐negative disease. These studies demonstrated improvement in OS with capecitabine‐containing regimens compared with non‐capecitabine‐containing regimens (HR 0.72, 95% CI 0.59 to 0.89; <a href="./references#CD011220-fig-0060" title="">Analysis 5.3</a>), again with low heterogeneity. Two of these employed capecitabine added as monotherapy (in entirely triple‐negative populations), which produced no significant benefit (HR 0.79, 95% CI 0.59 to 1.05; <a href="./references#CD011220-fig-0089" title="">Analysis 8.7</a>), with high heterogeneity (I² = 67%), and three utilised capecitabine as an addition to or a substitution into the existing regimen, with significant benefit (HR 0.66, 95% CI 0.49 to 0.88; <a href="./references#CD011220-fig-0081" title="">Analysis 7.7</a>), with low heterogeneity. </p> </section> <section id="CD011220-sec-0110"> <h6 class="title">Triple‐negative disease</h6> <p>Five studies reported data on OS for patients with triple‐negative disease, two of which recruited entirely triple‐negative cohorts. These studies demonstrated a large improvement in OS with capecitabine‐containing regimens compared with non‐capecitabine‐containing regimens (HR 0.70, 95% CI 0.57 to 0.86; <a href="./references#CD011220-fig-0061" title="">Analysis 5.4</a>), with low heterogeneity. Two of these studies added capecitabine as monotherapy, as above, which produced no significant benefit (HR 0.79, 95% CI 0.59 to 1.05; <a href="./references#CD011220-fig-0090" title="">Analysis 8.8</a>), with high heterogeneity (I² = 67%), and three gave capecitabine as an addition to or a substitution into the existing chemotherapy regimen, with substantial significant OS benefit (HR 0.61, 95% CI 0.46 to 0.82; <a href="./references#CD011220-fig-0082" title="">Analysis 7.8</a>), with low heterogeneity. </p> </section> </section> <section id="CD011220-sec-0111"> <h5 class="title">Adverse effects</h5> <section id="CD011220-sec-0112"> <h6 class="title">Febrile neutropenia</h6> <p>Five studies with 8086 participants reported rates of grade 3 and 4 febrile neutropenia. Data showed lower rates of febrile neutropenia with capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (OR 0.55, 95% CI 0.47 to 0.64; moderate‐certainty evidence; <a href="./references#CD011220-fig-0064" title="">Analysis 5.7</a>), although with high heterogeneity (I² = 93%). The three studies involving capecitabine monotherapy versus observation or non‐chemotherapy treatment (bisphosphonate) did not report this outcome, likely because febrile neutropenia was not an expected adverse effect. </p> </section> <section id="CD011220-sec-0113"> <h6 class="title">Diarrhoea</h6> <p>Eight studies with 11,207 participants reported rates of grade 3 and 4 diarrhoea. These data demonstrated higher rates of diarrhoea with capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (OR 2.46, 95% CI 2.01 to 3.01; moderate‐certainty evidence; <a href="./references#CD011220-fig-0068" title="">Analysis 5.11</a>), again with high heterogeneity (I² = 85%). </p> </section> <section id="CD011220-sec-0114"> <h6 class="title">Hand‐foot syndrome</h6> <p>Eight studies with 11,207 participants reported rates of grade 3 and 4 hand‐foot syndrome. These data demonstrated much higher rates of hand‐foot syndrome with capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens (OR 13.60, 95% CI 10.65 to 17.37; moderate‐certainty evidence; <a href="./references#CD011220-fig-0066" title="">Analysis 5.9</a>), with high heterogeneity (I² = 75%). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011220-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011220-sec-0115"></div> <section id="CD011220-sec-0116"> <h3 class="title" id="CD011220-sec-0116">Summary of main results</h3> <p>This review demonstrates treatment scenario‐specific and breast cancer subtype‐specific benefits for inclusion of capecitabine in chemotherapy.<br/><br/>In the metastatic setting, capecitabine was somewhat more efficacious in hormone receptor‐positive relative to hormone receptor‐negative and triple‐negative disease, confirming the core hypothesis. Both complete response rate and progression‐free survival (PFS) were significantly superior with inclusion of capecitabine for hormone receptor‐positive tumours, with hazard ratios (HRs) of 4.75 and 0.82, and a modest trend towards improved survival at 0.93 and significantly improved survival at 0.62 for the modest number of patients in the trials in which capecitabine was added to the control regimen. No advantage was seen for any of these parameters in hormone receptor‐negative disease, although with high heterogeneity for PFS. Inferior objective response rate (ORR), PFS, and overall survival (OS) were observed with capecitabine‐containing regimens in triple‐negative metastatic disease, although with high heterogeneity for all parameters.<br/><br/>Exploration of the metastatic setting in greater detail revealed substantially greater heterogeneity of design in assembled metastatic trials with capecitabine added to an existing regimen, substituted for a component of an existing regimen, or used as monotherapy. Studies exploring the addition of capecitabine to existing treatment appear to be the biggest contributor to the superior efficacy of capecitabine for metastatic hormone receptor‐positive cancer. Heterogeneity was high for PFS but not for OS. In a hormone receptor subtype‐specific analysis of the <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a> trial, the addition of capecitabine to docetaxel led to significant and clinically useful OS benefit for hormone receptor‐positive tumours (HR 0.65) but not for hormone receptor‐negative disease (HR 0.90). The smaller, and as yet unpublished, <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> trial, which compared similar arms, although with the addition of bevacizumab for all patients, showed the opposite effect, with superior PFS among hormone receptor‐negative patients and a trend towards inferior outcomes in hormone receptor‐negative patients, although OS has not been reported. This trial accounts for the high heterogeneity in PFS relative to OS for capecitabine addition trials in hormone receptor‐positive disease. With more even effects seen by subtype, the addition of capecitabine to bevacizumab as consolidation after docetaxel and bevacizumab in the relatively small <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a> study resulted in significant benefits for both PFS and OS in hormone receptor‐positive tumours and trends towards PFS benefits as well as significant OS benefits in hormone receptor‐negative and triple‐negative cancers. The differences between <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a> and <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> are difficult to reconcile with available data. As bevacizumab has greater impact in oestrogen receptor negative (ER‐) disease for PFS (although no overall impact for OS), this may have generated the observed differences, although further trials to clarify this issue are unlikely to be conducted. </p> <p>Single‐agent trials essentially represent head‐to‐head measures of drug efficacy, with PFS endpoints measuring basic efficacy and OS both addressing this and reflecting the optimal order of agents. In hormone receptor‐positive cancer, capecitabine generally appeared a reasonable choice, with non‐significantly superior PFS relative to exemestane/everolimus (<a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>), vinorelbine/gemcitabine (<a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a>), and eribulin (<a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a>). This was reflected in non‐significantly longer OS in the former two trials. The slightly shorter OS relative to eribulin in <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> may reflect lack of cross‐over to eribulin (0.4%) relative to frequent reverse cross‐over from eribulin to capecitabine (49.6%). Heterogeneity was low for PFS, possibly reflecting that capecitabine has robust activity in this disease subtype in the metastatic setting relative to a number of other agents. Higher heterogeneity for OS could stem from the differing line of treatment under study in clinical trials. In hormone receptor‐negative and triple‐negative patients, capecitabine again appeared a reasonable choice, showing no significant efficacy differences compared to other tested agents, with non‐significant superiority to vinorelbine/gemcitabine in hormone receptor‐negative cancers and non‐significant inferiority to eribulin in triple‐negative disease. Again, there was low heterogeneity for PFS, suggesting that capecitabine may be broadly comparable to a number of other agents for this disease subtype, whereas high heterogeneity for OS may reflect the diverse treatment lines involved in different trials. As monotherapy chemotherapy is favoured in the metastatic setting, it is unfortunate that no other studies have investigated the major agents in clinical practice in comparison to capecitabine monotherapy, namely, paclitaxel, docetaxel, and anthracyclines, to better delineate full efficacy. </p> <p>Substitution trials are somewhat akin to single‐agent trials comparing capecitabine to other agents in a standard combination. All trials indicate that capecitabine was equivalent for both disease‐free survival (DFS) and OS in hormone receptor‐positive and ‐negative disease, but was inferior in triple‐negative disease, with generally low heterogeneity. This differential appeared more a consequence of differing trials conducted in different subtypes than necessarily differential sensitivity. Cisplatin was superior to capecitabine in combination with docetaxel in a small trial in triple‐negative disease (<a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a>), which also gave rise to the higher heterogeneity in OS for hormone receptor‐negative tumours, whereas gemcitabine was equivalent to capecitabine when combined with docetaxel in hormone receptor‐positive and ‐negative cancers (<a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>), and capecitabine was equivalent to paclitaxel as a partner to bevacizumab across all subtypes (<a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a>). The benefit of cisplatin in triple‐negative breast cancer (TNBC) might be related to <i>BRCA</i> mutation status, but this was not assessed in <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a>. </p> <p>In the neoadjuvant setting, studies were often small and designs complex, and research frequently involved multiple study arms, such that useful composite conclusions could not be made. Across all trials, capecitabine incorporation did not significantly affect pathological complete response (pCR) in any breast cancer subtype. Sparse reporting of longer‐term follow‐up did not reveal any influence on survival, and data did not permit useful subtype‐specific analysis. However, on examination of individual trials, capecitabine/docetaxel showed greater efficacy in terms of pCR than doxorubicin and cyclophosphamide for hormone receptor‐positive but not hormone receptor‐negative tumours, in keeping with the greater efficacy of this combination in the metastatic setting (<a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>). The substitution of capecitabine for fluorouracil numerically increased pCR rates across subtypes and significantly increased pCR in triple‐negative cancers (<a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a>). No other combinations significantly influenced pCR. Collectively, no role for capecitabine was apparent in the neoadjuvant setting based on available study data. </p> <p>In contrast, in the adjuvant setting, inclusion of capecitabine significantly improved outcomes for hormone receptor‐negative and triple‐negative tumours, with DFS hazard ratios of 0.75 and 0.85 and OS hazard ratios of 0.71 and 0.69, respectively. By comparison, no significant benefit was observed for hormone receptor‐positive cancers. Heterogeneity was low for DFS and OS outcomes in all subtypes for the adjuvant setting. Trials assessing adjuvant capecitabine comprised two distinctive clinical situations: immediately after surgery (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>; <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a><a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>), and sequentially following (neo)adjuvant chemotherapy (<a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>; <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>). Overall adjuvant capecitabine monotherapy given without prior neoadjuvant chemotherapy showed no proven survival benefit. However adjuvant trials employing capecitabine in combination with docetaxel with an anthracycline‐taxane‐containing regimen displayed demonstrable OS benefit for hormone receptor‐negative breast cancer and for TNBC (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>), with low heterogeneity for both. Composite results show impressive 36% and 41% reductions in mortality in hormone receptor‐negative and triple‐negative populations, respectively. This effect was consistent even with exclusion of <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> from OS analysis, which is awaiting peer review publication. It is reassuring that the OS HR from <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> is similar to that in TNBC subgroup analyses from <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a> and <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>. </p> <p>Heterogenous outcomes were attained by the single‐agent addition of capecitabine after completion of standard neoadjuvant or adjuvant chemotherapy. In <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>, when capecitabine was given to participants failing to achieve a pCR after standard neoadjuvant chemotherapy, results were commensurate with those seen for concurrent inclusion in the immediate post‐surgery adjuvant setting, with mortality reduced by 48% in the triple‐negative cohort. In contrast, the similarly sized <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> study observed a non‐significant 8% reduction in mortality for triple‐negative disease when capecitabine was added after standard adjuvant or neoadjuvant chemotherapy. However, the <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> study population differed, as most patients (81.2%; n = 712) received adjuvant chemotherapy before randomisation to capecitabine or observation. Of note also, in a pre‐planned analysis. <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> did find significant DFS and OS benefits with addition of capecitabine for patients with non‐basal tumours. Theoretical reasons for this disparity include selection of only poorer prognosis non‐pCR patients in <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>, a moderately lower dose of capecitabine used in <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> (1000 mg/m² twice daily versus 1250 mg/m² twice daily), the potential for <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a> to have had larger numbers of non‐basal tumours, and the differing study populations ‐ South American for <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>, and Japanese and Korean for <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>. Notably, the three concurrent capecitabine adjuvant studies produced homogenous results despite disparate ethnic populations (Chinese, European, and North American, respectively), suggesting that the former three explanations may hold the answer (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>).<br/>This review did not identify new findings regarding toxicity. Capecitabine administration significantly increased the risk of hand‐foot syndrome, mucositis, and diarrhoea. Ischaemic cardiac events were numerically increased but not significantly so. Treatment‐related deaths were non‐significantly fewer. </p> <p>Quality of life assessments were confined to metastatic studies. Five of twelve studies reported quality of life outcomes, with no significant differences in these endpoints identified between groups in any trial. Heterogeneity of reported data precluded combined analysis. </p> <p>The differential activity identified for capecitabine between hormone receptor‐positive and ‐negative cancers was complex, with hormone receptor‐positive metastatic disease and hormone receptor‐negative early disease showing greatest sensitivity. Explanations for this difference may lie in the environment of the target cell in the two treatment scenarios. For metastatic disease, as well as for neoadjuvant treatment of the breast primary, malignant cells are actively growing as part of a macroscopic tumour mass. There is an established blood supply, and consequently hypoxia and nutritional deprivation are infrequent. By contrast, in the adjuvant scenario, eradication of single tumour cells and micro‐metastatic deposits is the goal. Evidence suggests that these cells are often harboured in the bone marrow, are quiescent and so are not proliferating, and do not have an established blood supply, such that hypoxia and poor nutrition are common. </p> <p>Given first the metastatic situation, although hormone receptor‐negative breast cancer is generally considered more chemo‐responsive, this concept is largely based on the higher pCR rate seen after neoadjuvant anthracycline‐ and/or taxane‐based chemotherapy. For example, one meta‐analysis demonstrated pCR rates of 8.3% versus 31.1% for human epidermal growth factor receptor 2 (HER2)‐negative hormone receptor‐positive and ‐negative cancers, respectively (OR 5.0, 95% CI 4.20 to 5.92; <a href="./references#CD011220-bbs2-0126" title="HoussamiN , MacaskillP , vonMinckwitzG , MarinovichML , MamounasE . Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.. European Journal of Cancer2012;48(18):3342-54.">Houssami 2012</a>). However, a meta‐analysis of docetaxel chemo‐responsiveness in the metastatic setting showed no difference between hormone receptor‐positive and ‐negative disease, with response rates of 46.8% and 44.7%, respectively (<a href="./references#CD011220-bbs2-0113" title="AndreF , BroglioK , PusztaiL , BerradaN , MackeyJR , NabholtzJM , et al. Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials. Oncologist2010;15(5):476-83.">Andre 2010</a>). As noted above, an individual pooled analysis in metastatic disease found response rates for capecitabine to be significantly higher in hormone receptor‐positive than in hormone receptor‐negative disease (<a href="./references#CD011220-bbs2-0114" title="BlumJ , BarriosC , FeldmanN , VermaS , McKennaE , LeeL , et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment2012;136(3):777-88.">Blum 2012</a>). Consequently, given these results and the noted synergy between docetaxel and capecitabine, the finding that capecitabine added efficacy preferentially to docetaxel in hormone receptor‐positive breast cancer is not unexpected. A look at possible cell biological drivers to the sensitivity difference reveals that hormone receptor‐positive tumours may be specifically more capecitabine‐prone, as continuous lower‐dose fluorouracil (the active moiety in capecitabine therapy) causes cell death via G2‐M‐phase cell cycle arrest and mitotic catastrophe, rather than via apoptotic death (<a href="./references#CD011220-bbs2-0146" title="YoshikawaR , KusunokiM , YanagiH , NodaM , FuruyamaJI , YamamuraT , et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Research2001;61(3):1029–37.">Yoshikawa 2001</a>), to which hormone receptor‐positive cells are less prone, potentially due to higher levels of the anti‐apoptotic protein Bcl‐2 (<a href="./references#CD011220-bbs2-0133" title="MerinoD , LokSW , VisvaderJE , LindemanGJ . Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Oncogene2016;35(15):1877-87.">Merino 2016</a>). </p> <p>In the adjuvant situation, after initial dissemination, many breast cancer cells enter a dormant phase, in which they are frequently resistant to adjuvant chemotherapy (<a href="./references#CD011220-bbs2-0115" title="BraunS , KentenichC , JanniW , HeppF , deWaalJ , WillgerothF , et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. Journal of Clinical Oncology2000;18(1):80–6.">Braun 2000</a>). Triple‐negative cancers have lower levels of dormancy than hormone receptor‐positive disease (<a href="./references#CD011220-bbs2-0127" title="KimRS , Avivar-ValderasA , EstradaY , BragadoP , SosaMS , Aguirre-GhisoJA , et al. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS One2012;7(4):e35569.">Kim 2012</a>), such that disseminated tumour cells and micro‐metastases are more likely to be cycling and consequently sensitive to chemotherapy. This would explain why patients with hormone receptor‐negative cancers may derive larger benefit from adjuvant chemotherapy in general, with capecitabine‐docetaxel synergy driving improved outcomes in <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>, <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>, and <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>. </p> <p>Beyond sensitivity to chemotherapy due to proliferation rates and apoptotic sensitivity, there is a possible role for pharmacokinetics in the observed differences. Capecitabine is a pro‐drug that is metabolised to fluorouracil by thymidine phosphorylase (TP), including in tumour cells. Fluorouracil then inhibits thymidine synthetase (TS), thereby reducing thymidine production for DNA synthesis. Following this, fluorouracil is deactivated by dihydropyrimidine dehydrogenase (DPD). Consequently, low TP or high TS or DPD could adversely affect prognosis. TS levels were higher in triple‐negative than in hormone receptor‐positive breast cancers (64% versus 16%; P = 0.023) and corresponded to shorter PFS (<a href="./references#CD011220-bbs2-0129" title="LeeSJ , ChoiYL , ParkYH , KimST , ChoEY , AhnJS , et al. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology2011;68(3):743–51.">Lee 2011</a>). This could contribute to lack of impact of capecitabine in the metastatic setting. Neither TP expression (as in <a href="./references#CD011220-bbs2-0129" title="LeeSJ , ChoiYL , ParkYH , KimST , ChoEY , AhnJS , et al. Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology2011;68(3):743–51.">Lee 2011</a>) nor DPD activity or expression (as in <a href="./references#CD011220-bbs2-0125" title="HoriguchiJ , YoshidaT , KoibuchiY , IijimaK , NinomiyaJ , TakeiH , et al. DPD activity and immunohistochemical DPD expression in human breast cancer. Oncology Reports2004;11(1):65–72.">Horiguchi 2004</a>) was different between hormone receptor‐positive and ‐negative cancers. </p> </section> <section id="CD011220-sec-0117"> <h3 class="title" id="CD011220-sec-0117">Overall completeness and applicability of evidence</h3> <p>A substantial number of otherwise suitable studies did not report outcomes by hormone receptor subtype despite having available data on individual patients, raising the possibility of publication bias and reducing the power of conclusions derived. However, with this proviso, sufficient trial data were available to allow comparisons by hormone receptor status as discussed with moderate to high levels of certainty in the three treatment scenarios.<br/><br/>Clinical trial design incorporating capecitabine in the adjuvant setting was heterogenous. Capecitabine was employed in combination with docetaxel in taxane‐anthracycline regimens, as monotherapy, and in sequence following neoadjuvant or adjuvant regimens. However all three phase 3 trials that demonstrated OS benefit in TNBC employed capecitabine in combination with docetaxel (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>). Notably, trials that demonstrated capecitabine to have no survival benefit studied monotherapy.<br/><br/>In the metastatic setting, heterogeneity of trial design made specific robust conclusions more difficult. The benefit for hormone receptor‐positive tumours relative to hormone receptor‐negative cancers appeared to be driven by concurrent or sequential delivery of capecitabine with docetaxel, although further confirmatory trials would be ideal to validate this conclusion. Unfortunately, the higher toxicity of the capecitabine and docetaxel combination, particularly in a palliative setting, makes such further studies unlikely and application to practice inappropriate in many cases. As monotherapy is favoured in metastatic breast cancer over "doublet" chemotherapy regimens, it is unfortunate that only <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> compared capecitabine to another monotherapy regimen (eribulin).<br/>In the neoadjuvant setting, where trials tend to be hypothesis‐generating for validation in larger adjuvant studies, heterogeneity of design, the tendency for multiple treatment arms to be studied within each trial, and small cohort sizes precluded useful conclusions as to hormone receptor subtype‐specific activity of capecitabine in this scenario. Consequently, there is no evidence that capecitabine is beneficial in the neoadjuvant setting.<br/>Unfortuately, a number of planned analyses were not possible due to lack of available data. These included comparison of breast cancer‐specific survival in the adjuvant setting, outcomes within hormone receptor‐positive and ‐negative subsets by HER2 status in all treatment scenarios, and capecitabine efficacy by line of treatment in the metastatic setting. This limitation could be overcome by access to individual patient data; however this was beyond the scope of our review. </p> </section> <section id="CD011220-sec-0118"> <h3 class="title" id="CD011220-sec-0118">Quality of the evidence</h3> <p>The robustness of conclusions differed between treatment scenarios; this difference was driven by both size and heterogeneity of studies conducted in each situation.<br/><br/>The most robust finding was the significant differential benefit between hormone receptor‐positive and ‐negative cancers in the adjuvant setting, with substantial benefit derived from inclusion of capecitabine only for hormone receptor‐negative and triple‐negative disease ‐ for both DFS and OS ‐ with low heterogeneity (I² &lt; 50% for all parameters). In this context, some doubt exists regarding the value of capecitabine added after completion of other chemotherapies, as studied in two trials totaling 1742 patients with high heterogeneity of outcome. Uncertainty arises from discrepancies between the outcomes of <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> and <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>, as discussed above. In contrast, remarkably consistent and substantial benefits are seen across the three trials studying the addition of capecitabine concurrently with docetaxel, with low heterogeneity in hormone receptor‐negative and triple‐negative cancers. Here 1669 hormone receptor‐negative patients and 1543 triple‐negative patients were treated across three trials of very similar design with very low heterogeneity for the OS outcome (I² = 0% for both hormone receptor‐negative and triple‐negative disease) (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>). Although no benefit was observed for hormone receptor‐positive disease, the smaller number of studies and the greater heterogeneity in trial design of these studies do not exclude some level of benefit here.<br/>In the metastatic setting, substantially greater variability of trial design and a wider range of alternative therapeutics were employed. The twelve eligible trials involving 4325 patients were broadly divisible into three designs with respect to capecitabine inclusion: four studies including 1783 patients, in which capecitabine monotherapy was compared to other treatments; four studies including 1145 patients, in which capecitabine was added to a regimen; and four trials involving 1397 patients, in which the drug was substituted for a component of a regimen. Given combined outcomes across all studies, although we saw significant PFS benefit for hormone receptor‐positive tumours that was not observed for other tumours, it is worth noting that trial heterogeneity was high (I² = 81%), and that only 3 of the 12 trials studied contributed DFS and OS data for comparison of all subtypes, and 6 of the 12 for comparison of hormone receptor‐positive and hormone receptor‐negative disease. In light of the different trial designs regarding incorporation of capecitabine into the chemotherapy regimen, it should also be noted that only a proportion of studies in each category contributed to outcome measures by subtype, thereby reducing the robustness of derived conclusions.<br/>For the neoadjuvant setting, six trials and 3152 participants were included. Study design heterogeneity prevented any robust conclusions with multiple agents compared to capecitabine. No hormone receptor‐specific differences were seen for capecitabine incorporation, and lack of hormone receptor‐specific DFS and OS data precluded validation of results seen in the adjuvant setting. </p> </section> <section id="CD011220-sec-0119"> <h3 class="title" id="CD011220-sec-0119">Potential biases in the review process</h3> <p>The capecitabine trials included in this review were invariably open‐label with no blinded placebo control. This may have introduced bias into reporting of toxicity. However, the more critical endpoints of response rate, PFS, DFS, RFS, and OS are less likely to have been adversely affected by such open‐label designs. </p> <p>Several randomised controlled studies are awaiting peer‐reviewed publication. Notably, <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>, which was one of three trials that demonstrated benefit of the addition of capecitabine for TNBC in the adjuvant setting, is yet to be published in a peer‐reviewed journal. However, as previously discussed, the hazard ratio for OS in <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> is similar to that of triple‐negative subgroup analyses from both <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a> and <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>. Nonetheless there is the potential for reporting bias, with <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> being a positive trial. Other trials as detailed in the Ongoing studies section of this review are pending peer‐reviewed publication, including the <a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> study. </p> <p>As with any collation of published studies relevant to a particular question in which the question is unlikely to have featured in pre‐determined primary or secondary outcomes, there is potential for publication bias with respect to data regarding outcomes by hormone receptor status. Post‐hoc analyses that did not show a significant difference may have been selectively omitted from published works relative to studies showing significant differential outcomes by hormone receptor status. </p> </section> <section id="CD011220-sec-0120"> <h3 class="title" id="CD011220-sec-0120">Agreements and disagreements with other studies or reviews</h3> <p>Other reviews in each of the three treatment scenarios explored herein have identified similar correlations to the work presented here. </p> <p>In the metastatic setting, a relatively contemporary review of randomised trials incorporating capecitabine included ten studies totaling 2002 patients (<a href="./references#CD011220-bbs2-0145" title="WangY , YangH , WeiJF , MengL . Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials. Current Medical Research and Opinion2012;28(12):1911-9.">Wang 2012</a>). Again, comparable results were attained for whole cohorts undifferentiated by hormone receptor status, with studies finding modest non‐significant increases in complete response rates for capecitabine inclusion with substantial heterogeneity. However, no analysis by hormone receptor status was made such that our own finding of superior complete response rates for capecitabine in hormone receptor‐positive disease only was not tested. Further, no analysis of DFS or OS was made, thereby leaving our findings of superior outcomes in hormone receptor‐positive but not in hormone receptor‐negative patients again unreported. However, our findings are supported by a pooled analysis of individual patient data from capecitabine monotherapy clinical trials in metastatic breast cancer, where significantly improved response rates, PFS, and OS with capecitabine were demonstrated in patients with hormone receptor‐positive versus hormone receptor‐negative tumours (<a href="./references#CD011220-bbs2-0114" title="BlumJ , BarriosC , FeldmanN , VermaS , McKennaE , LeeL , et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment2012;136(3):777-88.">Blum 2012</a>). </p> <p>A very recent review of seven adjuvant studies, based solely on TNBC patients or reporting outcomes for TNBC subsets, found benefit for DFS (HR 0.77; P = 0.001) and for OS similar to our findings (HR 0.69; P = 0.001). Although the stated intent was to study the addition of capecitabine to standard chemotherapy, in fact two included negative studies substituted capecitabine for cyclophosphamide ‐ <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a> and <a href="./references#CD011220-bbs2-0112" title="ZhangX , ZhouY , MaoF , LinY , GuanJ , SunQ . Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study. Medical Oncology2015;32(10):240. ">Zhang 2015</a> ‐ the latter of which has not been included in our analysis of studies adding capecitabine. </p> <p>In contrast, a previous review, which studied the addition of capecitabine only in the adjuvant setting without a prospective subtype focus, incorporating 9302 patients in eight trials, found no overall effect of capecitabine on DFS or OS (<a href="./references#CD011220-bbs2-0136" title="NatoriA , EthierJL , AmirE , CesconDW . Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials. European Journal of Cancer2017;77:40-7.">Natori 2017</a>), in keeping with the overall population in our study. These review authors observed that capecitabine appeared to exert a beneficial effect on DFS when added to a regimen in comparison to its effect when substituted for an existing component, although they did not demonstrate significant benefit of addition over standard treatment for any outcome measure. Further, they reported a significant beneficial effect on OS for the addition of capecitabine in trials with greater proportions of triple‐negative cancers. However, an OS benefit specifically in triple‐negative patients alone was not reported, potentially as the results of <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> and <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> were not available at the time of publication, and because they did not specifically extract patient cohorts by hormone receptor expression profile. In contrast, we found significant OS benefit for the whole cohort, as well as for hormone receptor‐negative and triple‐negative patients, from capecitabine addition, along with DFS benefit for hormone receptor‐negative and triple‐negative patients.<br/><br/>A review of capecitabine incorporation in the neoadjuvant setting included five trials totaling 3257 patients (<a href="./references#CD011220-bbs2-0130" title="LiQ , JiangY , WeiW , YangH , LiuJ . Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS One2013;8(1):e53403.">Li 2013</a>), four of which were included in our own review, which also included two newer studies. Findings were essentially identical to our own, showing no benefit for pCR from capecitabine inclusion on a background of significant heterogeneity. This study did not report DFS or OS, both of which we found to be unchanged by capecitabine addition. </p> <p>Worthy of comment is the as yet unpublished meta‐analysis of 15,457 individual patients from 12 neoadjuvant or adjuvant studies exploring the impact of capecitabine on outcomes that included assessment of results by receptor status, presented at the San Antonio Breast Cancer Symposium in 2019 (<a href="./references#CD011220-bbs2-0131" title="vanMackelenberghM , SeitherF , MöbusV , O'ShaugnessyJ , MartinM , JoenssuuH , et al. Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Cancer Research2020;80(4 Suppl):GS1-07. [DOI: 10.1158/1538-7445.SABCS19-GS1-07]">Mackelenbergh 2019</a>). A core difference regarding this analysis relative to our study was the combination of adjuvant and neoadjuvant trial outcomes. We found that data in available publications of neoadjuvant trials were insufficient to enable their incorporation into useful DFS and OS analyses. Nevertheless, results were in close concordance with our own based on adjuvant patients alone, also concluding that benefits were largely confined to TNBC subsets, and were driven by the utility of capecitabine when added to a regimen rather than substituted.<br/><br/>OS benefits in this presented meta‐analysis for capecitabine added to existing regimens in the TNBC population were more modest (HR 0.778; P = 0.004) than those observed in our own study (HR 0.61; P = 0.0004). This difference could be accounted for by inclusion of 345 neoadjuvant patients from the <a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a> study, for which no subtype‐related outcome data were available for this negative study; by inclusion of 773 neoadjuvant patients from the <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a> study, which added either capecitabine or gemcitabine to an existing regimen, which we therefore classified as a substitution study that also produced a negative result; and by exclusion of 561 patients from the <a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> study, which added capecitabine to docetaxel after anthracycline‐based therapy, presumptively because of lack of individual patient data, yielding a positive result. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011220-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram." data-id="CD011220-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph for metastatic studies." data-id="CD011220-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph for metastatic studies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph for adjuvant studies." data-id="CD011220-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph for adjuvant studies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph for neoadjuvant studies." data-id="CD011220-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias graph for neoadjuvant studies.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.1 OS all." data-id="CD011220-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.1 OS all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.7 PFS all." data-id="CD011220-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.7 PFS all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.13 ORR all." data-id="CD011220-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, outcome: 6.13 ORR all. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 1: OS all" data-id="CD011220-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 1: OS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 2: OS hormone receptor‐positive: sensitivity analysis of pooled analysis" data-id="CD011220-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 2: OS hormone receptor‐positive: sensitivity analysis of pooled analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 3: OS hormone receptor‐negative: sensitivity analysis of pooled analysis" data-id="CD011220-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 3: OS hormone receptor‐negative: sensitivity analysis of pooled analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 6: OS triple‐negative" data-id="CD011220-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 6: OS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 7: PFS all" data-id="CD011220-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 7: PFS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 8: PFS hormone receptor‐positive: sensitivity analysis of pooled analysis" data-id="CD011220-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 8: PFS hormone receptor‐positive: sensitivity analysis of pooled analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 9: PFS hormone receptor‐negative: sensitivity analysis of pooled analysis" data-id="CD011220-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 9: PFS hormone receptor‐negative: sensitivity analysis of pooled analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 12: PFS triple‐negative" data-id="CD011220-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 12: PFS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 13: ORR all" data-id="CD011220-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 13: ORR all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 14: ORR TNBC" data-id="CD011220-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 14: ORR TNBC </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 15: CBR all" data-id="CD011220-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 15: CBR all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 16: Complete response rate all" data-id="CD011220-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 16: Complete response rate all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 17: Complete response rate HR+" data-id="CD011220-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 17: Complete response rate HR+ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 18: Complete response rate HR‐" data-id="CD011220-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen, Outcome 18: Complete response rate HR‐ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 1: OS all" data-id="CD011220-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 1: OS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 2: OS HR+" data-id="CD011220-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 2: OS HR+ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 3: OS HR‐" data-id="CD011220-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 3: OS HR‐ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 4: OS triple‐negative" data-id="CD011220-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 4: OS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 5: PFS all" data-id="CD011220-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 5: PFS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 6: PFS HR+" data-id="CD011220-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 6: PFS HR+ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 7: PFS HR‐" data-id="CD011220-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 7: PFS HR‐ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 8: PFS triple‐negative" data-id="CD011220-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 8: PFS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 9: ORR all" data-id="CD011220-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 9: ORR all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 10: CBR all" data-id="CD011220-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 10: CBR all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 11: Complete response rate all" data-id="CD011220-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Metastatic: capecitabine monotherapy vs chemotherapy, Outcome 11: Complete response rate all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 1: OS all" data-id="CD011220-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 1: OS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 2: OS HR+" data-id="CD011220-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 2: OS HR+ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 3: OS HR‐" data-id="CD011220-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 3: OS HR‐ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 4: OS triple‐negative" data-id="CD011220-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 4: OS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 5: PFS all" data-id="CD011220-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 5: PFS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 6: PFS HR+" data-id="CD011220-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 6: PFS HR+ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 7: PFS HR‐" data-id="CD011220-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 7: PFS HR‐ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 8: PFS triple‐negative" data-id="CD011220-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 8: PFS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 9: ORR all" data-id="CD011220-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 9: ORR all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 10: CBR all" data-id="CD011220-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 10: CBR all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 11: Complete response rate all" data-id="CD011220-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 11: Complete response rate all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 12: Complete response rate HR+" data-id="CD011220-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 12: Complete response rate HR+ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 13: Complete response rate HR‐" data-id="CD011220-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Metastatic: addition of capecitabine vs chemotherapy/other, Outcome 13: Complete response rate HR‐ </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 1: OS all" data-id="CD011220-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 1: OS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 2: OS hormone receptor‐positive" data-id="CD011220-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 2: OS hormone receptor‐positive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 3: OS hormone receptor‐negative" data-id="CD011220-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 3: OS hormone receptor‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 4: OS triple‐negative" data-id="CD011220-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 4: OS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 5: PFS all" data-id="CD011220-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 5: PFS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 6: PFS hormone receptor‐positive" data-id="CD011220-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 6: PFS hormone receptor‐positive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 7: PFS hormone receptor‐negative" data-id="CD011220-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 7: PFS hormone receptor‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 8: PFS triple‐negative" data-id="CD011220-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 8: PFS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 9: ORR all" data-id="CD011220-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 9: ORR all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 10: ORR TNBC" data-id="CD011220-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 10: ORR TNBC </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 11: CBR all" data-id="CD011220-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 11: CBR all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 12: Complete response rate all" data-id="CD011220-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: Metastatic: substitution of capecitabine vs chemotherapy/other, Outcome 12: Complete response rate all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 1: OS (all)" data-id="CD011220-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 1: OS (all) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 2: OS hormone receptor‐positive" data-id="CD011220-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 2: OS hormone receptor‐positive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 3: OS hormone receptor‐negative" data-id="CD011220-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 3: OS hormone receptor‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 4: OS triple‐negative" data-id="CD011220-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 4: OS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 5: AE ‐ Anaemia" data-id="CD011220-fig-0062" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 5: AE ‐ Anaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 6: AE ‐ Neutropenia" data-id="CD011220-fig-0063" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 6: AE ‐ Neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 7: AE ‐ Febrile neutropenia" data-id="CD011220-fig-0064" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 7: AE ‐ Febrile neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 8: AE ‐ Thrombocytopenia" data-id="CD011220-fig-0065" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 8: AE ‐ Thrombocytopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 9: AE ‐ Hand‐foot syndrome" data-id="CD011220-fig-0066" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 9: AE ‐ Hand‐foot syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 10: AE ‐ Mucositis" data-id="CD011220-fig-0067" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 10: AE ‐ Mucositis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 11: AE ‐ Diarrhoea" data-id="CD011220-fig-0068" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 11: AE ‐ Diarrhoea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 12: AE ‐ Ischaemic heart disease" data-id="CD011220-fig-0069" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 12: AE ‐ Ischaemic heart disease </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-005.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 13: AE ‐ Treatment‐related death" data-id="CD011220-fig-0070" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-005.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5: Adjuvant all: capecitabine‐containing regimen vs other regimen, Outcome 13: AE ‐ Treatment‐related death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-005.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adjuvant All: Sensitivity analysis of combining DFS and RFS, Outcome 1: DFS and RFS together" data-id="CD011220-fig-0071" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Adjuvant All: Sensitivity analysis of combining DFS and RFS, Outcome 1: DFS and RFS together </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adjuvant All: Sensitivity analysis of combining DFS and RFS, Outcome 2: DFS and RFS: Hormone Receptor Positive" data-id="CD011220-fig-0072" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Adjuvant All: Sensitivity analysis of combining DFS and RFS, Outcome 2: DFS and RFS: Hormone Receptor Positive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adjuvant All: Sensitivity analysis of combining DFS and RFS, Outcome 3: DFS and RFS: Hormone Receptor Negative" data-id="CD011220-fig-0073" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Adjuvant All: Sensitivity analysis of combining DFS and RFS, Outcome 3: DFS and RFS: Hormone Receptor Negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Adjuvant All: Sensitivity analysis of combining DFS and RFS, Outcome 4: DFS and RFS: Triple negative" data-id="CD011220-fig-0074" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Adjuvant All: Sensitivity analysis of combining DFS and RFS, Outcome 4: DFS and RFS: Triple negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 1: DFS/RFS all" data-id="CD011220-fig-0075" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 1: DFS/RFS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 2: DFS/RFS hormone receptor‐positive" data-id="CD011220-fig-0076" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 2: DFS/RFS hormone receptor‐positive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 3: DFS/RFS hormone receptor‐negative" data-id="CD011220-fig-0077" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 3: DFS/RFS hormone receptor‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 4: DFS/RFS triple‐negative" data-id="CD011220-fig-0078" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 4: DFS/RFS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 5: OS (all)" data-id="CD011220-fig-0079" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 5: OS (all) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 6: OS hormone receptor‐positive" data-id="CD011220-fig-0080" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 6: OS hormone receptor‐positive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 7: OS hormone receptor‐negative" data-id="CD011220-fig-0081" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 7: OS hormone receptor‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 8: OS triple‐negative breast" data-id="CD011220-fig-0082" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen, Outcome 8: OS triple‐negative breast </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 1: DFS" data-id="CD011220-fig-0083" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 1: DFS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 2: DFS hormone receptor‐positive" data-id="CD011220-fig-0084" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 2: DFS hormone receptor‐positive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 3: DFS hormone receptor‐negative" data-id="CD011220-fig-0085" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 3: DFS hormone receptor‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 4: DFS triple‐negative" data-id="CD011220-fig-0086" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 4: DFS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 5: OS" data-id="CD011220-fig-0087" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 5: OS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 6: OS hormone receptor‐positive" data-id="CD011220-fig-0088" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 6: OS hormone receptor‐positive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-008.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 7: OS hormone receptor‐negative" data-id="CD011220-fig-0089" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-008.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 7: OS hormone receptor‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-008.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 8: OS triple‐negative" data-id="CD011220-fig-0090" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-008.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.8</div> <div class="figure-caption"> <p>Comparison 8: Adjuvant: capecitabine monotherapy vs chemotherapy/other, Outcome 8: OS triple‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-008.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 1: PCR all (breast and nodes)" data-id="CD011220-fig-0091" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 1: PCR all (breast and nodes) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 2: PCR hormone receptor‐positive" data-id="CD011220-fig-0092" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 2: PCR hormone receptor‐positive </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 3: PCR hormone receptor‐negative" data-id="CD011220-fig-0093" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 3: PCR hormone receptor‐negative </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 4: PCR triple‐negative (breast and nodes)" data-id="CD011220-fig-0094" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 4: PCR triple‐negative (breast and nodes) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 5: DFS all" data-id="CD011220-fig-0095" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.5</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 5: DFS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 6: OS all" data-id="CD011220-fig-0096" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.6</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 6: OS all </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 7: AE ‐ Anaemia" data-id="CD011220-fig-0097" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.7</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 7: AE ‐ Anaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 8: AE ‐ Neutropenia" data-id="CD011220-fig-0098" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.8</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 8: AE ‐ Neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 9: AE ‐ Febrile neutropenia" data-id="CD011220-fig-0099" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.9</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 9: AE ‐ Febrile neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 10: AE ‐ Thrombocytopenia" data-id="CD011220-fig-0100" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.10</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 10: AE ‐ Thrombocytopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 11: AE ‐ Hand‐foot syndrome" data-id="CD011220-fig-0101" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.11</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 11: AE ‐ Hand‐foot syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 12: AE ‐ Mucositis" data-id="CD011220-fig-0102" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.12</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 12: AE ‐ Mucositis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 13: AE ‐ Diarrhoea" data-id="CD011220-fig-0103" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.13</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 13: AE ‐ Diarrhoea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 14: AE ‐ Ischaemic heart disease" data-id="CD011220-fig-0104" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.14</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 14: AE ‐ Ischaemic heart disease </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011220-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/urn:x-wiley:14651858:media:CD011220:CD011220-CMP-009.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 15: AE ‐ Treatment‐related death" data-id="CD011220-fig-0105" src="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_t/tCD011220-CMP-009.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.15</div> <div class="figure-caption"> <p>Comparison 9: Neoadjuvant: addition of capecitabine vs standard chemotherapy, Outcome 15: AE ‐ Treatment‐related death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/media/CDSR/CD011220/image_n/nCD011220-CMP-009.15.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011220-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Capecitabine‐containing regimens compared to chemotherapy regimens without capecitabine for metastatic breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Capecitabine‐containing regimens compared to chemotherapy regimens without capecitabine for metastatic breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with metastatic breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> capecitabine‐containing regimens<br/><b>Comparison:</b> chemotherapy regimens without capecitabine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with chemotherapy regimens without capecitabine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with capecitabine‐containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Overall survival (OS)<br/>median follow‐up: range 18.6 months to 37.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of death<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 1.01<br/>(0.98 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4325<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Heterogeneity was detected and was explained by variations in chemotherapy backbones. The certainty of evidence was not downgraded, as variations in chemotherapy are likely to occur in clinical practice </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>370 per 1000<br/>(361 to 381) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OS: hormone receptor‐positive<br/>median follow‐up: range 18.6 months to 37.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of death<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 0.90<br/>(0.80 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1565<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>As above</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>338 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000<br/>(281 to 343) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>OS: hormone receptor‐negative<br/>median follow‐up: range 18.6 months to 34.3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of death<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 1.05<br/>(0.91 to 1.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1408<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>As above</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>590 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>608 per 1000<br/>(556 to 657) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Progression‐free survival (PFS)<br/>median follow‐up: range 18.6 months to 37.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of progression<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 0.89<br/>(0.83 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>4325<br/>(12 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>745 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>704 per 1000<br/>(678 to 731) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PFS: hormone receptor‐positive<br/>median follow‐up: range 18.6 months to 37.6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of progression<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 0.77<br/>(0.68 to 0.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1372<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>750 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>656 per 1000<br/>(610 to 701) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>PFS: hormone receptor‐negative<br/>median follow‐up: range 20.6 months to 34.3 months </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>1‐year risk of progression<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>HR 1.01<br/>(0.85 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>900<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>880 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>883 per 1000<br/>(835 to 920) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Objective response rate<br/>follow‐up range: 1.5 months to 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>318 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000<br/>(268 to 354) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/>(0.84 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4200<br/>(12 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life<br/>assessed with: EORTC QLQ‐C30 or Rotterdam Symptom Checklist<br/>assessed at baseline and at 2 years (or later) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not estimable. In general, there did not seem to be differences in global health scores between the 2 treatment groups at around 2 years' follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(5 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most studies used the validated EORTC QLQ‐C30 questionnaire (4 studies) or the Rotterdam Symptom Checklist (1 study), and measures were patient‐reported </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/>CI: confidence interval; EORTC QLQ‐C30: European Organization for Research and Treatment of Cancer core quality of life questionnaire; HR:<b>h</b>azard ratio; ORR: objective response rate; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk in the comparator arm was based on 1‐year estimates from 11 studies for OS (<a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>; <a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a>; <a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a>; <a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a>; <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>; <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a>; <a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a>; <a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a>; <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>; <a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a>; <a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a>), as well as on data from a subset of studies that reported the event rate at 1 year in the comparator arm based on hormone receptor status (i.e. hormone receptor‐positive: <a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>; <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>; <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>; hormone receptor‐negative: <a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a>; <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a>; <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>).<br/><sup>b</sup>Baseline risk in the comparator arm was based on 1‐year estimates from all 12 studies that reported on PFS, as well as on data from one study for hormone receptor status (i.e. hormone receptor‐positive: <a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a>; hormone receptor‐negative: <a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a>).<br/><sup>c</sup>Studies were open‐label with limited independent assessment/central review of these outcomes. We thought some bias may be introduced by lack of blinding when PFS and ORR were assessed; therefore we downgraded the certainty of evidence by one level for risk of bias.<br/><sup>d</sup>This outcome was downgraded because all measures were patient‐reported, taking place in open‐label studies, and therefore was at high risk of bias. Although most studies used the validated EORTC QLQ‐C30 questionnaire; there was also variability in time frames when women were given the questionnaires and different lengths of follow‐up. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Capecitabine‐containing regimens compared to chemotherapy regimens without capecitabine for metastatic breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011220-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens for neoadjuvant treatment</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Capecitabine‐containing regimens compared to non‐capecitabine‐containing for neoadjuvant treatment of ER‐positive versus ER‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> capecitabine‐containing regimens<br/><b>Comparison:</b> regimens without capecitabine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐capecitabine‐containing regimens</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with capecitabine‐containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pathological complete response (pCR): breast and axillary nodes<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>202 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221 per 1000<br/>(193 to 252) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.12<br/>(0.94 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3152<br/>(6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No serious concerns, although it is noted that <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a> was deemed to be at high risk of selection bias </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pCR: hormone receptor‐positive<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 1000<br/>(42 to 101) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.22<br/>(0.76 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>964<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>pCR: hormone receptor‐negative<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>219 per 1000<br/>(118 to 368) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.28<br/>(0.61 to 2.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>646<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease‐free survival<br/>median follow‐up: range 3 years to 5.4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of recurrence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.02<br/>(0.86 to 1.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2499<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000<br/>(218 to 292) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival<br/>median follow‐up: range 3 years to 5.4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of death</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.97<br/>(0.77 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2499<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>164 per 1000<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000<br/>(129 to 198) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Febrile neutropenia<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/>(64 to 112) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.31<br/>(0.97 to 1.77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2890<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>72 per 1000<br/>(50 to 104) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.95<br/>(1.32 to 2.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2686<br/>(3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hand‐foot syndrome<br/>follow‐up: range 3 months to 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000<br/>(136 to 232) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 6.77<br/>(4.89 to 9.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3021<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; ER: oestrogen receptor; HR: hazard ratio; OR: odds ratio; RCT: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk in the control arm was based on three studies (<a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a>; <a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a>; <a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a>), which reported on hormone receptor‐positive and hormone receptor‐negative data separately.<br/><sup>b</sup>Downgraded by 1/2 point due to imprecision (confidence intervals include no effect; appreciable benefit and harm) and by an additional 1/2 point for reporting bias (neither of the two largest studies reported pCR by hormone receptor status).<br/><sup>c</sup>Baseline risk in the control arm was based on 5‐year estimates from two studies (<a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a>; <a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a>).<br/><sup>d</sup>Downgraded by 1/2 point due to imprecision (wide confidence intervals) and by 1/2 point for risk of detection bias because all studies were open‐label, and toxicity assessment (by assessor or patient) may be influenced by lack of blinding of treatment arm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens for neoadjuvant treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011220-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens or no chemotherapy for early breast cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens or no chemotherapy for ER‐positive vs ER‐negative breast cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with early breast cancer<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> capecitabine‐containing regimens<br/><b>Comparison:</b> non‐capecitabine‐containing regimens or no chemotherapy </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№. of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with non‐capecitabine‐containing regimens or no chemotherapy</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with capecitabine‐containing regimens</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Disease‐free survival (DFS)<br/>median follow‐up: range 3.6 years to 10.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of recurrence<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.93<br/>(0.86 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13547<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>166 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000<br/>(145 to 168) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>DFS: hormone receptor‐positive<br/>median follow‐up: range 3.6 years to 10.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of recurrence<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 1.03<br/>(0.91 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5604<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>289 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/>(267 to 329) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>DFS: hormone receptor‐negative<br/>median follow‐up: range 3.6 years to 10.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of recurrence<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.76<br/>(0.65 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2879<br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>429 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>347 per 1000<br/>(305 to 389) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>median follow‐up: range 3.6 years to 10.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>5‐year risk of death<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.89<br/>(0.81 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>13547<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>MODERATE<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000<br/>(85 to 102) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Febrile neutropenia<br/>follow‐up: range 4 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>109 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/>(54 to 73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.55<br/>(0.47 to 0.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8086<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea<br/>follow‐up: range 4 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>59 per 1000<br/>(48 to 71) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 2.46<br/>(2.01 to 3.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11207<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hand‐foot syndrome<br/>follow‐up: range 4 months to 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(112 to 171) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 13.60<br/>(10.65 to 17.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11207<br/>(8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>CI: confidence interval; ER: oestrogen receptor; HR: hazard ratio; OR: odds ratio; RCT: randomised controlled trial; RFS: recurrence‐free survival. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Baseline risk in the control arm was based on 5‐year estimates from seven studies for DFS/RFS (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>; <a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>; <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>), and data from the Oxford overview on women ≥ 50 years of age with ER‐positive breast cancer (Figure 5 in <a href="./references#CD011220-bbs2-0117" title="Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365(9472):1687-717.">EBCTCG 2005</a>) and &lt; 50 years of with ER‐poor breast cancer (Figure 5 in <a href="./references#CD011220-bbs2-0117" title="Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet2005;365(9472):1687-717.">EBCTCG 2005</a>) for DFS hormone receptor‐positive and hormone receptor‐negative breast cancer, respectively.<br/><sup>b</sup>Downgraded by 1/2 point due to some concerns related to attrition bias in three studies and by 1/2 point for indirectness due to inclusion in some studies of people with worse prognosis than in other studies.<br/><sup>c</sup>Baseline risk in the control arm was based on 5‐year estimates from seven studies (<a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a>; <a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a>; <a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a>; <a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a>; <a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a>; <a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a>; <a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a>).<br/><sup>d</sup>Downgraded by 1/2 point due to inconsistency (substantial heterogeneity; confidence intervals do not overlap in the case of febrile neutropenia or diarrhoea) and by 1/2 point for risk of detection bias because all studies were open‐label and toxicity assessment (by assessor or patient) may be influenced by lack of blinding of treatment arm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens or no chemotherapy for early breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011220-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies summarising treatment regimens</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Setting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Capecitabine‐containing arm</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator arm</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0001" title="FoedermayrM , SebestaM , RudasM , BerghoffAS , PrombergerR , PreusserM , et al. Abstract P1-08-40: BRCA-1 promotor methylation and p53 mutation in triple-negative breast cancer patients refractory to taxane-based neoadjuvant chemotherapy. Cancer Research2013;73(24 Supplement):P1-08-40. [DOI: 10.1158/0008-5472.sabcs13-p1-08-40]StegerG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-ZeinitzerE , et al. Final results of ABCSG-24, a randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer and comparing ED/EDC + trastuzumab (T) to ED/EDC as neoadjuvant treatment for early HER-2 positive breast cancer. Cancer Research2009;69(24 Suppl):Abstract no. 1081. StegerGG , GreilR , JakeszR , LangA , MlineritschB , Melbinger-Zeinitzer E et al. A randomized phase III study comparing epirubicin, docetaxel, and capecitabine (EDC) to epirubicin and docetaxel (ED) as neoadjuvant treatment for early breast cancer - First results of the Austrian breast and colorectal cancer study group-trial 24 (ABCSG-24). European Journal of Cancer Supplement2009;7(2-3):3. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC). European Journal of Cancer Supplement2010;8(3):60. StegerGG , GreilR , JakeszR , LangA , MlineritschB , RudasM , et al. Pathologic complete response (pCR) in patient subgroups: an analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC). In: Journal of Clinical Oncology. Vol. 28. 2010:Abstract no. 530. StegerGG , GreilR , JakeszR , MlineritschB , LangA , RudasM , et al. ABCSG-24: Efficacy of anthracycline- and taxane-based neoadjuvant therapy (plus or minus) capecitabine (C) in triple-negative early breast cancer (TNBC). Annals of Oncology2010;21:viii79. StegerGG , GreilR , LangA , RudasM , FitzalF , MlineritschB , et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of Oncology2014;25(2):366-71. [DOI: http://dx.doi.org/10.1093/annonc/mdt508]">ABCSG‐24</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + epirubicin + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0011" title='HuoberJ , LoiblS , UntchM , RB-EsfahaniS , SolbachC , TeschH , et al. Abstract PD02-06: New molecular biomarkers for resistance to trastuzumab in primary HER2 positive breast cancer - a translational investigation from the neoadjuvant GeparQuattro study. Cancer Research2010;70(24 Suppl):D02-6. HuoberJB , DenkertC , vonMinckwitzG , PrinzlerJ , KronenwettR , Darb-Esfahani Silvia, et al. Impact of expression levels of mRNA HER2 and ESR1 on the pathologic complete remission (pCR) rate after neoadjuvant treatment with anthracycline-taxane containing chemotherapy in combination with trastuzumab in the GeparQuattro trial. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 523. LoiS , MichielsS , SalgadoR , SirtaineN , JoseV , FumagalliD , et al. Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Research2013;73(24 Suppl):Abstract no. S1-05. [DOI: 10.1158/0008-5472.sabcs13-s1-05]MinckwitzG , RezaiM , LoiblS , FaschingPA , Huober, J, TeschH , et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. Journal of Clinical Oncology2010;28(12):2015-23. [DOI: 10.1200/JCO.2009.23.8303]RiethdorfS , MüllerV , ZhangL , RauT , LoiblS , KomorM , et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research2010;16(9):2634-45. UntchM , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study “GeparQuattro”. European Journal of Cancer Supplements2008;6(7):47. [DOI: 10.1016/S1359-6349(08)70313-6]vonMinckwitzG , RezaiM , FaschingPA , HuoberJ , TeschH , BauerfeindI , et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro). Annals of Oncology2014;25(1):81-9. vonMinckwitzG , RezaiM , LoiblS , FaschingP , HuoberJ , TeshH , et al. Evaluating the efficacy of capecitabine given concomitantly or in sequence to epirubicin/cyclophosphamide -&gt; docetaxel as neoadjuvant treatment for primary breast cancer. First efficacy analysis of the GBG/AGO intergroup-study "GeparQuattro". Breast Cancer Research and Treatment2007;106(Suppl):S21-2. vonMinckwitzG , RezaiM , LoiblS , FaschingPA , HuoberJ , TeschH , et al. Adding capecitabine and trastuzumab to neoadjuvant breast cancer chemotherapy - first survival analysis of the GBG/AGO intergroup-study GeparQuattro. Cancer Research2012;72(24 Suppl):P1-14-01. [DOI: 10.1158/0008-5472.sabcs12-p1-14-01]WitzelI , MullerV , LoiblS , FehmT , vonMinckwitzG , EidtmannH , et al. Monitoring serum HER2 levels in the neoadjuvant nullGeparquattronull trial - A decrease predicts pathological complete remission. European Journal of Cancer Supplement2010;8(3):61. '>GeparQuattro</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1421</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin + cyclophosphamide &gt; docetaxel &gt; capecitabine or epirubicin + cyclophosphamide &gt; docetaxel + capecitabine </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin + cyclophosphamide &gt; docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0014" title="AhnJB , OhJH , KwonY , ChungKW , KangHS , ShinKH , et al. Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC). Annals of Oncology2004;15(3 Suppl):215PD. JeongJH , JungSY , ParkIH , LeeKS , KangHS , KimSW , et al. Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Investigational New Drugs2012;30(1):408-16. [DOI: 10.1007/s10637-010-9555-7]LeeHG , LeeJJ , JungKH , KwonY , ShinEH , ChungKW , et al. Phase III randomized trial of primary chemotherapy with doxorubicin/cyclophosphamide (AC) vs docetaxel/capecitabine (TX) for stage II/III breast cancer (BC): interim analysis. Journal of Clinical Oncology2004;22(14 Suppl):Abstract no. 607. LeeKS , LeeES , KwonYM , NamBH , KwonHS , ChungKW , et al. Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC) [abstract no: 5052]. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S224. LeeKS , RoJ , NamBH , LeeES , KwonY , KwonHS , ChungKW , et al. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Research and Treatment2008;109(3):481-9. [DOI: 10.1007/s10549-007-9672-y]LeeS , KimSW , KimSK , LeeKS , KimEA , KwonY , et al. Locoregional recurrence of breast conserving surgery after preoperative chemotherapy in Korean women with locally advanced breast cancer. Journal of Breast Cancer2011;14(4):289-95. [DOI: 10.4048/jbc.2011.14.4.289]">Lee 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin + cyclophosphamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0016" title="BearHD , TangG , RastogiP , GeyerCE , AndreR , AtkinsJN , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy: NSABP protocol B-40. Cancer Research2011;71(24 Suppl):Abstract no. PD07-08. BearHD , TangG , RastogiP , GeyerCE , LiuQ , RobidouxA , et al. Abstract PD2-1: The effect on overall and disease-free survival (OS &amp; DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Cancer Research2015;75(9 Suppl):PD2-1. BearHD , TangG , RastogiP , GeyerCE , RobidouxA , AtkinsJN , BaezL , et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Journal of Clinical Oncology2011;29(18 Suppl):Abstract no. LBA1005. BearHD , TangG , RastogiP , GeyerCE , ZoonCK , KidwellKM , et al. The effect on surgical complications of bevacizumab added to neoadjuvant chemotherapy for breast cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology2017;24(7):1853-60. BearHD , TangG , RastogiP , Geyer CE Jr, LiuQ , RobidouxA , et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology2015;16(9):1037-48. BearHD , TangG , RastogiP , Geyer CE Jr, RobidouxA , AtkinsJN , et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. New England Journal of Medicine2012;366(4):310-20. ">NSABP‐40</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel &gt; doxorubicin + cyclophosphamide ± bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Docetaxel or docetaxel + gemcitabine &gt; doxorubicin + cyclophosphamide ± bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0025" title="YooC , KimSB , AhnJH , KimJE , JungKH , GongGY , et al. A randomized phase II trial of capecitabine plus vinorelbine followed by docetaxel versus adriamycin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for breast cancer. Cancer Research and Treatment2014;47(3):406-15. ">Yoo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + vinorelbine &gt; docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin + cyclophosphamide &gt; docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0026" title="ZhangM , WeiW , LiuJ , YangH , JiangY , TangW , et al. Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer. OncoTargets and Therapy2016;9:3443-50. ">Zhang 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + epirubicin + cyclophosphamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fluorouracil + epirubicin + cyclophosphamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0003" title="LiJ , ShaoZ , YangS , JiangJ , WangC , LiuY , et al. CBCSG-10, the addition of capecitabine to adjuvant chemotherapy in triple-negative breast cancer. In: Breast. Vol. 24. 2015:S53. [DOI: http://dx.doi.org/10.1016/S0960-9776%2815%2970127-X]ZhiminS , LiJ , PangD , WangC , JianJ , YangS , et al. CBCSG-10: adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer. In: ASCO Meeting Abstracts. Vol. 34. 2016:1012. ">CBCSG‐10</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel &gt; epirubicin + cyclophosphamide + capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Docetaxel &gt; fluorouracil + epirubicin + cyclophosphamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0006" title="BarriosCE , LluchA , Ruiz-BorregoM , BinesJ , TorrecillasL , CarrascoE , et al. Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2013;73(24 Suppl):OT3-1-06. [DOI: 10.1158/0008-5472.SABCS13-OT3-1-06]LluchA , GomezH , Ruiz-BorregoM , BinesJ , LlombartA , RamosM , et al. Abstract P5-10-15: First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Cancer Research2010;70(24 Suppl):P5-10-5-P5--5. LluchA , Ruiz-BorregoM , BarriosCH , BinesJ , TorrecillasL , SegallaJGM , et al. 422 Final safety data from a randomised phase III trial (CIBOMA/2004-01_GEICAM/2003-11) assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer; a study From Coalicion Iberoamericana De Investigacion En Oncologia Mamaria (CIBOMA) and Grupo Espanol De Investigacion En Cancer De Mama (GEICAM). European Journal of Cancer2012;48(1):S169-70. ">CIBOMA 2004‐01</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant chemotherapy &gt; adjuvant capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0007" title="MasudaN , LeeSJ , OhtaniS , ImYH , LeeES , YokotaI , et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine2017;376(22):2147-59. OhtaniS , MasudaN , Im Y-H, Im S-A, Park B-W, Kim S-B, et al. Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X (JBCRG-04). Cancer Research2013;73(24 Suppl):P3-12-03. [DOI: 10.1158/0008-5472.sabcs13-p3-12-03]ToiM , LeeSJ , LeeES , OhtaniS , ImYH , ImSA , et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). Cancer Research2016;76(4 Suppl 1):Abstract S1-07. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-07]">CREATE‐X</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoadjuvant chemotherapy &gt; adjuvant capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0009" title="JoensuuH , HemminkiA , TannerM , PaijaO , KokkoR , AsolakR , et al. Phase III, randomized study of docetaxel (T) + capecitabine (X) (TX) followed by cyclophosphamide (C) + epirubicin (E) + X (CEX) vs. T followed by C + E + fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): an interim safety analysis. Journal of Clinical Oncology2005;23(16 Suppl):57S. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , AsolaR , KokkoR , et al. Significant improvement in recurrence-free survival (RFS) when capecitabine (X) is integrated into docetaxel (T) -&gt; 5-FU + epirubicin + cyclophosphamide (CEF) adjuvant therapy for high-risk early breast cancer (BC): interim analysis of the FinXX-trial. Cancer Research2009;69(2 Suppl):Abstract no. 82. JoensuuH , Kellokumpu-LehtinenP , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): efficacy in patients with triple-negative breast cancer (BC). Journal of Clinical Oncology2010;28(15):Abstract no. 531. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , AsolaR , et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncology2009;10(12):1145-51. [DOI: 10.1016/S1470-2045(09)70307-9]JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract S4-1: FinXX Final 5-year analysis: results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer. Cancer Research2010;70(24 Suppl):Abstract no. S4-1. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of Clinical Oncology2012;30(1):11-8. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncology2017;3(6):793-800. JoensuuH , Kellokumpu-Lehtinen P-L, HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Adjuvant capecitabine in combination with docetaxel (T), epirubicin (E), and cyclophosphamide (C) in the treatment of early breast cancer (BC): 10-year survival results from the randomized FinXX trial. Journal of Clinical Oncology2016;34(15 Suppl):1001. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. JoensuuH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica2014;53(2):186-94. [DOI: 10.3109/0284186X.2013.820840]LindmanH , Kellokumpu-LehtinenPL , HuovinenR , Jukkola-VuorinenA , TannerM , KokkoR , et al. Abstract PD01-02: Integration of capecitabine into anthracycline-and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. Cancer Research2010;70(24 Suppl):D01-2. ">FINXX</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel &gt; epirubicin + cyclophosphamide + capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Docetaxel &gt; fluorouracil + epirubicin + cyclophosphamide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0010" title="BermejoB , Ruiz, A, BorregoMR , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Randomized phase III study of adjuvant chemotherapy for node-positive early breast cancer (BC) patients (pts) comparing epirubicin plus cyclophosphamide followed by docetaxel (EC-T) versus epirubicin plus docetaxel followed by capecitabine (ET-X): efficacy analysis of the GEICAM/2003-10 trial. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1027. MartinM , Ruiz SimonA , Ruiz BorregoM , RibellesN , Rodriguez-LescureA , Munoz-MateuM , et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. Journal of Clinical Oncology2015;33(32):3788-95. ">GEICAM 2003‐10</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + epirubicin + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin + cyclophosphamide &gt; docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0012" title="ReimerT , JoelB , vonMinckwitzG , PotenbergJ , ConradB , GrafH , et al. Quality of life (QoL) in elderly patients (pts) with early-stage breast cancer treated with ibandronate (I) with or without capecitabine (X): results of the GBG 32 ICE trial. European Journal of Cancer Supplement2009;7(2-3):219-20. ReimerT , NitzU , PotenbergJ , ConradB , GrafH , JustM , et al. ICE Study: A prospective, multi-centre, controlled, open-label, randomized phase III trial of ibandronate (I) with or without capecitabine (X) in elderly patients (pts) with early breast cancer (GBG 32). European Journal of Cancer Supplements2009;7(2):215. [DOI: 10.1016/S1359-6349(09)70737-2]vonMinckwitzG , ReimerT , PotenbergJ , ConradB , SchürerU , EidtmannH , et al. Abstract S3-04: The phase III ICE study: adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. Cancer Research2015;75(9 Suppl):S3-4. ">ICE</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + ibandronate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0022" title="BayaniJ , MordenJ , SkariaS , BlissP , GrieveR , HarnettA , et al. Abstract P4-11-03: Androgen receptor expression is an independent marker of lower residual risk in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-03. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-03]BlissJM , CanneyP , VelikovaG , Barrett-LeeP , MoysesH , McDermaidM , et al. Abstract P5-10-07: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) followed by capecitabine (X) or CMF in 129 UK hospitals (CRUK/05/019) 771. Cancer Research2010;70(24 Suppl):5-10. CameronD , Barrett-LeeP , CanneyP , BanerjiJ , BartlettJ , BloomfieldD , et al. Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). Cancer Research2012;72(24 Suppl):Abstract no. S3-3. [DOI: 10.1158/0008-5472.sabcs12-s3-3]CameronD , Barrett-LeeP , VelikovaG , CanneyP , MoysesH , McDermaidM , et al. Abstract P5-10-06: TACT2 randomised adjuvant trial in early breast cancer (EBC): tolerability and toxicity of standard 3 weekly epirubicin (E) versus accelerated epirubicin (aE) in 129 UK hospitals (4391 patients) (CRUK/05/019). Cancer Research2010;70(24 Suppl):Abstract no. P5-10-06. CameronD , MordenJP , CanneyP , VelikovaG , ColemanR , BartlettJ , et al. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology2017;18(7):929-45. CanneyP , Barrett-LeeP , BartlettJ , BertelliG , ColemanR , EarlH , et al. The UK TACT2 Trial: non-inferiority of capecitabine compared with CMF after epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). European Journal of Cancer2014;50:S99-100. CanneyP , ColemanR , MordenJ , Barrett-LeeP , BanerjiJ , WardleyA , et al. 200 TACT2 Trial in early breast cancer (EBC): differential rates of amenorrhoea in premenopausal women following adjuvant epirubicin (E) or accelerated epirubicin (aE) followed by capecitabine (X) or CMF (CRUK/05/019). European Journal of Cancer2012;48(Suppl 1):S102. [DOI: 10.1016/S0959-8049(12)70268-X]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. 1231 Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-S184. [DOI: 10.1016/s0959-8049(16)30535-4]ChapmanH , BloomfieldD , CameronD , BlissJ , Barrett-LeeP , CanneyP , et al. Cost-effectiveness analysis of the use of pegfilgrastim to enable accelerated adjuvant chemotherapy in the TACT2 trial (CRUK/05/019). European Journal of Cancer2015;51(Suppl 3):S183-4. MordenJ , BlissJ , BayaniJ , LaingR , AgrawalR , ThomasJ , et al. Intrinsic subtypes and BCL2 as predictive and prognostic biomarkers in the TACT2 trial (CRUK/05/019). Cancer Research2015;75(9 Suppl):Abstract no. P4-11-04. [DOI: http://dx.doi.org/10.1158/1538-7445.SABCS14-P4-11-04]VelikovaG , Barrett-LeeP , BloomfieldD , BruntM , CanneyP , ColemanR , et al. Quality of life results of the UK TACT2 Trial: more intensive chemotherapy for early breast cancer has a measurable impact on patient-reported symptoms and functioning (CRUK/05/019). European Journal of Cancer2014;50:S109. ">TACT2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitibine + epirubicin (dose dense or standard)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epirubicin (dose dense or standard) &gt; cyclophosphamide + methotrexate + fluorouracil</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0024" title="NCT00089479. A randomized, open-label, multicenter, phase III trial comparing regimen of adriamycin plus cytoxan followed by either taxotere or taxotere plus Xeloda as adjuvant therapy for female patients with high-risk breast cancer [A study of Xeloda (capecitabine) in women with high-risk breast cancer]. clinicaltrials.gov/ct2/show/NCT000894792004;(PDQ; NO17629; NCT00089479). O'ShaughnessyJ , KoeppenH , CrockettM , LacknerM , SpoerkeJM , WilsonT , et al. Abstract P6-09-01: Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062. Cancer Research2013;73(24 Suppl):Abstract no. P6-09-01. O'ShaughnessyJ , KoeppenH , XiaoY , LacknerMR , PaulD , StokoeC , et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research2015;21(19):4305-11. O'ShaughnessyJ , LoeschDM , PaulD , StokoeCT , PippenJE , BlumJL , et al. ER as a predictor of early breast cancer (EBC) outcomes in patients. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 590. O'ShaughnessyJ , PaulD , StokoeC , Pippen JrJ , BlumJL , KrekowL , et al. Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer 24 2672. Cancer Research2010;70(24 Suppl):S4-2. O'ShaughnessyJ , PippenJE , DevchandP , StokoeCT , BlumJL , KrekowL , et al. Adjuvant capecitabine for invasive lobular/mixed early breast cancer (EBC): USON 01062 exploratory analyses. Journal of Clinical Oncology2012;30(15 Suppl):Abstract no. 547. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. O'ShaughnessyJ , WilsonTR , LevinMK , CrockettMW , SpoerkeJM , XiaoY , et al. Low cytolytic T-cell CD8 expression in mesenchymal triple negative (TN) breast cancers and overexpression of the adhesion protein CD24 in ER+ breast cancers that recur within 3 years of adjuvant chemotherapy. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 582. PippenJE , PaulD , StokoeCT , BlumJL , KrekowL , HolmesFA , et al. Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) -&gt; docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: exploratory Ki-67 analyses. Journal of Clinical Oncology2011;29(15 Suppl):Abstract no. 500. ">USON 01062</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adjuvant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin + cyclophosphamide &gt; docetaxel + capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Doxorubicin + cyclophosphamide &gt; docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>309</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Everolimus ± exemestane</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gemcitabine + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + trastuzumab + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trastuzumab + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cisplatin + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glembatumumb vedotin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vinorelbine + gemcitabine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gemcitabine + docetaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eribulin mesylate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab + docetaxel OR paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + docetaxel OR paclitaxel</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metastatic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bevacizumab + paclitaxel</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview of included studies summarising treatment regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011220-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality of life assessments in patients with metastatic breast cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>QoL collected or reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Questionnaire and any methods used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Main results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Collected as listed in NCT01783444 trial record but not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rotterdam Symptom Checklist at baseline and on Day 1 of each cycle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"QoL was not different between treatment arms. There was no decrease in the overall valuation of life in either arm. Additional data will be presented in a separate publication" (p 1758) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire‐C30, completed at screening, at randomisation, every 3 cycles before progression, and at (but not after) disease progression </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Mean change from baseline for global health score did not differ between the treatment groups (data not shown). More detailed patient‐reported outcome results and exploratory analyses will be reported separately" (p 1358) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORTC QLQ‐C30 but only in selected centres, where there were validated EORTC questionnaire translations. Primary QoL analysis used the "last observation forward' approach to replacing missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Analysis included 454 patients from 15 countries. Global Health Score was selected as the primary parameter for statistical testing. No significant differences between treatment arms at Day 127 were noted. There was a trend towards less deterioration of GHS in the combination arm over time" (p 2817) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (version 3.0) and breast module Quality of Life Questionnaire BR23 (version 1.0) at baseline, at 6 weeks, and at 3, 6, 12, 18, and 24 months, or until disease progression or initiation of other antitumour treatment. The principal pre‐specified outcome was overall QoL, expressed as change from baseline in Global Health Status (GHS)/QoL measured on a 0 (worst) to 100 (best) scale </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"&gt; 95% available at baseline, completion rates decreased with time in both treatment arms. GHS/QoL scores low at baseline in both eribulin and capecitabine arms. Over time, average GHS/QoL scores improved in both arms; linear‐mixed and pattern‐mixed model showed no significant difference between groups" (p 599) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EORCT QLQ‐30 at baseline, at each tumour assessment (every 12 weeks), and 28 days after discontinuation of study treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Baseline QoL questionnaires available from all participants in safety population in both arms. End of treatment QoL questionnaires were available from 49% in paclitaxel group and 51% in capecitabine group. Analysis of mean global health status showed no major difference between treatment groups and little change from baseline over time. Highest mean baseline symptom scores in both groups were for fatigue, pain, and insomnia; mean scores showed no meaningful increase (reflecting deterioration in QoL) over time. Mean scores for appetite loss, dyspnoea, and financial difficulties varied slightly over time with little difference between groups. Mean scores for physical, emotional, role, cognitive, and social functioning showed slight or no change over time and no differences between treatment groups" (p 130) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>EORTC QLQ‐C30: European Organization for Research and Treatment of Cancer core quality of life questionnaire. </p> <p>GHS: global health status.</p> <p>N/A: not applicable.</p> <p>QoL: quality of life.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Quality of life assessments in patients with metastatic breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011220-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Toxicities for capecitabine‐containing regimens vs non‐capecitabine‐containing regimens for metastatic breast cancer</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Treatment vs comparator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Febrile neutropenia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Diarrhoea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Hand‐foot syndrome</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Capecitabine regimen (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Capecitabine regimen (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Capecitabine regimen (n/N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparator (n/N)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0002" title="JerusalemG , deBoerRH , HurvitzS , YardleyDA , KovalenkoE , EjlertsenB , et al. Everolimus plus exemestane vs everolimus or capecitabine monotherapy for estrogen receptor-positive, HER2-negative advanced breast cancer: the BOLERO-6 randomized clinical trial. JAMA Oncology2018;4(10):1367-74. JerusalemGHM , KovalenkoE , YardleyDA , De BoerRH , HurvitzSA , EjlertsenB , et al. Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study. In: Journal of Clinical Oncology. Vol. 36. 2018:Abstract no. 1005. ">BOLERO6</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine vs everolimus + exemestane</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/104</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0004" title="ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , LluchA , et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. Journal of Clinical Oncology2005;23(16 Suppl):24S. ChanS , RomieuG , HuoberJ , DelozierT , Tubiana-HulinM , SchneeweissA , et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology2009;27(11):1753-60. [DOI: 10.1200/JCO.2007.15.8485]FumoleauP , RomieuG , ChanS , HuoberJ , Tubiana-JulinM , SchneeweissA , et al. Impact of symptoms and toxicity on quality of life: exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer. Journal of Clinical Oncology2006;24(18 Suppl):48s. LevyC , FumoleauP . Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?Cancer Treatment Reviews2005;31(4 Suppl):S17-22. ">Chan 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel vs gemcitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0005" title="BellR , Anton-TorresA , JassemJ , MoralesS , CameronD , ButtonP , et al. Beyond CHAT: overall survival (OS) update from the chat study of first-line trastuzumab (H) plus docetaxel (T) with or without capecitabine (X) in HER2-positive metastatic breast cancer (MBC). Annals of Oncology2010;21(Suppl 8):viii99. WardlevA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study. EJC Supplements2008;6(7):109-10. [DOI: 10.1016/S1359-6349(08)70525-1]WardleyA , Anton-TorresA , Otero ReyesD , JassemJ , ToacheLMZ , AlcedoJC . CHAT - an open-label, randomised phase II study of trastuzumab plus deocetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis [abstract no: 1997] 1997. Breast Cancer Research &amp; Treatment2005;94(Suppl 1):S281-81. WardleyA , Anton-TorresA , PivotX , Morales-VasquezF , ZetinaL , deFatima Dias GauiM , et al. Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer. In: Breast Cancer Research and Treatment. Vol. Suppl. 2007:Abstract no. 309. WardleyAM , PivotX , Morales-VasquezF , ZetinaLM , de Fatima Dias, GauiM , et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Journal of Clinical Oncology2010;28(6):976-83. ">CHAT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + trastuzumab + docetaxel vs trastuzumab + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0008" title="FanY , XuBH , YuanP , MaF , WangJY , DingXY , et al. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Annals of Oncology2013;24(5):1219-25. [DOI: 10.1093/annonc/mds603]FanY , XuBH , YuanP , WangJY , MaF , DingXY , et al. Results of a randomized phase II study demonstrate benefit of platinum-based regimen in the first-line treatment of triple negative breast cancer (TNBC). Cancer Research2011;71(24):Abstract no. P5-19-04. ">Fan 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel vs cisplatin + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0013" title="DovalD , CinieriS , BozcukH , Pierga J-Y, AltundagK , WangX , et al. Abstract P2-12-16: Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast cancer. Cancer Research2015;75(9 Suppl):P2-12. GligorovJ , BinesJ , AlbaE , MustacchiG , CinieriS , GuptaV , et al. Abstract P2-17-01: Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC). Cancer Research2015;75(9 Suppl):P2-17. GligorovJ , DovalD , BinesJ , AlbaE , CortesP , PiergaJY , et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncology2014;15(12):1351-60. GligorovJ , DovalD , BinesJ , JiangZ , AlbaE , CortesP , et al. Efficacy and safety of maintenance bevacizumab (bev) with or without capecitabine (cap) after initial first-line bev plus docetaxel (doc) for HER2-negative metastatic breast cancer (mbc): IMELDA randomised phase III trial. Annals of Oncology2014;25(4 Suppl):iv116-7. [DOI: 10.1093/annonc/mdu329.2]MustacchiG , BinesJ , AlbaE , CortesP , DovalD , De DuclaS , et al. Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC). Cancer Research2017;77(4 Suppl):Abstract no. P5-15-06. ">IMELDA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab vs bevacizuamb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine vs glembatumumb vedotin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0017" title="MavroudisD , ArdavanisA , BoukovinasI , VarthalitisI , SyrigosK , PotamianouA , et al. A multicenter randomized study comparing vinorelbine plus gemcitabine versus capecitabine monotherapy as salvage treatment in patients with advanced breast cancer pretreated with taxane and anthracycline chemotherapy: a preliminary report. Journal of Clinical Oncology2006;24(18 Suppl):42s, abstract no. 658. PallisAG , BoukovinasI , ArdavanisA , VarthalitisI , MalamosN , GeorgouliasV , et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Annals of Oncology2012;23(5):1164-9. ">Pallis 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine vs vinorelbine + gemcitabine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel vs docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50/178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/178</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0018" title="SeidmanAD , BrufskyA , AnsariRH , HartLL , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology2011;22(5):1094-101. [DOI: 10.1093/annonc/mdq578]SeidmanAD , BrufskyA , AnsariRH , RubinsakJR , SteinRS , SchwartzbergLS , et al. Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Journal of Clinical Oncology2009;27(15):1000. SeidmanAD , ChanS , WangJ , ZhuC , XuC , XuB . A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer. The Oncologist2014;19(5):443-52. [DOI: 10.1634/theoncologist.2013-0428]">Seidman 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + docetaxel vs gemcitabine + docetaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57/226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/237</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0020" title="AwadaA , KaufmanPA , YelleL , CortesJ , WandersJ , O'ShaughnessyJ , et al. A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-03. CortésJ , PérezJ , HeY , Metzger-FilhoO . Abstract P3-13-06: Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research2015;75(9 Suppl):Abstract no. P3-13-06. CortesJ , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: a phase III, open-label, randomized study. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1050. CortesJ , AwadaA , TwelvesC , YelleL , WandersJ , OlivoMS , et al. Quality of life in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine in a phase III, open-label, randomized study. Cancer Research2012;72(24 Suppl):Abstract no. P1-12-08. [DOI: 10.1158/0008-5472.sabcs12-p1-12-08]CortesJ , HudgensS , TwelvesC , PerezEA , AwadaA , YelleL , et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Research and Treatment2015;154(3):509-20. CortesJ , PerezJ , HeY , Metzger-FilhoO . Efficacy of eribulin in patients with invasive lobular carcinoma of the breast: data from a pooled analysis. Cancer Research. Conference: 37th Annual CTRC AACR San Antonio Breast Cancer Symposium San Antonio, TX United States. Conference Start2015;75(9 Suppl):Abstract no. P3-13-06. KaufmannPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Onkologie2013;36:98. KaufmanP , TwelvesC , CortesJ , VahdatLT , OlivoM , YiH , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(26 Suppl):Abstract no. 137. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , VelikovaG , et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of Clinical Oncology2015;33(6):594-601. KaufmanPA , AwadaA , TwelvesC , YelleL , PerezEA , WandersJ , et al. Abstract S6-6: A phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Research2012;72(24 Suppl):Abstract no. S6-6. [DOI: 10.1158/0008-5472.sabcs12-s6-6]KaufmanPA , CortesJ , AwadaA , YelleL , PerezEA , WandersJ , et al. A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1049. KaufmanPA , YelleL , CortesJ , PerezEA , AwadaA , WandersJ , et al. Abstract P3-13-04: Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301. Cancer Research2013;73(24 Suppl):Abstract no. P3-13-04. [DOI: 10.1158/0008-5472.sabcs13-p3-13-04]PerezE , O'ShaughnessyJ , TwelvesC , CortesJ , AwadaA , YelleL , et al. New metastases versus increase in size of pre-existing lesions and its correlation with overall survival in patients with MBC treated with eribulin or capecitabine in study 301, a phase III randomised trial. European Journal of Cancer2013;49:S419. PivotX , ImSA , GuoM , MarméF . Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer (Tokyo, Japan)2018;25(3):370-4. PivotX , MarméF , KoenigsbergR , GuoM , BerrakE , WolferA . Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Annals of Oncology2016;27(8):1525-31. TwelvesC , AwadaA , CortesJ , YelleL , VelikovaG , OlivoMS , et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer2016;10:77-84. TwelvesC , AwadaA , KaufmanPA , YelleL , PerezEA , VelikovaG , et al. Quality of life (QoL) and content validity in objective tumor response. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1055. TwelvesC , CortesJ , KaufmanPA , YelleL , AwadaA , BinderTA , et al. &quot;New&quot; metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Research2015;17(150):12 pages. TwelvesC , CortesJ , OlivoM , HeY , AwadaA . 393P - Efficacy of eribulin in a second-line or later setting patients (pts) with metastatic beast cancer (mbc): a pooled analysis. Annals of Oncology2014;25(Suppl 4):iv129-30. TwelvesC , CortesJ , VahdatL , OlivoM , HeY , KaufmanPA , et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies [Erratum appears in Breast Cancer Res Treat. 2015 Jan;149(1):313; PMID: 25573650]. Breast Cancer Research &amp; Treatment2014;148(3):553-61. TwelvesC , CortesJ , VahdatLT , OlivoMS , HeY , KaufmanPA , et al. Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status. Journal of Clinical Oncology2014;32(15 Suppl):Abstract no. 631. TwelvesC , CortesJ , VahdatLT , WandersJ , AkereleC , KaufmanPA . Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clinical Breast Cancer2010;10(2):160-3. [DOI: 10.3816/CBC.2010.n.023]">Study 301</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine vs eribulin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79/546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/544</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0021" title="LueckHJ , LuebbeK , BischoffJ , MaassN , FeiselG , TomeO , et al. A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1082. ">TABEA</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab + docetaxel OR paclitaxel vs bevacizumab + docetaxel OR paclitaxel </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011220-bbs2-0023" title="BeslijaS , BrodowiczT , GreilR , InbarMJ , KahanZ , KaufmanB , et al. First-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): a randomized phase III trial. Cancer Research2011;71(24 Suppl):Abstract no. OT2-01-02. BrodowiczT , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British Journal of Cancer2014;111(11):2051-7. BrodowiczT , PienkowskiT , BeslijaS , MelicharB , LangI , InbarMJ , et al. Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). Cancer Research2013;73(24 Suppl):Abstract no. P6-06-40. ChristophZC , IstvanL , SemirB , ZsuzsannaK , InbarMJ , SalomonSM , et al. Hand-foot-syndrome (HFS) is a strong predictor for OS and PFS in HER2-negative metastatic breast cancer (mBC) treated with first-line capecitabine (CAP) + bevacizumab (BEV): results of a subanalysis of the randomized phase III CECOG TURANDOT trial. Cancer Research2015;75(9 Suppl):Abstract no. P3-06-10. InbarM , LangI , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Randomized phase III study of first-line bevacizumab in combination with capecitabine or paclitaxel for HER2-negative LR/MBC: interim safety data. European Journal of Cancer2011;47(Suppl 1):S346. [DOI: 10.1016/S0959-8049(11)71495-2]InbarMJ , LangI , KahanZ , GreilR , BeslijaS , Stemmer, SM, et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): subgroup analysis of TURANDOT. Journal of Clinical Oncology2013;31(15 Suppl):Abstract no. 1040. KahanZ , PetruzelkaL , EniuA , AnghelR , KoynovK , VrbanecD , et al. Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): subgroup analysis of the open-label non-inferiority TURANDOT phase III trial. Cancer Research2013;73(8 Suppl):Abstract no. LB-177. LangI , BrodowiczT , RyvoL , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncology2013;14(2):125-33. [DOI: 10.1016/S1470-2045(12)70566-1]LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG PHASE III TURANDOT TRIAL: first-line bevacizumab (BEV) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21:viii98. LangI , InbarM , GreilR , KahanZ , BeslijaS , StegerGG , et al. Safety subgroup analyses from the CECOG phase III TURANDOT trial: First-line bevacizumab (Bev) in combination with capecitabine (X) or paclitaxel (P) for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC). Annals of Oncology2010;21(8 Suppl):viii98. LangI , InbarM , StegerG , GreilR , ZvirbuleZ , BeslijaS , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial. European Journal of Cancer,Supplement2009;7(2-3):277-8. LangI , InbarMJ , GreilR , StegerGG , BeslijaS , KahanZ , et al. Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): preliminary safety data from the CECOG phase III TURANDOT trial. Journal of Clinical Oncology2010;28(15 Suppl):Abstract no. 1126. LangI , InbarMJ , KahánZ , GreilR , BeslikjaS , StemmerSM , et al. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer2012;48(17):3140-9. [DOI: 10.1016/j.ejca.2012.04.022]LangI , InbarMJ , KahanZ , GreilR , BeslijaS , StemmerSM , et al. Abstract P5-17-03: Quality of life (QOL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC). Cancer Research2012;72(24 Suppl):Abstract no. P5-17-03. [DOI: 10.1158/0008-5472.sabcs12-p5-17-03]ZielinskiC , LangI , BeslijaS , KahanZ , InbarMJ , StemmerSM , et al. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. British Journal of Cancer2016;114(2):163-70. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncology2016;17(9):1230-9. ZielinskiC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. First efficacy results from the TURANDOT phase III trial comparing two bevacizumab (bev)-containing regimens as first-line therapy for HER2-negative metastatic breast cancer (mbc). Annals of Oncology2012;23(9 Suppl):ix116. [DOI: doi:10.1093/annonc/mds393]ZielinskiCC , LangI , InbarM , KahanZ , GreilR , BeslijaS , et al. Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). European Journal of Cancer2015;51(4):S263-4. ">TURANDOT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capecitabine + bevacizumab vs bevacizumab + paclitaxel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/160</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>All toxicities are G3 or G4, except <a href="./references#CD011220-bbs2-0019" title="GluckS , RusselC , O'ShaughnessyJ , YuanG , OdomD , SherrillB , et al. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC) treated with capecitabine (C) and docetaxel (D): an exploratory data analysis. Journal of Clinical Oncology2009;27(15):1024. GluckS , RussellC , O'ShaughnessyJ , McKennaEF , HuS , OdomD , et al. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast2013;22(6):1087-93. [DOI: 10.1016/j.breast.2013.08.016]LeonardR , CervantesG , LuiW , MauriacL , MilesD , MoiseyenkoV , et al. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC). European Journal of Cancer2001;37(6):S151. [DOI: 10.1016/S0959-8049(01)81043-1]LeonardR , MalinovszkyL . Poorer survival of patients in UK and Russia in an international randomised trial of chemotherapy for metastatic breast cancer. European Journal of Cancer2002;38(Suppl 3):S65-75; abstract no. 131. LeonardR , O'ShaughnessyJ , VukeljaS , GorbounovaV , Chan-NavarroCA , MaraninchiD , et al. Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?Annals of Oncology2006;17(9):1379-85. [DOI: 10.1093/annonc/mdl134]MilesD , VukeljaS , MoiseyenkoV , CervantesG , MauriacL , HazelG , et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clinical Breast Cancer2004;5(4):273-8. O'ShaughnessyJ , MilesD , VukeliaS , MoiseyenkoV , AyoubJP , CervantesG , et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of Clinical Oncology2002;20(12):2812-23. O'ShaughnessyJ . Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial. Oncology (Huntington)2002;16(10 Suppl 12):17-22. VukeljaSJ , MoisenyenkoVM , LeonardR , ContePF , GarinA , McKendrickJ , et al. Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: latest results. Breast Cancer Research &amp; Treatment2001;69(3):269. ">SO140999</a>, for which grade of toxicity was not specified in reporting. </p> <p><a href="./references#CD011220-bbs2-0015" title="SchmidP , MeliskoM , YardleyDA , BlackwellK , ForeroA , OuelletteG , et al. METRIC: a randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC). Annals of Oncology2016;27(6 Suppl):VI97. ">METRIC</a> ‐ 1 episode of fatal neutropenic sepsis noted in the glematumumab vedotin arm, and none in the capecitabine arm, but no rates of febrile neutropenia reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Toxicities for capecitabine‐containing regimens vs non‐capecitabine‐containing regimens for metastatic breast cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/full#CD011220-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011220-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 OS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.98, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 OS hormone receptor‐positive: sensitivity analysis of pooled analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 All studies excluding pooled analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1565</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Pooled analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.83, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 OS hormone receptor‐negative: sensitivity analysis of pooled analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 All studies excluding pooled analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1408</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Pooled analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.62, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 OS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.01, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 PFS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.82, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 PFS hormone receptor‐positive: sensitivity analysis of pooled analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.73, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 All studies excluding pooled analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.68, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Pooled analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 PFS hormone receptor‐negative: sensitivity analysis of pooled analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.83, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 All studies excluding pooled analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.85, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Pooled analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.64, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 PFS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.04, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 ORR all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 ORR TNBC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.27, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 CBR all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.76, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Complete response rate all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.85, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Complete response rate HR+ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.75 [1.17, 19.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Complete response rate HR‐ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.39, 1.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Metastatic all: capecitabine‐containing regimen vs non‐capecitabine‐containing regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011220-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metastatic: capecitabine monotherapy vs chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 OS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 OS HR+ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.86, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 OS HR‐ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.91, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 OS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.98, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 PFS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 PFS HR+ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 PFS HR‐ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 PFS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.94, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 ORR all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 CBR all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Complete response rate all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [0.51, 8.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Metastatic: capecitabine monotherapy vs chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011220-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metastatic: addition of capecitabine vs chemotherapy/other</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 OS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.66, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 OS HR+ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.47, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 OS HR‐ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.59, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 OS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.19, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 PFS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.60, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 PFS HR+ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.55, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 PFS HR‐ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.39, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 PFS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.31, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 ORR all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.07, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 CBR all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.17, 21.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Complete response rate all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.86, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Complete response rate HR+ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.62 [0.95, 22.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Complete response rate HR‐ <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.46, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Metastatic: addition of capecitabine vs chemotherapy/other</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011220-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metastatic: substitution of capecitabine vs chemotherapy/other</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 OS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.99, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 OS hormone receptor‐positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.84, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 OS hormone receptor‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 OS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.03, 2.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 PFS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.93, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 PFS hormone receptor‐positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.78, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 PFS hormone receptor‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.79, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 PFS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.28, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 ORR all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.58, 0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 ORR TNBC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.10, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 CBR all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.10, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Complete response rate all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Metastatic: substitution of capecitabine vs chemotherapy/other</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011220-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adjuvant all: capecitabine‐containing regimen vs other regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 OS (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 OS hormone receptor‐positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 OS hormone receptor‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.59, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 OS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.57, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 AE ‐ Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.33, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 AE ‐ Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9849</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.74, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 AE ‐ Febrile neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8086</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.47, 0.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 AE ‐ Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.57, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 AE ‐ Hand‐foot syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.60 [10.65, 17.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 AE ‐ Mucositis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.03, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 AE ‐ Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [2.01, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 AE ‐ Ischaemic heart disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [0.70, 16.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.13 AE ‐ Treatment‐related death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.21, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Adjuvant all: capecitabine‐containing regimen vs other regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011220-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Adjuvant All: Sensitivity analysis of combining DFS and RFS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 DFS and RFS together <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.85, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.85, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 DFS and RFS: Hormone Receptor Positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.91, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 DFS and RFS: Hormone Receptor Negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.64, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.64, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.41, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 DFS and RFS: Triple negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.72, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.2 RFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.31, 0.91]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Adjuvant All: Sensitivity analysis of combining DFS and RFS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011220-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 DFS/RFS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 DFS/RFS hormone receptor‐positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3955</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.92, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 DFS/RFS hormone receptor‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 DFS/RFS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.61, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 OS (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.71, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 OS hormone receptor‐positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.69, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 OS hormone receptor‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.49, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 OS triple‐negative breast <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.46, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Adjuvant: addition or substitution of capecitabine‐ vs anthracycline‐taxane‐containing regimen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011220-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Adjuvant: capecitabine monotherapy vs chemotherapy/other</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 DFS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.82, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 DFS hormone receptor‐positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.78, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 DFS hormone receptor‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 DFS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.71, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 OS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 OS hormone receptor‐positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.38, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.7 OS hormone receptor‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.59, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.8 OS triple‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.59, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Adjuvant: capecitabine monotherapy vs chemotherapy/other</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011220-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Neoadjuvant: addition of capecitabine vs standard chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 PCR all (breast and nodes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.94, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 PCR hormone receptor‐positive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.76, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 PCR hormone receptor‐negative <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>646</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.61, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 PCR triple‐negative (breast and nodes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.72, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.5 DFS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.86, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.6 OS all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.7 AE ‐ Anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.54, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.8 AE ‐ Neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.69, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.9 AE ‐ Febrile neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.97, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.10 AE ‐ Thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.54, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.11 AE ‐ Hand‐foot syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.77 [4.89, 9.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.12 AE ‐ Mucositis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.11, 2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.13 AE ‐ Diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.32, 2.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.14 AE ‐ Ischaemic heart disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [0.37, 13.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.15 AE ‐ Treatment‐related death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.17, 2.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Neoadjuvant: addition of capecitabine vs standard chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011220.pub2/references#CD011220-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011220.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011220-note-0036">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011220-note-0030">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011220-note-0033">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011220-note-0027">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD011220-note-0024">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD011220-note-0021">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011220-note-0018">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011220-note-0012">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011220-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011220\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011220\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011220\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011220\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011220\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011220.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011220.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011220.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011220.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011220.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724359664"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011220.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724359668"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011220.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e60de0b6df3fd',t:'MTc0MDcyNDM2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 